UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended November 30, 2024

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 000-55546

 

CLS HOLDINGS USA, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

45-1352286

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

516 S. 4th Street, Las Vegas Nevada, 89101

(Address of principal executive offices) (Zip Code)

 

(888) 359-4666

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No

 

State the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date: 164,734,517 shares of $0.0001 par value common stock outstanding as of January 8, 2025. 

 

 

 

 

CLS HOLDINGS USA, INC.

 

FORM 10-Q

Quarterly Period Ended November 30, 2024

 

TABLE OF CONTENTS

 

 

Page

 

 

FORWARD-LOOKING STATEMENTS

3

 

 

AVAILABLE INFORMATION

3

 

 

PART I. FINANCIAL INFORMATION

 

Item 1.

Financial Statements

4

 

Condensed Consolidated Balance Sheets as of November 30, 2024 (Unaudited) and May 31, 2024 (Audited)

4

 

Condensed Consolidated Statements of Operations for the Three and Six Months Ended November 30, 2024 and 2023 (Unaudited)

5

 

Condensed Consolidated Statements of Stockholders’ Deficit for the Six Months Ended November 30, 2024 and 2023 (Unaudited)

6

 

Condensed Consolidated Statements of Cash Flows for the Six Months Ended November 30, 2024 and 2023 (Unaudited)

7

 

Notes to the Consolidated Financial Statements (Unaudited)

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

29

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

37

Item 4.

Controls and Procedures

37

 

 

PART II. OTHER INFORMATION

 

Item 1.

Legal Proceedings

38

Item 1A.

Risk Factors

38

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

38

Item 3.

Defaults Upon Senior Securities

38

Item 4.

Mine Safety Disclosures

38

Item 5.

Other Information

38

Item 6.

Exhibits

38

 

 

SIGNATURES

39

 

 

 

 

EXPLANATORY NOTE

 

Unless otherwise noted, references in this report to “CLS Holdings USA, Inc.,” the “Company,” “we,” “our” or “us” means CLS Holdings USA, Inc. and its subsidiaries.

 

FORWARD-LOOKING STATEMENTS

 

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to, among other things, the impact of the COVID-19 virus on our business, the results of our initiatives to retain our employees and strengthen our relationships with our customers and community, the effect of our initiatives to expand market share and achieve growth, the expected development of our business and joint ventures, results of operations and financial performance, liquidity, working capital and capital requirements, the effects of the additional dilution on our common stock that may occur as a result of the amendments to our convertible debentures, and anticipated future events. These forward-looking statements also relate to our ability to obtain debt or equity capital on reasonable terms, or at all, to finance our operations, and to identify, finance and close potential acquisitions and joint ventures, whether our joint venture partner will make its capital contribution, our ability to comply with applicable cannabis-related regulations and obtain regulatory approvals, market acceptance of our services and product offerings, our ability to protect and commercialize our intellectual property, our ability to use net operating losses to offset certain cannabis-related tax liabilities and our ability to grow our wholesale and processing businesses and joint ventures. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology.

 

These forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any expected future results, levels of activity or performance expressed or implied by these forward-looking statements.

 

We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered together with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

 

AVAILABLE INFORMATION

 

We file certain reports under the Securities Exchange Act of 1934 (the “Exchange Act”). Such filings include annual and quarterly reports. The reports we file with the Securities and Exchange Commission (“SEC”) are available on the SEC’s website at (http://www.sec.gov).

 

 

 

Item 1. Financial Statements.

CLS HOLDINGS USA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   

November 30,

   

May 31,

 
   

2024

   

2024

 
   

(unaudited)

         

ASSETS

               

Current assets

               

Cash and cash equivalents

  $ 592,584     $ 600,007  

Accounts Receivable

    1,152,082       682,894  

Inventory

    1,805,661       1,968,573  

Prepaid expenses and other current assets

    39,934       49,309  

Total current assets

    3,590,261       3,300,783  
                 

Property, plant and equipment, net of accumulated depreciation of $3,572,740 and $3,318,550

    2,184,815       2,423,553  

Right of use assets, operating leases

    1,385,830       1,475,351  

Intangible assets, net of accumulated amortization of $351,824 and $348,015

    8,327       9,978  

Goodwill

    557,896       557,896  

Other assets

    157,500       157,500  
                 

Total assets

  $ 7,884,629     $ 7,925,061  
                 

LIABILITIES AND STOCKHOLDERS' DEFICIT

               

Current liabilities

               

Accounts payable and accrued liabilities

  $ 4,400,037     $ 3,356,059  

Accrued interest

    15,600       3,600  

Due to related party

    40,000       -  

Lease liability - operating leases, current

    484,601       443,467  

Lease liability - financing leases, current

    108,410       96,224  

Taxes Payable

    9,888,537       8,899,863  

Notes payable, current

    128,898       139,345  

Notes payable - related party, current

    1,514,362       988,472  

Convertible notes payable, current

    126,043       302,005  
                 

Total current liabilities

    16,706,488       14,229,035  

Noncurrent liabilities

               

Lease liability - operating leases, non-current

    1,188,793       1,318,644  

Lease liability - financing leases, non-current

    39,899       100,252  

Notes payable, non-current, net of discount of $0 and $193,756

    34,702       407,951  

Notes payable - related party, non-current

    666,122       1,078,551  

Convertible notes payable, non-current

    1,535,283       3,699,426  
                 

Total Liabilities

    20,171,287       20,833,859  
                 

Commitments and contingencies

    -       -  
                 

Stockholder's deficit

               

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued

    -       -  

Common stock, $0.0001 par value; 345,000,000 shares authorized; 164,734,517 and 124,500,873 shares issued and outstanding at November 30, 2024 and May 31, 2024, respectively

    16,474       12,450  

Additional paid-in capital

    103,046,249       101,519,599  

Common stock subscribed

    65,702       65,702  

Accumulated deficit

    (114,275,584 )     (113,367,050 )

Stockholder's deficit attributable to CLS Holdings, Inc.

    (11,147,159 )     (11,769,299 )

Non-controlling interest

    (1,139,499 )     (1,139,499 )

Total stockholder's deficit

    (12,286,658 )     (12,908,798 )
                 

Total liabilities and stockholders' deficit

  $ 7,884,629     $ 7,925,061  

 

See accompanying notes to these financial statements.

 

 

CLS HOLDINGS USA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   

For the

   

For the

   

For the

   

For the

 
   

Three Months Ended

   

Three Months Ended

   

Six Months Ended

   

Six Months Ended

 
   

November 30, 2024

   

November 30, 2023

   

November 30, 2024

   

November 30, 2023

 
                                 
                                 

Revenue

    4,161,270       5,197,214       8,966,435       10,311,741  

Cost of goods sold

    2,389,245       3,025,595       5,146,141       5,866,196  

Gross margin

    1,772,025       2,171,619       3,820,294       4,445,545  
                                 

Selling, general and administrative expenses

    2,095,099       2,606,918       4,279,932       5,336,818  

Total operating expenses

    2,095,099       2,606,918       4,279,932       5,336,818  
                                 

Operating income (loss)

    (323,074 )     (435,299 )     (459,638 )     (891,273 )
                                 

Other (income) expense:

                               

Interest expense, net

    295,715       410,841       455,118       868,313  

Employee retention tax credit income

    (50,103 )     -       (50,103 )     (924,862 )

(Gain) on settlement of debt

    (949,793 )     -       (949,793 )     -  

(Gain) on settlement of accounts payable

    -       -       -       (4,375 )

Total other (income) expense

    (704,181 )     410,841       (544,778 )     (60,924 )
                                 

Income (Loss) before income taxes

    381,107       (846,140 )     85,140       (830,349 )
                                 

Provision for income tax

    (468,778 )     (456,040 )     (993,674 )     (933,564 )
                                 

Net loss

    (87,671 )     (1,302,180 )     (908,534 )     (1,763,913 )
                                 

Non-controlling interest

    -       (92 )     -       (2,200 )
                                 

Net loss attributable to CLS Holdings, Inc.

    (87,671 )     (1,302,272 )     (908,534 )     (1,766,113 )
                                 

Net loss per share - basic

    0.00       (0.02 )     (0.01 )     (0.02 )
                                 

Net loss per share - diluted

    (0.00 )     (0.02 )     (0.01 )     (0.02 )
                                 

Weighted average shares outstanding - basic

    167,203,078       72,543,141       146,045,945       72,543,141  
                                 

Weighted average shares outstanding - diluted

    167,203,078       72,543,141       146,045,945       72,543,141  

 

See accompanying notes to these financial statements.

 

 

CLS HOLDINGS USA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT

(Unaudited)

 

   

Common Stock

   

Additional

Paid In

   

Stock

   

Accumulated

   

Non-controlling

         
   

Amount

   

Value

   

Capital

   

Payable

   

Deficit

   

Interest

   

Total

 
                                                         

Balance, August 31, 2023

    72,543,141     $ 7,255     $ 96,147,784     $ 65,702     $ (109,343,287 )   $ (1,139,759 )   $ (14,262,305 )

Discount on convertible notes payable

    -       -       62,400       -       -       -       62,400  

Loss for the three months ended November 30, 2023

    -       -       -       -       (1,302,272 )     92       (1,302,180 )

Balance, November 30, 2023

    72,543,141     $ 7,255     $ 96,210,184     $ 65,702     $ (110,645,559 )   $ (1,139,667 )   $ (15,502,085 )
                                                         

Balance, May 31, 2023

    72,543,141     $ 7,255     $ 96,147,784     $ 65,702     $ (108,879,446 )   $ (1,141,867 )   $ (13,800,572 )

Discount on convertible notes payable

    -       -       62,400       -       -       -       62,400  

Loss for the six months ended November 30, 2023

    -       -       -       -       (1,766,113 )     2,200       (1,763,913 )

Balance, November 30, 2023

    72,543,141     $ 7,255     $ 96,210,184     $ 65,702     $ (110,645,559 )   $ (1,139,667 )   $ (15,502,085 )
                                                         
                                                         

Balance, August 31, 2024

    181,348,418     $ 18,135     $ 103,742,716     $ 65,702     $ (114,187,913 )   $ (1,139,499 )   $ (11,500,859 )

Shares purchased from related party

    (1,125,000 )     (112 )     (39,888 )     -       -       -       (40,000 )

Shares and warrants cancelled in debt settlement

    (15,488,901 )     (1,549 )     (679,961 )     -       -       -       (681,510 )

Amortization of employee stock options

    -       -       23,382       -       -       -       23,382  

Loss for the three months ended November 30, 2024

    -       -       -       -       (87,671 )     -       (87,671 )

Balance, November 30, 2024

    164,734,517     $ 16,474     $ 103,046,249     $ 65,702     $ (114,275,584 )   $ (1,139,499 )   $ (12,286,658 )
                                                         

Balance, May 31, 2024

    124,500,873     $ 12,450     $ 101,519,599     $ 65,702     $ (113,367,050 )   $ (1,139,499 )   $ (12,908,798 )

Conversion of notes payable

    56,847,545       5,685       2,194,315       -       -       -       2,200,000  

Shares purchased from related party

    (1,125,000 )     (112 )     (39,888 )     -       -       -       (40,000 )

Shares and warrants cancelled in debt settlement

    (15,488,901 )     (1,549 )     (679,961 )     -       -       -       (681,510 )

Amortization of employee stock options

    -       -       52,184       -       -       -       52,184  

Loss for the six months ended November 30, 2024

    -       -       -       -       (908,534 )     -       (908,534 )

Balance, November 30, 2024

    164,734,517     $ 16,474     $ 103,046,249     $ 65,702     $ (114,275,584 )   $ (1,139,499 )   $ (12,286,658 )

 

See accompanying notes to these financial statements.

 

 

CLS HOLDINGS USA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   

For the Six

   

For the Six

 
   

Months Ended

   

Months Ended

 
   

November 30, 2024

   

November 30,2023

 

CASH FLOWS FROM OPERATING ACTIVITIES

               

Net loss

  $ (908,534 )   $ (1,763,913 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Share-based compensation

    52,184       -  

Amortization of debt discounts and fees

    193,756       335,999  

Depreciation and amortization expense

    256,530       332,748  

Gain on settlement of accounts payable

    -       (4,375 )

Gain on settlement of debt

    (949,793 )     -  

Bad debt expense

    -       393  

Changes in assets and liabilities:

               

Accounts receivable

    (469,188 )     (502,200 )

Prepaid expenses and other current assets

    9,375       78,765  

Inventory

    162,912       371,079  

Right of use asset

    209,922       186,424  

Accounts payable and accrued expenses

    1,043,978       1,000,336  

Accrued interest

    87,638       216,098  

Deferred tax liability

    988,674       933,564  

Operating lease liability

    (209,118 )     (180,287 )

Net cash provided by operating activities

    468,336       1,004,631  
                 

CASH FLOWS FROM INVESTING ACTIVITIES

               

Payments to purchase property, plant and equipment

    (16,141 )     (44,248 )

Payment for construction security deposit

    -       (58,175 )

Net cash used in investing activities

    (16,141 )     (102,423 )
                 

CASH FLOWS FROM FINANCING ACTIVITIES

               

Cash received from the issuance of convertible notes payable

    2,600,000       -  

Cash received from issuance of note payable - related party

    150,000       -  

Principal payment on notes and cancellation of shares

    (2,600,000 )     -  

Principal payments on convertible notes payable

    (48,093 )     (100,000 )

Principal payments on notes payable

    (76,819 )     (477,084 )

Principal payments on notes payable -related party

    (436,539 )     -  

Proceeds of loan payable

    -       960,000  

Repayments of loan payable

    -       (481,943 )

Principal payments on finance leases

    (48,167 )     (41,931 )

Net cash used in financing activities

    (459,618 )     (140,958 )
                 

Net (decrease) increase in cash and cash equivalents

    (7,423 )     761,250  
                 

Cash and cash equivalents at beginning of period

    600,007       998,421  
                 

Cash and cash equivalents at end of period

  $ 592,584     $ 1,759,671  
                 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

               

Interest paid

  $ 115,333     $ 163,783  

Income taxes paid

  $ -     $ -  
                 

NONCASH INVESTING AND FINANCING ACTIVITIES:

               

Shares issued for conversion of notes payable

  $ 2,200,000     $ -  

Capitalized interest

  $ 75,638     $ -  

Initial ROU asset and lease liability - operating

  $ 120,401     $ 224,899  

Discount on convertible note payable

  $ -     $ 62,400  
Cancellation of shares held by related party   $ 40,000     $ -  

 

See accompanying notes to these financial statements.

 

 

CLS HOLDINGS USA, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

November 30, 2024

(Unaudited)

 

Note 1: Nature of Business and Significant Accounting Policies

 

Basis of Presentation

 

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in US dollars. The Company has adopted a fiscal year end of May 31st.

 

Principals of Consolidation

 

The accompanying consolidated financial statements include the accounts of CLS Holdings USA, Inc.; its direct and indirect wholly owned operating subsidiaries, CLS Nevada, Inc., (“CLS Nevada”), CLS Labs, Inc. (“CLS Labs”), CLS Labs Colorado, Inc. (“CLS Colorado”), CLS Massachusetts, Inc. (“CLS Massachusetts”), and Alternative Solutions, LLC (“Alternative Solutions”); and wholly owned inactive subsidiaries CLS Labs Colorado, Inc. (“CLS Colorado”) and CLS Massachusetts, Inc. (“CLS Massachusetts”). Alternative Solutions is the sole owner of the following three entities (collectively, the “Oasis LLCs”): Serenity Wellness Center, LLC (“Serenity Wellness Center”); Serenity Wellness Products, LLC (“Serenity Wellness Products”); and Serenity Wellness Growers, LLC (“Serenity Wellness Growers”). The accompanying consolidated financial statements also include the accounts of CLS CBD in which the company owns a 95% ownership interest and a variable interest entity, Kealii Okamalu, LLC (“Kealii Okamalu”), in which the Company owns a 50% interest. All material intercompany transactions have been eliminated upon consolidation of these entities.

 

Nature of Business

 

CLS Holdings USA, Inc. (the “Company”) was originally incorporated as Adelt Design, Inc. (“Adelt”) on March 31, 2011 to manufacture and market carpet binding art. Production and marketing of carpet binding art never commenced.

 

We currently operate a retail marijuana dispensary within walking distance to the Las Vegas Strip and a small-scale cultivation facility, as well as a product manufacturing facility and a wholesale distribution operation in North Las Vegas. The vertically integrated business model drives strong margins to the bottom line on a portion of sales at the dispensary.

 

Our retail dispensary is a single location operation in Nevada and occupies over 5,000 square feet. This location, which is easily accessible by tourists, is currently open 19.5 hours per day for walk-in service. Curbside and in store express pick up is available between the hours of 8:00 AM and 12:00 AM. Oasis dispensary also delivers cannabis to residents between the hours of 8:00 AM and 10:00 PM. The central location provides logistical convenience for delivery to all parts of the Las Vegas valley.

 

Our wholesale operations, which occupies approximately 10,000 square feet of a 22,000 square foot warehouse, began sales to third parties in August 2017 and completed construction and received a certificate of occupancy for its state-of-the-art extraction facility in December of 2019. We have made sales to over 88 external customers as of November 30, 2024. Our existing product line includes vaporizers, tinctures, ethanol produced THC distillate, and live and cured hydrocarbon concentrates. At present, the City Trees cultivation facility only grows breeding stock to preserve valuable genetics and does not offer its crops for sale or processing. As a result, all raw materials for manufacturing are sourced from third parties.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Reclassification

 

Certain reclassifications, not affecting previously reported net income or cash flows, have been made to the previously issued financial statements to conform to the current period presentation.

 

 

Cash, Cash Equivalents, and Restricted Cash

 

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. The Company had cash and cash equivalents of $592,584 and $600,007 as of November 30, 2024 and May 31, 2024, respectively.

 

Allowance for Doubtful Accounts

 

The Company generates the majority of its revenues and corresponding accounts receivable from the sale of cannabis, and cannabis related products. The Company evaluates the collectability of its accounts receivable considering a combination of factors. In circumstances where it is aware of a specific customer’s inability to meet its financial obligations to it, the Company records a specific reserve for bad debts against amounts due in order to reduce the net recognized receivable to the amount it reasonably believes will be collected. For all other customers, the Company recognizes reserves for bad debts based on past write-off experience and the length of time the receivables are past due. The Company had bad debt expense of $0 and $93 during the three months ended November 30, 2024 and 2023.

 

Inventory

 

Inventories are stated at the lower of cost or market. Cost is determined using a perpetual inventory system whereby costs are determined by acquisition costs of individual items included in inventory. Market is determined based on net realizable value. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable values. Our cannabis products consist of prepackaged purchased goods ready for resale, along with produced tinctures and extracts developed under our production license.

 

Property, Plant and Equipment

 

Property and equipment is recorded at the lower of cost or estimated net recoverable amount, and is depreciated using the straight-line method over its estimated useful life. Property acquired in a business combination is recorded at estimated initial fair value. Property, plant, and equipment are depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based upon the following life expectancy:

 

 

 

Years

 

Office equipment

 

 

3 to 5

 

Furniture & fixtures

 

 

3 to 7

 

Machinery & equipment

 

 

3 to 10

 

Leasehold improvements

 

Term of lease

 

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated, and any resulting gain or loss is reflected in operations.

 

Long-Lived Assets

 

The Company reviews its property and equipment and any identifiable intangibles including goodwill for impairment on an annual basis utilizing the guidance set forth in the Statement of Financial Accounting Standards Board ASC 350 “Intangibles – Goodwill and Other” and ASC 360 “Property, Plant, and Equipment.” At November 30, 2024, the net carrying value of goodwill on the Company’s balance sheet remained at $557,896.

 

Employee Retention Tax Credit

 

Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), the Company was eligible for a refundable employee retention tax credit (the “ERTC”), subject to certain criteria. As ERTCs are not within the scope of ASC 740, Income Taxes, the Company has chosen to account for the ERTCs by analogizing to the International Standard IAS 20, Accounting/or Government Grants and Disclosure of Government Assistance (“IAS 20”). In accordance with IAS 20, an entity recognizes government grants only when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. During the three months ended November 30, 2024 and 2023, the Company received an aggregate of $50,103 and $0, respectively, and during the six months ended November 30, 2024 and 2023, the Company received an aggregate of $50,103 and $924,862, respectively; these amounts were accounted for as other income on the Company’s condensed consolidated statement of operations.

 

 

Comprehensive Income

 

ASC 220-10-15 “Reporting Comprehensive Income,” establishes standards for reporting and displaying of comprehensive income, its components and accumulated balances. Comprehensive income is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220-10-15 requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The Company does not have any items of comprehensive income in any of the periods presented.

 

Non-Controlling Interests

 

The Company reports “non-controlling interest in subsidiary” as a component of equity, separate from parent’s equity, on the Consolidated Balance Sheets. In addition, the Company’s Consolidated Statements of Operations includes “net income (loss) attributable to non-controlling interest.” There was no non-controlling interest reported during the three and six months ended November 30, 2024. During the three and six months ended November 30, 2023, the Company reported a non-controlling interest in the amount of $(92) and ($2,200), respectively, representing 50% of the income (loss) incurred by its partially owned subsidiary, Kealii Okamalu.

 

Variable Interest Entities

 

The Company’s consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and variable interest entities (“VIE”), where the Company is the primary beneficiary under the provisions of ASC 810, Consolidation (“ASC 810”). A VIE must be consolidated by its primary beneficiary when, along with its affiliates and agents, the primary beneficiary has both: (i) the power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) the obligation to absorb losses or the right to receive the benefits of the VIE that could potentially be significant to the VIE. The Company reconsiders whether an entity is still a VIE only upon certain triggering events and continually assesses its consolidated VIEs to determine if it continues to be the primary beneficiary.

 

Concentrations of Credit Risk

 

The Company maintains its cash in bank deposit accounts and other accounts, the balances of which at times may be uninsured or exceed federally insured limits. From time to time, some of the Company’s funds are also held by escrow agents; these funds may not be federally insured. The Company continually monitors its banking relationships and consequently has not experienced any losses in such accounts.

 

Advertising and Marketing Costs

 

All costs associated with advertising and promoting products are expensed as incurred. Total recognized advertising and marketing expenses were $96,709 and $103,448 for the three months ended November 30, 2024 and 2023, respectively, and $174,710 and $227,059 for the six months ended November 30, 2024 and 2023, respectively.

 

Research and Development

 

Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $281 and $431 for the three months ended November 30, 2024 and 2023, respectively, and $421 and $1,887 for the six months ended November 30, 2024 and 2023, respectively.

 

Fair Value of Financial Instruments

 

Pursuant to Accounting Standards Codification (“ASC”) No. 825–- Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheets. The carrying amounts of the Company’s cash and cash equivalents, notes receivable, convertible notes payable, accounts payable and accrued expenses, none of which is held for trading, approximate their estimated fair values due to the short-term maturities of those financial instruments.

 

 

A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

 

Level 1–- Quoted prices in active markets for identical assets or liabilities.

 

Level 2–- Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

 

Level 3–- Significant unobservable inputs that cannot be corroborated by market data.

 

Revenue Recognition

 

Revenue from the sale of cannabis products is recognized by Oasis at the point of sale, at which time payment is received, the product is delivered, and the Company’s performance obligation has been met. Management estimates an allowance for sales returns.

 

The Company also recognizes revenue from Serenity Wellness Products LLC and Serenity Wellness Growers LLC, d/b/a City Trees (“City Trees”). City Trees recognizes revenue from the sale of the following cannabis products and services to licensed dispensaries, cultivators and distributors within the State of Nevada:

 

 

Premium organic medical cannabis sold wholesale to licensed retailers

 

 

 

 

Recreational marijuana cannabis products sold wholesale to licensed distributors and retailers

 

 

 

 

Extraction products such as oils and waxes derived from in-house cannabis production

 

 

 

 

Processing and extraction services for licensed medical cannabis cultivators in Nevada

 

 

 

 

High quality cannabis strains in the form of vegetative cuttings for sale to licensed medical cannabis cultivators in Nevada

 

Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from commercial sales of products and licensing agreements by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.

 

Disaggregation of Revenue

 

The following table represents a disaggregation of revenue for the three and six months ended November 30, 2024 and 2023:

 

   

For the Three

   

For the Three

 
   

Months Ended

   

Months Ended

 
   

November 30, 2024

   

November 30, 2023

 

Cannabis Dispensary

    2,706,856       3,104,064  

Cannabis Production

    1,454,414       2,093,150  
    $ 4,161,270     $ 5,197,214  

 

   

For the Six

   

For the Six

 
   

Months Ended

   

Months Ended

 
   

November 30, 2024

   

November 30, 2023

 

Cannabis Dispensary

    5,773,932       6,412,606  

Cannabis Production

    3,192,503       3,899,135  
    $ 8,966,435     $ 10,311,741  

 

 

Basic and Diluted Earnings or Loss Per Share

 

Basic net earnings per share is based on the weighted average number of shares outstanding during the period, while fully diluted net earnings per share is based on the weighted average number of shares of common stock and potentially dilutive securities assumed to be outstanding during the period using the treasury stock method. Potentially dilutive securities consist of options and warrants to purchase common stock, and convertible debt. Basic and diluted net loss per share are computed based on the weighted average number of shares of common stock outstanding during the period. At November 30, 2024 and 2023, the Company had the following potentially dilutive instruments outstanding: at November 30, 2024, a total of 46,300,414 shares (14,549,685 issuable upon the exercise of warrants, 23,733,229 issuable upon the conversion of convertible notes payable and accrued interest, 8,000,000 shares issuable upon the conversion of stock options, and 17,500 in stock to be issued); and at November 30, 2023, a total of 73,715,637 shares (21,181,449 issuable upon the exercise of warrants, 52,516,688 issuable upon the conversion of convertible notes payable and accrued interest, and 17,500 in stock to be issued).

 

The Company uses the treasury stock method to calculate the impact of outstanding stock options and warrants. Stock options and warrants for which the exercise price exceeds the average market price over the period have an anti-dilutive effect on earnings per common share and, accordingly, are excluded from the calculations.

 

A net loss causes all outstanding stock options and warrants to be anti-dilutive. As a result, the basic and dilutive losses per common share are the same for the three months ended November 30, 2024 and 2023. For the three months ended November 30, 2024 and 2023, the Company excluded from the calculation of fully diluted earnings per share the following instruments which were anti-dilutive: shares issuable pursuant to the conversion of notes payable and accrued interest, shares issuable pursuant to the exercise of warrants, and shares of common stock issuable.

 

Income Taxes

 

The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

 

Section 280E of the Internal Revenue Code, as amended, prohibits businesses from deducting certain expenses associated with trafficking controlled substances (within the meaning of Schedule I and II of the Controlled Substances Act). The IRS has invoked Section 280E in tax audits against various cannabis businesses in the U.S. that are permitted under applicable state laws. Although the IRS has issued a clarification allowing the deduction of certain expenses, the bulk of operating costs and general administrative costs are generally not permitted to be deducted. The operations of certain of the Company’s subsidiaries are subject to Section 280E. This results in permanent differences between ordinary and necessary business expenses deemed non-deductible under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income or loss.

 

Commitments and Contingencies

 

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims brought to such legal counsel’s attention as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

 

 

Recent Accounting Pronouncements

 

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

 

Note 2: Going Concern

 

As shown in the accompanying financial statements, the Company has incurred net losses from operations resulting in an accumulated deficit of $114,275,584 as of November 30, 2024. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with revenues from operations.

 

Note 3: Accounts Receivable

 

Accounts receivable was $1,152,082 and $682,894 at November 30, 2024 and May 31, 2024, respectively. The Company had bad debt expense of $0 and $93 during the three months ended November 30, 2024 and 2023. The Company had bad debt expense of $0 and $393 during the six months ended November 30, 2024 and 2023. No allowance for doubtful accounts was necessary during the three months ended November 30, 2024 and 2023.

 

Note 4: Inventory

 

Inventory, consisting of material, overhead, labor, and manufacturing overhead, is stated at the lower of cost (first-in, first-out) or market, and consists of the following:

 

   

November 30,

   

May 31,

 
   

2024

   

2024

 

Raw materials

  $ 287,064     $ 386,803  

Finished goods

    1,518,597       1,581,770  

Total

  $ 1,805,661     $ 1,968,573  

 

Raw materials consist of cannabis plants and the materials that are used in our production process prior to being tested and packaged for consumption. Finished goods consist of pre-packaged materials previously purchased from other licensed cultivators and our manufactured edibles and extracts.

 

Note 5: Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets consisted of the following at November 30, 2024 and May 31, 2024:

 

   

November 30,

   

May 31,

 
   

2024

   

2024

 

Prepaid license fees

    7,000       14,659  

Other prepaid expenses

    32,934       34,650  

Total

  $ 39,934     $ 49,309  

 

Prepaid expenses primarily of (i) annual license fees charged by the State of Nevada; (ii) insurance costs; (iii) supplies; (iv) rent; and (v) board fees.

 

 

Note 6: Property, Plant and Equipment

 

Property, plant and equipment consisted of the following at November 30, 2024 and May 31, 2024:

 

   

November 30,

2024

   

May 31,

2024

 

Office equipment

  $ 163,126     $ 163,126  

Furniture and fixtures

    149,478       148,358  

Machinery & Equipment

    2,522,795       2,519,455  

Leasehold improvements

    2,922,156       2,911,164  

Less: accumulated depreciation

    (3,572,740 )     (3,318,550 )

Property, plant, and equipment, net

  $ 2,184,815     $ 2,423,553  

 

The Company made payments in the amounts of $16,141 and $44,248 for property and equipment during the six months ended November 30, 2024 and 2023, respectively.

 

Depreciation expense totaled $121,219 and $158,497 for the three months ended November 30, 2024 and 2023, respectively. Depreciation expense totaled $254,880 and $317,250 for the six months ended November 30, 2024 and 2023, respectively.

 

Note 7: Right of Use Assets and Liabilities Operating Leases

 

The Company has operating leases for offices and warehouses. The Company’s leases have remaining lease terms of 1 year to 10.5 years, some of which include options to extend.

 

The Company’s lease expense for the three months ended November 30, 2024 and 2023 was entirely comprised of operating leases and amounted to $140,612 and $123,408, respectively. The Company’s lease expense for the six months ended November 30, 2024 and 2023 was entirely comprised of operating leases and amounted to $278,097 and $257,611, respectively.

 

The Company’s right of use (“ROU”) asset amortization for the three months ended November 30, 2024 and 2023 was $106,422 and $89,736, respectively. The Company’s ROU asset amortization for the six months ended November 30, 2024 and 2023 was $209,922 and $186,424, respectively.

 

The Company has recorded total right of use assets of $4,384,520 and liabilities in the amount of $4,341,120 through November 30, 2024.

 

Right of use assets – operating leases are summarized below:

 

   

November 30,

2024

 

Amount at inception of leases

  $ 4,504,921  

Amount amortized

    (2,913,203 )

Prior Period Impairment of Quinn River Lease

    (205,888 )

Balance – November 30, 2024

  $ 1,385,830  

 

Operating lease liabilities are summarized below:

 

Amount at inception of leases

  $ 4,461,521  

Amount amortized

    (2,788,127 )

Balance – November 30, 2024

  $ 1,673,394  

 

Warehouse and offices

  $ 1,463,997  

Land

    205,888  

Office equipment

    3,509  

Balance – November 30, 2024

  $ 1,673,394  
         

Lease liability

  $ 1,673,394  

Less: current portion

    (484,601 )

Lease liability, non-current

  $ 1,188,793  

 

 

Maturity analysis under these lease agreements is as follows:

 

Twelve months ended November 30, 2025

  $ 676,970  

Twelve months ended November 30, 2026

    395,348  

Twelve months ended November 30, 2027

    321,828  

Twelve months ended November 30, 2028

    322,329  

Twelve months ended November 30, 2029

    263,561  

Thereafter

    155,779  

Total

  $ 2,135,815  

Less: Present value discount

    (462,421 )

Lease liability

  $ 1,673,394  

 

Note 8: Intangible Assets

 

Intangible assets consisted of the following at November 30, 2024 and May 31, 2024:

 

   

November 30, 2024

 
           

Accumulated

                 
   

Gross

   

Amortization

   

Impairment

   

Net

 

License & Customer Relations

  $ 110,000     $ (110,000 )     -       -  

Tradenames - Trademarks

    222,000       (222,000 )     -       -  

Domain Names

    28,151       (19,824 )     -       8,327  

Total

  $ 357,993     $ (351,824 )     -     $ 8,327  

 

   

May 31, 2024

 
           

Accumulated

                 
   

Gross

   

Amortization

   

Impairment

   

Net

 

License & Customer Relations

    110,000       (110,000 )     -       -  

Tradenames - Trademarks

    222,000       (222,000 )     -       -  

Domain Names

    25,993       (16,015 )     -       9,978  

Total

  $ 357,993     $ (348,015 )   $ -     $ 9,978  

 

Total amortization expense charged to operations for the three months ended November 30, 2024 and 2023 was $825 and $7,750, respectively. Total amortization expense charged to operations for the six months ended November 30, 2024 and 2023 was $1,651 and $15,501, respectively.

 

Remaining amortization expense for intangible assets as of November 30, 2024 is as follows:

2025

  $ 2,478  

2026

    3,304  

2027

    2,545  
    $ 8,327  

 

Note 9: Goodwill

 

Goodwill in the amount of $557,896 is carried on the Company’s balance sheet at November 30, 2024 and May 31, 2024 in connection with the acquisition of Alternative Solutions on June 27, 2018.

 

Goodwill Impairment Test

 

The Company assessed its intangible assets as of May 31, 2024 for purposes of determining if an impairment existed as set forth in ASC 350 – Intangibles – Goodwill and Other and ASC 360 – Property Plant and Equipment. Pursuant to ASC 360, the Company determined that the fair value of its intangible assets exceeded the carrying value of goodwill at May 31, 2024. As a result, no impairment was recorded. At November 30, 2024 and May 31, 2024, the net amount of goodwill on the Company’s balance sheet was $557,896.

 

 

Note 10: Other Assets

 

Other assets included the following as of November 30, 2024 and May 31, 2024:

 

   

November 30,

   

May 31,

 
   

2024

   

2024

 

Security deposits

    157,500       157,500  
    $ 157,500     $ 157,500  

 

Note 11: Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consisted of the following at November 30, 2024 and May 31, 2024:

 

   

November 30,

2024

   

May 31,

2024

 

Trade accounts payable

  $ 3,708,509     $ 2,508,769  

Accrued payroll and payroll taxes

    313,275       313,296  

Accrued liabilities

    378,253       533,994  

Total

  $ 4,400,037     $ 3,356,059  

 

Note 12: Due to Related Party

 

On November 1, 2024, the Company acquired and cancelled 1,125,000 shares of common stock from a board member at a cost of $40,000. These shares were valued at $0.0557 per shares, which was the closing price on the date of the cancellation; a gain in the amount of $22,663 was recorded on this transaction. The purchase price of $40,000 had not been paid at November 30, 2024.

 

Note 13: Notes Payable

 

   

November 30, 2024

   

May 31, 2024

 

Debenture 2

Debenture in the principal amount of $250,000 (the “Debenture 2”) dated December 21, 2021, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 2 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 75,758 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 2 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $10,428 on Debenture 2.

 

On May 31, 2023, the Debenture 2 was amended as follows: (1) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and Interest monthly through the maturity date.

 

On December 31, 2023, the Debenture 2 was amended as follows: The original issue discount in the amount of $187,000 was reduced to $37,500. A gain on extinguishment of debt in the amount of $111,807 was recognized in connection with this transaction, and a discount in the amount of $6,501 was recorded.

 

During the three and six months ended November 30, 2024, the Company amortized discounts on the Debenture 2 in the aggregate amount of $0 and $197, respectively. During the three and six months ended November 30, 2024, the Company made principal and interest payments in the amount of $0 and $17,917, respectively, on Debenture 2. As of November 30, 2024, Debenture 2 has been paid in full.

    -       17,917  

 

 

   

November 30, 2024

   

May 31, 2024

 

Debenture 6

Debenture in the principal amount of $500,000 (the “Debenture 6”) dated January 4, 2022, which bears interest, payable quarterly commencing nine months after issuance, at a rate of 15% per annum. Principal on Debenture 6 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 6 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,154 on Debenture 6. The Company recorded an original issue discount in the amount of $375,000 on Debenture 6.

 

On May 31, 2023, the Debenture 6 was amended as follows: (1) the maturity date was extended to October 31, 2024; (2) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and interest monthly through the maturity date.

 

On December 31, 2023, the Debenture 6 was amended as follows: The original issue discount in the amount of $375,000 was reduced to $75,000. A gain on extinguishment of debt in the amount of $402,370 was recognized in connection with this transaction, and a discount in the amount of $209,783 was recorded.

 

During the three months and six ended November 30, 2024, the Company amortized discounts in the amount of $183,263 and $193,560, respectively, on Debenture 6. During the three and six months ended November 30, 2024, the Company capitalized interest in the amount of $10,708 on Debenture 6. During the three months and six ended November 30, 2024, the Company made principal payments in the amount of $511,340 on Debenture 6 (see note 17). At November 30, 2024, all amounts due under Debenture 6 have been paid in full.

    -       500,632  
                 

Promissory Note 6 (PN 6)

PN6 in the principal amount of $250,000 (the “PN6”) dated February 22, 2024, which bears interest a rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $11,799 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments in the amount of $29,890 and $58,902, respectively, on PN6. During the three and six months ended November 30, 2024, the Company made interest payments on PN6 in the amount of $5,508 and $11,895, respectively.

    163,600       222,502  

Notes Payable

  $ 163,600     $ 741,052  

Less: Discount

    -       (193,756 )

Notes Payable, Net of Discount

  $ 163,600     $ 547,296  

 

   

November 30, 2024

   

May 31, 2024

 

Total Notes Payable, Current Portion

  $ 128,898     $ 139,345  

Total Notes Payable, Long-term Portion, net of discount

  $ 34,702     $ 407,951  

 

 

Note 14: Convertible Notes Payable

 

   

November 30, 2024

   

May 31, 2024

 

US Convertible Debenture 2 (Navy Capital Green Fund)

Convertible debenture in the principal amount of $1,000,000 (the “U.S. Convertible Debenture 2”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 2. The U.S. Convertible Debenture 2 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 2 was convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40.

 

On July 26, 2019, U.S. Convertible Debenture 2 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. convertible Debenture 2, the conversion price of U.S. Convertible Debenture 2 would be reduced to such issuance price, and the exercise price of the warrant issuable in connection with U.S. Convertible Debenture 2 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 2 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 2 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $813,724 on the U.S. Convertible Debenture 2.

 

On April 15, 2021, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $509,700 during the year ended May 31, 2021.

 

On September 15, 2022, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of debentures with a principal amount of $675,668 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $11,261 were converted to 2,410,279 shares of common stock and warrants to purchase 1,205,140 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $450,446 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $422,331 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $223,515 and $198,816, respectively.

 

On December 29, 2023, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) principal payments in the amount of $8,000 per month are due for 48 months beginning January 31, 2024, and a balloon payment in the amount of $235,658 will be due on January 31, 2028; (iv) accrued interest in the amount of $54,053 was added to the principal balance. A loss on extinguishment of debt in the amount of $344,036 was charged to operations in connection with this transaction. During the years ended May 31, 2024 and 2023, the Company accrued interest in the amounts of $37,526 and $27,717, on the U.S. Convertible Debenture 2, respectively. During the three and six months ended November 30, 2024, the Company made principal payments in the amount of $471,387 and $481,005, respectively, on the U.S. Convertible Debenture 2 (see note 17). During the three and six months ended November 30, 2024, the Company made interest payments in the amount of $6,381 on the U.S. Convertible Debenture 2. At November 30, 2024, all amounts due under U.S. Convertible Debenture 2 have been paid in full.

  $ -       481,005  

 

 

   

November 30, 2024

   

May 31, 2024

 

Canaccord Debentures

Convertible debentures payable in the aggregate principal amount of $12,012,000 (the “Canaccord Debentures”) dated December 12, 2018, which bear interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the Canaccord Debentures. The Canaccord Debentures were to mature on a date that was three years following issuance. The Canaccord Debentures were convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. The Canaccord Debentures have other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The Canaccord Debentures are unsecured obligations of the Company and rank pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. During the three months ended November 30, 2019, in two separate transactions, principal in the aggregate amount of $25,857 was converted into an aggregate of 8,081 shares of the Company’s common stock, and warrants to purchase 4,040 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement. No discount was recorded for the fair value of the warrants issued. Because the market price of the Company’s common stock was less than the conversion price on the date of issuance of the Canaccord Debentures, a discount was not recorded on the Canaccord Debentures.

 

On March 31, 2021, the Canaccord Debentures were amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; (ii) the maturity date was extended from December 12, 2021 to December 12, 2022; (iii) the mandatory conversion threshold was reduced from a daily volume weighted average trading price of greater than $4.80 per share to $2.40 per share for the preceding ten consecutive trading days; and (iv) the exercise price of the warrants issuable upon conversion was reduced from $4.40 to $1.60 and the expiration of the warrants extended until March 31, 2024. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $3,286,012 during the year ended May 31, 2021. During the year ended May 31, 2022, principal in the aggregate amount of $281,000 was converted into an aggregate of 234,167 shares of the Company’s common stock, and warrants to purchase 117,084 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement.

 

On September 15, 2022, the Canaccord Debentures were further amended as follows: (i) the conversion price of debentures with a principal amount of $7,965,278 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $132,755 were converted to 28,414,149 shares of common stock and warrants to purchase 14,207,075 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $52,53,873 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $4,547,660 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $2,623,852 and $1,923,808, respectively.

 

On December 28, 2023, the Canaccord Debentures were amended as follows: (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) the maturity date was extended to January 31, 2028; (iv) accrued interest in the amount of $186,111 was added to the principal balance and accrued interest in the amount of $465,012 was forgiven (v) Put Rights (the “Put Rights”) were granted to the debenture holders granting each debenture holder the right to require the Company to redeem all or any part of the debenture in cash at a redemption price of 60% of face value (a loss on extinguishment of debt in the amount of $1,727,071 was charged to operations in connection with this transaction); (vi) interest accruing through February 28, 2025 will be added to the principal balance rather than paid to debenture holders; (v) debenture holders were granted an additional put right in the event the Company’s cash available for debt service for any fiscal quarter exceeds $750,000, subject to pro ration, to require the Company to redeem all or any part of such debenture holder’s outstanding Canaccord Debentures in cash at a redemption price equal to the aggregate principal amount of the Canaccord Debentures being so redeemed, (vi) a provision that the Company shall redeem on the last day of each calendar month beginning March 31, 2025 a portion of the outstanding Canaccord Debentures less the amount of interest paid on such date was added; and (vii) subject to the receipt of regulatory approvals, a security interest in certain of the Company’s assets (such as licenses, inventory (including work in process), equipment (excluding equipment subject to purchase money financing) and contract rights (excluding investments in entities other than wholly owned subsidiaries)) to the holders of the Canaccord Debentures and to other holders of the Company’s debt, now or in the future, as the Company may elect was granted.

 

On January 4, 2024, debenture holders exercised Put Rights with regard to the Canaccord Debentures with a principal amount of $3,875,095, the Company made a cash payment to the debenture holders in the amount of $2,325,056 representing 60% of the principal amount of these debentures, and the principal amount of $1,550,039 representing 40% of the principal amount of these debentures was forgiven. The principal balance of the Canaccord Dentures subsequent to the January 4 Put Rights exercise was $1,544,231. Interest at the rate of 8.0% per annum on this amount will be capitalized monthly through February 28, 2025. Principal and interest payments in the amount of $28,522 will be due monthly beginning March 31, 2025 and continuing through December 31, 2027; on January 31, 2028 a balloon payment in the amount of $1,038,777 will be due. A gain on settlement of debt in the amount of $2,015,051 was recognized in connection with this transaction. During the three and six months ended November 30, 2024, the Company capitalized interest in the amounts of $32,788 and $64,930 on the Canaccord Debentures.

 

On December 27, 2024, the Company executed a Supplemental Indenture to amend that certain debenture indenture by and between the Company and Odyssey Trust Company, as Trustee, dated as of December 12, 2018, as supplemented March 31, 2021, as supplemented September 15, 2022, and as supplemented December 28, 2023, in order to amended the terms of its outstanding $1,378,778 principal amount unsecured convertible debentures Canaccord Debentures issued December 12, 2018 to provide the Company an option to redeem all outstanding Canaccord Debentures in cash at a redemption price equal to $600 per $1,000 principal amount of Canaccord Debentures; any accrued but unpaid interest through to and including the redemption date shall not be paid and shall be cancelled. See note 22.

    1,661,326       1,596,396  

 

 

   

November 30, 2024

   

May 31, 2024

 

US Convertible Debenture 1 (Navy Capital Green Co-Invest Fund)

Convertible debenture in the principal amount of $4,000,000 to a related party (the “U.S. Convertible Debenture 1”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 1. The U.S. Convertible Debenture 1 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 1 was convertible into units (the “Convertible Debenture Units”) at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. On July 26, 2019, U.S. Convertible Debenture 1 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. Convertible Debenture 1, the conversion price of U.S. Convertible Debenture 1 would be reduced to such issuance price, and the exercise price of the warrant Issuable in connection with U.S. Convertible Debenture 1 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 1 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 1 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $3,254,896 on the U.S. Convertible Debenture 1.

 

On April 15, 2021, the U.S. Convertible Debenture 1 was amended as follows: (i) the conversion price of the debenture was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $2,038,803 during the year ended May 31, 2021 in connection with the amendment.

 

On September 15, 2022, the U.S. Convertible Debenture 1 was further amended as follows: (i) the conversion price of debentures with a principal amount of $2,702,674 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $45,044 were converted to 9,641,118 shares of common stock and warrants to purchase 4,820,560 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $1,801,783 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $1,689,368 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $894,090 and $795,278, respectively.

 

On December 29, 2023, the U.S. Convertible Debenture 1 was amended as follows: (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) the maturity date was extended to January 31, 2028; (iv) accrued interest in the amount of $215,414 was added to the principal balance. A loss on extinguishment of debt in the amount of $1,376,083 was charged to operations in connection with this transaction. During the three and six months ended November 30, 2024, the Company made principal payments in the amount of $1,885,556 and $1,924,030, respectively, on the U.S. Convertible Debenture 1 (see note 17). During the three and six months ended November 30, 2024, the Company made interest payments in the amount of $25,226 on the U.S. Convertible Debenture 1. At November 30, 2024, all amounts due under U.S. Convertible Debenture 1 have been paid in full.

    -       1,924,030  
                 

Total Convertible Notes Payable

  $ 1,661,326     $ 4,001,431  

 

   

November 30, 2024

   

May 31, 2024

 

Total – Convertible Notes Payable, Current Portion

  $ 126,043     $ 302,005  

Total – Convertible Notes Payable, Long-term Portion

  $ 1,535,283     $ 3,699,426  

 

 

Note 15: Notes Payable Related Party

 

   

November 30, 2024

   

May 31, 2024

 

Promissory Note 1 (APN1)

PN1 Debenture in the principal amount of $475,000 (the “PN1”) dated January 2, 2024, which bears interest at a rate of 12% per annum. Principal and interest payments are due monthly for 36 months in the amount $15,917 beginning February 29, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN1 in the amount of $36,142 and $71,221, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN1 in the amount of $11,610 and $24,284, respectively.

  $ 362,840     $ 434,061  
                 

Promissory Note 2 (PN2)

PN2 in the principal amount of $465,000 (the “PN2”) dated January 2, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 36 months in the amount $15,582 beginning February 29, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN2 in the amount of $35,382 and $69,722, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN2 in the amount of $11,366 and $23,773, respectively.

    355,201       424,923  
                 

Promissory Note 3 (PN3)

PN3 in the principal amount of $450,000 (the “PN3”) dated February 22, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $21,239 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN3 in the amount of $53,802 and $106,023, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN3 in the amount of $9,914 and $21,410, respectively.

    294,480       400,503  
                 

Promissory Note 4 (PN4)

PN4 in the principal amount of $300,000 (the “PN4”) dated February 22, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $14,159 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN4 in the amount of $35,868 and $70,682, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN4 in the amount of $6,609 and $14,274, respectively.

    196,320       267,002  
                 

Promissory Note 5 (PN5)

PN5 in the principal amount of $350,000 (the “PN5”) dated February 22, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $16,519 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN5 in the amount of $41,487 and $82,463, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN5 in the amount of $7,711 and $16,653, respectively.

    229,040       311,503  
                 

Promissory Note 7 (PN7)

PN7 in the principal amount of $100,000 (the “PN7”) dated March 6, 2024, which bears interest at the rate of 12% per annum. Interest only payments are due quarterly in the amount of $3,500 for four quarters beginning March 29, 2024. The loan is due on February 28, 2025. During the three and six months ended November 30, 2024, the Company made principal payments on PN7 in the amount of $0. During the three and six months ended November 30, 2024, the Company made interest payments on the PN7 in the amount of $3,500 and $7,000, respectively.

    100,000       100,000  
                 

Promissory Note 8 (PN8)

PN8 in the principal amount of $134,000 (the “PN8”) dated April 30, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $6,308 beginning May 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN8 in the amount of $15,664 and $30,867, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN8 in the amount of $3,529 and $6,979, respectively.

    98,164       129,031  

 

 

   

November 30, 2024

   

May 31, 2024

 

Promissory Note 9 (PN9)

PN9 in the principal amount of $2,600,000 (the “PN9”) dated August 28, 2024. Principal in the amount of $2,200,000 automatically converted into 56,847,545 shares of the Company’s common stock on August 30,2024; the remaining principal in the amount of $400,000 bears interest at the rate of 12% per annum and is due on August 28, 2025. The conversion of the $2,200,000 in principal was at the market price per share of $0.0387 on the date of the note, and no gain or loss was recognized on this transaction. See note 17. No interest was accrued on this note during the three months ended November 30, 2024. During the three and six months ended November 30, 2024, the Company accrued interest on the PN9 in the amount of $12,000.

    400,000       -  
                 

Promissory Note 10 (PN10)

PN10 in the principal amount of $150,000 (the “PN10”) dated October 15, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $7,061 beginning November 30, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN10 in the amount of $5,561. During the three and six months ended November 30, 2024, the Company made interest payments on the PN10 in the amount of $1,500.

    144,439       -  
                 

Total

  $ 2,180,484     $ 2,067,023  

 

   

November 30, 2024

   

May 31, 2024

 

Total Notes Payable – Related Party, Current Portion

  $ 1,514,362     $ 988,472  

Total Notes Payable – Related Party, Long Term Portion

  $ 666,122     $ 1,078,551  

 

Aggregate maturities of notes payable, convertible notes payable, and notes payable – related parties as of November 30, 2024 are as follows:

 

For the twelve months ended November 30,

 

2025

  $ 1,769,303  

2026

    866,804  

2027

    309,042  

2028

    1,060,261  

Total

  $ 4,005,410  

 

Note 16: Lease Liabilities - Financing Leases

 

   

November 30, 2024

   

May 31, 2024

 

Financing lease obligation under a lease agreement for extraction equipment dated March 14, 2022 in the original amount of $359,900 payable in forty-eight monthly installments of $10,173 including interest at the rate of 15.89%. During the three and six months ended November 30, 2024, the Company made principal payments on this lease obligation in the amounts of $23,168 and $47,266, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on this lease obligation in the amounts of $6,421 and $13,772, respectively.

  $ 145,851     $ 193,117  
                 

Financing lease obligation under an agreement for equipment dated June 20, 2022 in the original amount of $12,400 payable in forty-eight monthly installments of $350 including interest at a rate of 15.78%. During the three and six months ended November 30, 2024, the Company made principal payments on this lease obligation in the amounts of $456 and $901, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on this lease obligation in the amounts of $69 and $149, respectively.

  $ 2,458       3,359  
                 

Total

  $ 148,309     $ 196,476  
                 

Current portion

  $ 108,410     $ 96,224  

Long-term maturities

    39,899       100,252  

Total

  $ 148,309     $ 196,476  

 

 

Aggregate maturities of lease liabilities – financing leases as of November 30, 2024 are as follows:

 

For the period ended November 30,

 

2025

  $ 108,410  

2026

    39,899  

Total

  $ 148,309  

 

Note 17: Stockholders Equity

 

The Company’s authorized capital stock consists of 345,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share.

 

Common stock transactions for the six months ended November 30, 2024

 

On August 30, 2024, the Company issued 56,847,545 shares of common stock pursuant to the conversion $2,200,000 of the principal amount of a note payable (see note 15). No gain or loss was recorded on this transaction as the conversion occurred according to the terms of the note.

 

On September 10, 2024, the Company settled three notes payable in the aggregate principal amount of $2,868,282 for a cash payment in the amount of $2,600,000. In addition, the noteholders returned for cancellation a total of 15,488,901 shares of the Company’s common stock and warrants to purchase 6,177,216 shares of the Company’s common stock. The cancelled shares were valued at the closing price of the Company’s common stock on the date of the cancellation, or $0.044 per share for a total value of $681,510. The warrants were valued at $4,136 using the Black-Sholes valuation model. A gain in the amount of $949,793 was recorded on this transaction. See note 18.

 

On November 1, 2024, the Company acquired and cancelled 1,125,000 shares of common stock from a board member at a cost of $40,000. These shares were valued at $0.0557 per shares, which was the closing price on the date of the cancellation; the amount of $22,663 was charged to additional paid-in capital on this related party transaction. The purchase price of $40,000 was unpaid at November 30, 2024. (see note 12)

 

Common stock transactions for the six months ended November 30, 2023

 

None.

 

Warrants

 

Warrants for the six months ended November 30, 2024:

 

The following table summarizes the significant terms of warrants outstanding at November 30, 2024. This table does not include the unit warrants. See Unit Warrants section below.

 

Range of

exercise

Prices

   

Number of

warrants

Outstanding

   

Weighted

average

remaining

contractual

life (years)

   

Weighted

average

exercise

price of

outstanding

Warrants

   

Number of

warrants

Exercisable

   

Weighted

average

exercise

price of

exercisable

Warrants

 
                                             
$ 0.40-0.4125       14,549,685       1.12     $ 0.40       14,549,685     $ 0.40  
          14,549,685       1.12     $ 0.40       14,549,685     $ 0.40  

 

 

Transactions involving warrants are summarized as follows. This table does not include the unit warrants. See Unit Warrants section below.

 

   

Number of

Shares

   

Weighted Average

Exercise Price

 

Warrants outstanding at May 31, 2023

    21,181,449     $ 0.40  

Granted

    -     $ -  

Exercised

    -     $ -  

Cancelled / Expired

    (454,548 )   $ 0.41  

Warrants outstanding at May 31, 2024

    20,726,901     $ 0.40  

Granted

               

Exercised

    -     $ -  

Cancelled / Expired

    (6,177,216 )   $ 0.40  

Warrants outstanding at November 30, 2024

    14,549,685     $ 0.40  

 

Stock Options

 

Stock options for the six months ended November 30, 2024

 

During the six months ended November 30, 2024, 41,667 options issued to the Company’s previous Chief Science Officer expired.

 

The following table summarizes the significant terms of options outstanding at November 30, 2024.

 

Range of

exercise

Prices

   

Number of

options

Outstanding

   

Weighted

average

remaining

contractual

life (years)

   

Weighted

average

exercise

price of

outstanding

Options

   

Number of

Options

Exercisable

   

Weighted

average

exercise

price of

exercisable

Option

 
                                             
$ 0.039       8,000,000       9.15     $ 0.039       2,520,832     $ 0.039  

 

Transactions involving options are summarized as follows.

 

   

Number of

Shares

   

Weighted Average

Exercise Price

 

Options outstanding at May 31, 2024

    8,041,667     $ 0.039  

Granted

    -     $ -  

Exercised

    -     $ -  

Cancelled / Expired

    (41,667 )   $ -  

Options outstanding at November 30, 2024

    8,000,000     $ 0.039  

 

The Company valued options using the Black-Scholes valuation model utilizing the following variables during the six months ended November 30, 2024:

 

   

November 30,

 
   

2024

 

Volatility

    269.44 %

Dividends

  $ -  

Risk-free interest rates

    3.8 %

Expected term (years)

    5.00  

 

 

Stock options for the three months ended November 30, 2023

 

None.

 

During the three and six months ended November 30, 2024, the Company charged $23,382 and $52,184, respectively, to stock-based compensation expense, in connection with the vesting of stock options. There were no comparable charges during the three and six months ended November 30, 2023.

 

The aggregate intrinsic value of options outstanding and exercisable at November 30, 2024 and 2023 was $16,637 and $0, respectively. Aggregate intrinsic value represents the difference between the fair value of the Company’s stock on the last day of the fiscal period, which was $0.045 as of November 30, 2024, and the exercise price multiplied by the number of options outstanding and exercisable.

 

Note 18: Gain on Settlement of Debt

 

On August 28, 2024, the Company raised $2,600,000 in cash from the issuance of PN9. See note 13. On August 30, 2024, the Company issued 56,847,545 shares of common stock pursuant to the conversion $2,200,000 of the principal amount of a note payable (see note 15). No gain or loss was recorded on this transaction as the conversion occurred according to the terms of the note.

 

On September 10, 2024, the Company utilized the proceeds of PN9 to settle three notes payable in the aggregate principal amount of $2,868,282 for a cash payment in the amount of $2,600,000. See note 17. In addition, the noteholders returned for cancellation a total of 15,488,901 shares of the Company’s common stock and warrants to purchase 6,177,216 shares of the Company’s common stock. The cancelled shares were valued at the closing price of the Company’s common stock on the date of the cancellation, or $0.044 per share for a total value of $681,510. The warrants were valued at $4,136 using the Black-Sholes valuation model. A gain in the amount of $949,793 was recorded on this transaction.

 

The Company valued the warrants using the Black-Scholes valuation model utilizing the following variables during the six months ended November 30, 2024:

 

   

November 30,

 
   

2024

 

Volatility

    104.68 %

Dividends

  $ -  

Risk-free interest rates

    4.36 %

Expected term (years)

    1.05  

 

Note 19: Related Party Transactions

 

As of November 30, 2024 and May 31, 2024, the Company had accrued salary due to Michael Abrams, a former officer of the Company prior to his September 1, 2015 termination, in the amount of $16,250.

 

During the three months ended November 30, 2024, the Company made payments of $10,000 to one of its three directors and a payment of $5,000 to one director for their participation on the Board, for a total of $15,000. The Company also made a payment of $5,000 to one director for consulting fees. During the six months ended November 30, 2024, the Company made payments of $20,000 to one of its three and directors and $15,000 to one of its directors for their participation on the Board, for a total of $35,000; the Company also made a payment of $5,000 to one of its directors for consulting fees.

 

The Company’s CEO has waived his board fees for the period.

 

On November 1, 2024, the Company acquired and cancelled 1,125,000 shares of common stock from a board member at a cost of $40,000. These shares were valued at $0.0557 per shares, which was the closing price on the date of the cancellation. The amount of $22,663 was charged to additional paid-in capital on this transaction. The purchase price of $40,000 had not been paid at November 30, 2024.

 

On August 28, 2024 the Company issued PN9, a note payable to a related party, in the principal amount of $2,600,000. Principal in the amount of $2,200,000 automatically converted into 56,847,545 shares of the Company’s common stock on August 30,2024; the remaining principal in the amount of $400,000 bears interest at the rate of 12% per annum and matures on August 28, 2025. See note 15.

 

 

On October 15, 2024 the Company issued PN10, a note payable to a related party, in the principal amount of $150,000. Principal PN10 bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $7,061 beginning November 30, 2024. See note 15.

 

At November 30, 2024, there are nine related party notes outstanding with a total principal amount of $2,180,484. See note 15.

 

Note 20: Income Taxes

 

The following table summarizes the Company’s income tax accrued for the three months ended November 30, 2024 and 2023:

 

The Company accounts for income taxes under FASB ASC 740-10, which provides for an asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized based on anticipated future tax consequences, using currently enacted tax laws, attributed to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts calculated for income tax purposes.

 

The components of the income tax provision include:

 

   

Three Months Ended November 30,

 
   

2024

   

2023

 

Revenue

  $ 4,161,270     $ 5,197,214  

Directly attributable costs

    (1,928,995 )     (3,025,595 )

Deferred

    2,232,275       2,171,619  

Tax rate

    21 %     21 %

Tax expense

  $ 468,778     $ 456,040  

 

   

Six Months Ended November 30,

 
   

2024

   

2023

 

Revenue

  $ 8,966,435     $ 10,311,741  

Directly attributable costs

    (4,234,657 )     (5,866,196 )

Deferred

    4,731,778       4,445,545  

Tax rate

    21 %     21 %

Tax expense

  $ 993,674     $ 933,564  

 

Note: Change in uncertain tax position with all tax expense recorded in current year due to change in estimate. No prior year net operating loss was considered.

 

Due to the accrual of taxes related to Section 280E of the Internal Revenue Code, as amended, the Company has an uncertain tax accrual that is currently being expensed as a change in estimate. The Company has net operating losses that it believes are available to it to offset this expense; however, there can be no assurance under current interpretations of tax laws for cannabis companies that the Company will be allowed to use these net operating losses to offset Section 280E tax expenses.

 

During the three months ended November 30, 2024, the Company received a notification from the Internal Revenue Service (“IRS”) that the Company has been assessed the amount of $111,441, consisting of estimated tax owed of $71,959, penalties of $26,771, and interest of $12,711 for failure to file its tax return for the year ended May 31, 2022. The Company made a good faith payment to the IRS in the amount of $5,000 pursuant to this notice during the three months ended November 30, 2024. The accounting firm responsible for this tax filing on behalf of the Company has been terminated, and the Company is pursuing this firm for recovery of penalties and interest assessed.

 

Note 21: Commitments and Contingencies

 

Legal Matters

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of the date of filing of this report, there were no pending or threatened lawsuits.

 

 

Lease Arrangements

 

The Company leases several facilities for office, warehouse, and retail space. Currently lease commitments are as follows:

 

 

A lease that commenced in February 2019 for 1,400 square feet of office space located at 1718 Industrial Road, Las Vegas, NV 89102, for a term of eighteen months, and for rent of $1,785 per month. In June 2020, this lease was extended to November 30, 2022, with the monthly rent increasing to $1,867 until September 2021, after which time it will be subject to annual increases of 3%. The lease was extended again on April 1, 2022, effective September 1, 2022 until November 30, 2024. The monthly rent increased on September 1, 2022 to $2,084. Effective September 1, 2024, the monthly rent was increased to $2,310, and the term of the lease was extended to November 30, 2029.

 

 

 

 

A lease that commenced January 2018 for 1,000 square feet of storefront space plus 5,900 square feet of warehouse space located at 1800 Industrial Road, Suites 102, 160, and 180, Las Vegas, NV 89102, for a term of five years and for initial base rent of $7,500 per month, with annual increases of 3%. In February 2020, this lease was extended to February 28, 2030 and the monthly rent was increased by $600. At November 30, 2024, the monthly rent on this lease was $10,679.

 

 

 

 

A lease that commenced in February 2019 for 2,504 square feet of office space located at 1800 Industrial Road, Suite 100, Las Vegas, NV 89102 for a term of eighteen months and for initial rent of $3,210 per month, with annual increases of 4%. In February 2020, this lease was extended to February 28, 2030, and the lease was modified to include annual rent increases of 3%. At November 30, 2024, the monthly rent on this lease was $3,758.

 

 

 

 

A lease that commenced in January 2016 for 22,000 square feet of warehouse space located at 203 E. Mayflower Avenue, North Las Vegas, NV 89030 for a term of five years and initial rent of $11,000 per month, which amount increased to $29,000 per month on January 1, 2020. In June 2020, this lease was extended to February 28, 2026, and the monthly rent was amended as follows: $25,000 for the months of April, May, and June 2020; $22,500 for the months of March 2021 through February 2022; $23,175 for the months of March 2022 through February 2023; 23,870 for the months of March 2023 through February 2024; $24,586 for the months of March 2024 through February 2025; and $25,323 for the months of March 2025 through February 2026.

 

 

 

 

A lease that commenced in October 2023 for 2,547 square feet of office space located at 516 S. 4th Street, Las Vegas, NV 89101 for a term of five years and initial rent of $5,083 per month through September 30, 2024. The monthly rent will increase to $5,236 for the months of October 2024 through September 2025; $5,393 for the months of October 2025 through September 2026; $5,554 for the months of October 2026 through September 2027; and $5,721 for the months of October 2027 through September 2028.

 

In connection with the Company’s planned Colorado operations, on April 17, 2015, pursuant to an Industrial Lease Agreement (the “Lease”), CLS Labs Colorado leased 14,392 square feet of warehouse and office space (the “Leased Real Property”) in a building in Denver, Colorado where certain intended activities, including growing, extraction, conversion, assembly and packaging of cannabis and other plant materials, are permitted by and in compliance with state, city and local laws, rules, ordinances and regulations. The Lease had an initial term of seventy-two (72) months and provided CLS Labs Colorado with two options to extend the term of the lease by up to an aggregate of ten (10) additional years. In August 2017, as a result of the Company’s decision to suspend its proposed operations in Colorado, CLS Labs Colorado asked its landlord to be relieved from its obligations under the Lease.

 

In August 2017, the Company’s Colorado subsidiary received a demand letter from its Colorado landlord requesting the forfeiture of the $50,000 security deposit, $10,000 in expenses, $15,699 in remaining rent due under the lease agreement and $30,000 to buy out the remaining amounts due under the lease. The $50,000 security deposit was forfeited to the Landlord and the Landlord has made no additional demands for payment or attempts at collection since August of 2017. These expenses, which are a liability of the Company’s Colorado subsidiary, have been accrued on the balance sheet as of November 30, 2024.

 

Note 22: Subsequent Events

 

Termination of Chief Operating Officer

 

On December 17, 2024, the Company terminated the employment of Joseph Ramalho, its Chief Operating Officer. 

 

 

Amendments to Convertible Debentures 

 

On December 27, 2024, the Company executed a Supplemental Indenture to amend that certain debenture indenture by and between the Company and Odyssey Trust Company, as Trustee, dated as of December 12, 2018, as supplemented March 31, 2021, as supplemented September 15, 2022, and as supplemented December 28, 2023 (collectively, the “Debenture Indenture”), in order to amended the terms of its outstanding $1,378,778 principal amount unsecured convertible debentures (the “December Debentures”) issued December 12, 2018 to provide the Company an option to redeem all outstanding December Debentures in cash at a redemption price equal to $600 per $1,000 principal amount of December Debentures; any accrued but unpaid interest through to and including the redemption date shall not be paid and shall be cancelled. See note 14.

 

Secured Promissory Notes

 

On January 7, 2025, the Company entered into four secured promissory notes in the aggregate amount of $1,000,000.  These notes bear interest at the rate of 12%, are payable in 24 equal monthly installments beginning January 31, 2025, and are due on December 31, 2026Three of these notes with an aggregate principal amount of $900,000 are payable to related parties.

 

 

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.

 

History

 

We were incorporated on March 31, 2011 as Adelt Design, Inc. to manufacture and market carpet binding art. Production and marketing of carpet binding art never commenced. On November 20, 2014, we adopted amended and restated articles of incorporation, thereby changing our name to CLS Holdings USA, Inc. On April 29, 2015, we entered into a merger agreement with CLS Labs and a newly-formed, wholly owned subsidiary of the Company (the “Merger Sub”) and effected the Merger (the “Merger”). Upon the consummation of the Merger, the separate existence of the Merger Sub ceased and CLS Labs, the surviving corporation in the Merger, became a wholly owned subsidiary of the Company, with the Company acquiring the stock of CLS Labs. As a result of the Merger, we acquired the business of CLS Labs and abandoned our previous business.

 

CLS Labs was originally incorporated in the state of Nevada on May 1, 2014 under the name RJF Labs, Inc. before changing its name to CLS Labs, Inc. on October 24, 2014. It was formed to commercialize a proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter.

 

We have been issued a U.S. patent with respect to our proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter. We have not commercialized our proprietary process and due to the current Nevada State laws governing these types of extraction methods, we do not intend to commercialize the proprietary process in the future. CLSH is engaged in attempting to find a buyer for the patent who may be able to use it in another state or another application.

 

Current Business and Outlook

 

We generate revenues through: (i) our retail dispensary (Oasis), and (ii) our City Trees cultivation and processing of cannabis and wholesale of cannabis-related products for Oasis and third-parties. We continue to explore opportunities for growth through the acquisition of companies, the creation of joint ventures, licensing agreements, and fee-for-service arrangements with growers and dispensaries of cannabis products. We believe that we can ultimately establish a position as one of the premier cannabinoid extraction and processing companies in the industry. We have created our own brand of concentrates for consumer use, which we sell wholesale to cannabis dispensaries. We are attempting to create a “gold standard” national brand by standardizing the testing, compliance and labeling of our products in an industry currently comprised of small, local businesses with erratic and unreliable product quality, testing practices and labeling.

 

Finally, we intend to grow through select acquisitions in secondary and tertiary markets, targeting newly regulated states that we believe offer a competitive advantage. Our goal at this time is to become a successful regional cannabis company.

 

Results of Operations for the Three Months Ended November 30, 2024 and 2023

 

The table below sets forth our selected expenses as a percentage of revenue for the applicable periods:

 

   

Three Months

Ended

   

Three Months

Ended

 
   

November 30, 2024

   

November 30, 2023

 

Revenue

    100 %     100 %

Cost of Goods Sold

    57 %     58 %

Gross Margin

    43 %     42 %

Selling, General, and Administrative Expenses

    50 %     50 %
                 

Interest expense

    7 %     8 %

Provision for Income Tax

    11 %     8 %

 

 

The table below sets forth certain statistical and financial highlights for the applicable periods:

 

   

Three Months

Ended

   

Three Months

Ended

 
   

November 30, 2024

   

November 30, 2023

 

Number of Customers Served (Dispensary)

    57,152       68,586  

Revenue

  $ 4,161,270     $ 5,197,214  

Gross Profit

  $ 1,772,025     $ 2,171,619  

Selling, General, and Administrative Expenses

  $ 2,095,099     $ 2,606,918  

 

Revenues

 

We had revenue of $4,161,270 during the three months ended November 30, 2024, a decrease of $1,035,944, or 10%, compared to revenue of $5,197,214 during the three months ended November 30, 2023. Our cannabis dispensary accounted for $2,706,856, or 65%, of our revenue for the three months ended November 30, 2024, a decrease of $397,208, or 13%, compared to $3,104,064 during the three months ended November 30, 2023. Dispensary revenue decreased during the second quarter of fiscal year 2025 because our average sales per day decreased from $34,111 during the first quarter of fiscal year 2024 to $29,746 during the first quarter of fiscal year 2025. Our cannabis production accounted for $1,454,414, or 35%, of our revenue for the three months ended November 30, 2024, a decrease of $638,736 or 31%, compared to $2,093,150 for the three months ended November 30, 2023.

 

Cost of Goods Sold

 

Our cost of goods sold for the three months ended November 30, 2024 was $2,389,2445, a decrease of $720,055, or 12%, compared to cost of goods sold of $3,025,595 for the three months ended November 30, 2023. The decrease in cost of goods sold for the three months ended November 30, 2024 was primarily due to a decrease in sales. Cost of goods sold was 57.4% of sales during the three months ended November 30, 2024 resulting in a gross margin of 42.6%. Cost of goods sold was 58.2% of sales during the three months ended November 30, 2023 resulting in a gross margin of 41.8%. Cost of goods sold during the second quarter of the 2025 fiscal year primarily consisted of product cost of $1,842,336, labor and overhead of $460,250, supplies and materials of $83,659, and licenses and fees of $3,000. Cost of goods sold during the second quarter of the 2024 fiscal year primarily consisted of product cost of $2,478,302, labor and overhead of $417,254, supplies and materials of $124,474, and licenses and fees of $8,475.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses, or SG&A, decreased by $511,819, or approximately 10%, to $2,095,099 during the three months ended November 30, 2024, compared to $2,606,918 for the three months ended November 30, 2023. The decrease in SG&A expenses for the three months ended November 30, 2024 was primarily due to our across-the-board cost-cutting efforts.

 

SG&A expense during the three months ended November 30, 2024 was primarily attributable to an aggregate of $1,579,192 in costs associated with operating the Oasis LLCs, a decrease of $625,926 compared to $2,205,118 during the three months ended November 30, 2023. The major components of the decrease were as follows: professional fees of $40,053 compared to $186,144; office and facilities expenses of $444,946 compared to $525,014; payroll and related costs of $1,102,732 compared to $1,170,765; sales and marketing costs of $96,709 compared to $103,048; travel of $63,274 compared to $131,426; insurance costs of $69,563 compared to $122,069; and taxes & licenses of $133,036 compared to $181,457. The amount of SG&A expenses allocated to cost of sales during the period also increased from $328,172 to $444,885, further reducing the net amount of SG&A expenses. There were no categories of SG&A expenses within the Oasis LLCs that increased during the period compared to the prior year.

 

Finally, SG&A increased by $114,108 during the three months ended November 30, 2024 as a result of an increase in the expenses associated with the ongoing implementation of other aspects of our business plan and our general corporate overhead to $401,800 from $515,908 during the three months ended November 30, 2023. The major component of this increase compared to the second quarter of fiscal 2025 was an increase professional fees in the amount of $95,732 related to our refinancing efforts.

 

Interest Expense, Net

 

Our interest expense was $295,715 for the three months ended November 30, 2024, a decrease of $115,126, or 13%, compared to $410,841 for the three months ended November 30, 2023. The decrease consisted primarily of a decrease in the amount of $128,498 related to interest on our notes and debentures due to decreased principal balances. This decrease was partially offset by an increase in the amortization of discounts on our notes payable in the amount of $20,741.

 

 

Employee Retention Tax Credit

 

During the three months ended November 30, 2023, the Company received the amount of $50,103 under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). This amount was recorded as other income. There was no comparable transaction in the current period.

 

Gain on settlement of debt

 

During the three months ended November 30, 2023, we recorded a gain on settlement of debt in the amount of $949,793 related to the payment of notes payable in the principal amount of $2,868,282 for a cash payment in the amount of $2,600,000. In addition, the noteholders returned for cancellation a total of 15,488,901 shares of the Company’s common stock and warrants to purchase 6,177,216 shares of the Company’s common stock. The cancelled shares were valued at the closing price of the Company’s common stock on the date of the cancellation, or $0.044 per share for a total value of $677,374. There was no comparable transaction in the prior period.

 

Provision for Income Taxes

 

We recorded a provision for income taxes in the amount of $468,778 during the three months ended November 30, 2024 compared to $456,040 during the three months ended November 30, 2023, an increase of $12,738 pr 1%. Although we have net operating losses that we believe are available to us to offset this entire tax liability, which arises under Section 280E of the Code because we are a cannabis company, as a conservative measure, we have accrued this liability.

 

Net Loss

 

For the reasons above, our net loss for the three months ended November 30, 2024 was $87,671 compared to a net loss of $1,302,180 for the three months ended November 30, 2023, a decrease of $1,214,601, or 69%.

 

Non-Controlling Interest

 

During the three months ended November 30, 2024 and 2023, the income (loss) associated with the non-controlling interest in Kealii Okamalu was ($0) and ($92), respectively. This amount is comprised of the third-party portion of the operating loss of the Quinn River Joint Venture and our loss on equity investment.

 

Net Loss Attributable to CLS Holdings USA, Inc.

 

Our net loss attributable to CLS Holdings USA, Inc. for the three months ended November 30, 2024 was $87,671 compared to a net loss of $1,302,272 for the three months ended November 30, 2023, a decrease of $1,214,601 or 48%.

 

Results of Operations for the Six Months Ended November 30, 2024 and 2023

 

The table below sets forth our selected expenses as a percentage of revenue for the applicable periods:

 

   

Six Months

Ended

   

Six Months

Ended

 
   

November 30, 2024

   

November 30, 2023

 

Revenue

    100 %     100 %

Cost of Goods Sold

    57 %     58 %

Gross Margin

    43 %     42 %

Selling, General, and Administrative Expenses

    48 %     50 %
                 

Interest expense

    5 %     8 %

Provision for Income Tax

    11 %     8 %

 

 

The table below sets forth certain statistical and financial highlights for the applicable periods:

 

   

Six Months

Ended

   

Six Months

Ended

 
   

November 30, 2024

   

November 30, 2023

 

Number of Customers Served (Dispensary)

    123,409       140,152  

Revenue

  $ 8,966,435     $ 10,311,741  

Gross Profit

  $ 3,820,294     $ 4,445,545  

Selling, General, and Administrative Expenses

  $ 4,279,932     $ 5,336,818  

 

Revenues

 

We had revenue of $8,966,435 during the six months ended November 30, 2024, a decrease of $1,345,306, or 13%, compared to revenue of $10,311,741 during the six months ended November 30, 2023. Our cannabis dispensary accounted for $5,773,932, or 64%, of our revenue for the six months ended November 30, 2024, a decrease of $638,674, or 10%, compared to $6,412,606 during the six months ended November 30, 2023. Dispensary revenue decreased during the second quarter of fiscal year 2025 because our average sales per day decreased from $35,042 during the second quarter of fiscal year 2024 to $31,552 during the second quarter of fiscal year 2025. Our cannabis production accounted for $3,192,503, or 35%, of our revenue for the six months ended November 30, 2024, a decrease of $706,632 or 18%, compared to $3,899,135 for the six months ended November 30, 2023.

 

Cost of Goods Sold

 

Our cost of goods sold for the six months ended November 30, 2024 was $5,146,141, a decrease of $720,055, or 12%, compared to cost of goods sold of $5,866,196 for the six months ended November 30, 2023. The decrease in cost of goods sold for the six months ended November 30, 2024 was primarily due to a decrease in sales. Cost of goods sold was 57.4% of sales during the six months ended November 30, 2024 resulting in a gross margin of 42.6%. Cost of goods sold was 56.9% of sales during the six months ended November 30, 2023 resulting in a gross margin of 43.1%. Cost of goods sold during the second quarter of the 2025 fiscal year primarily consisted of product cost of $4,054,387, labor and overhead of $911,484, supplies and materials of $172,612, and licenses and fees of $7,658. Cost of goods sold during the second quarter of the 2024 fiscal year primarily consisted of product cost of $2,478,302, labor and overhead of $417,254, supplies and materials of $124,474, and licenses and fees of $8,475.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses, or SG&A, decreased by $1,056,886, or approximately 20%, to $4,279,932 during the six months ended November 30, 2024, compared to $5,336,818 for the six months ended November 30, 2023. The decrease in SG&A expenses for the six months ended November 30, 2024 was primarily due to our across-the-board cost-cutting efforts.

 

SG&A expense during the six months ended November 30, 2024 was primarily attributable to an aggregate of $3,280,715 in costs associated with operating the Oasis LLCs, a decrease of $1,130,283 compared to $4,410,998 during the six months ended November 30, 2023. The major components of the decrease were as follows: professional fees of $82,553 compared to $417,016; office and facilities expenses of $898,094 compared to $1,075,350; payroll and related costs of $2,215,895 compared to $2,342,484; sales and marketing costs of $173,165 compared to $218,509; travel of $153,320 compared to $231,796; insurance costs of $153,909 compared to $219,736; and taxes & licenses of $292,618 compared to $369,043. The amount of SG&A expenses allocated to cost of sales during the period also increased from $691,098 to $848,143, further reducing the net amount of SG&A expenses. There were no categories of SG&A expenses within the Oasis LLCs that increased during the period compared to the prior year.

 

Finally, SG&A increased by $73,397 during the six months ended November 30, 2024 as a result of an increase in the expenses associated with the ongoing implementation of other aspects of our business plan and our general corporate overhead to $999,218 from $925,821 during the six months ended November 30, 2023. The major component of this increase compared to the second quarter of fiscal 2025 was an increase professional fees in the amount of $129,394 related to our refinancing efforts.

 

 

Interest Expense, Net

 

Our interest expense was $455,118 for the six months ended November 30, 2024, a decrease of $413,195, or 48%, compared to $868,313 for the six months ended November 30, 2023. The decrease consisted primarily of a decrease in the amount of $205,794 related to interest on our notes and debentures due to decreased principal balances; a decrease of $68,513 in interest in short-term financing; and a decrease of $131,680 in amortization of the discount on notes payable.

 

Employee Retention Tax Credit

 

During the six months ended November 30, 2024, the Company received the amount of $50,103 under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) compared to $934,862 during the prior period, a decrease of $874,759 or 95%.

 

Gain on settlement of debt

 

During the six months ended November 30, 2024, we recorded a gain on settlement of debt in the amount of $949,793 related to the payment of notes payable in the principal amount of $2,868,282 for a cash payment in the amount of $2,600,000. In addition, the noteholders returned for cancellation a total of 15,488,901 shares of the Company’s common stock and warrants to purchase 6,177,216 shares of the Company’s common stock. The cancelled shares were valued at the closing price of the Company’s common stock on the date of the cancellation, or $0.044 per share for a total value of $677,374. There was no comparable transaction in the prior period.

 

Gain on settlement of accounts payable

 

During the six months ended November 30, 2023, we settled an outstanding vendor account in the amount of $8,375 for a cash payment of $4,000 representing a gain in the amount of $4,375. There was no comparable transaction in the current period.

 

Provision for Income Taxes

 

We recorded a provision for income taxes in the amount of $993,674 during the six months ended November 30, 2024 compared to $933,564 during the six months ended November 30, 2023, an increase of $60,110 or 6%. Although we have net operating losses that we believe are available to us to offset this entire tax liability, which arises under Section 280E of the Code because we are a cannabis company, as a conservative measure, we have accrued this liability.

 

Net Loss

 

For the reasons above, our net loss for the six months ended November 30, 2024 was $908,534 compared to a net loss of $1,763,913 for the six months ended November 30, 2023, a decrease of $857,579, or 49%.

 

Non-Controlling Interest

 

During the six months ended November 30, 2024 and 2023, the income (loss) associated with the non-controlling interest in Kealii Okamalu was ($0) and ($2,200), respectively. This amount is comprised of the third-party portion of the operating loss of the Quinn River Joint Venture and our loss on equity investment.

 

Net Loss Attributable to CLS Holdings USA, Inc.

 

Our net loss attributable to CLS Holdings USA, Inc. for the six months ended November 30, 2024 was $908,534 compared to a net loss of $1,766,113 for the six months ended November 30, 2023, a decrease of $857,579 or 49%.

 

 

Non-GAAP Measures

 

EBITDA and Adjusted EBITDA are non-GAAP financial performance measures and should not be considered as alternatives to net income(loss) or any other measure derived in accordance with GAAP. These non-GAAP measure have limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of our financial results as reported in accordance with GAAP. Because not all companies use identical calculations, these presentations may not be comparable to other similarly titled measures of other companies. As required by the rules of the SEC, we provide below a reconciliation of these non-GAAP financial measures contained herein to the most directly comparable measure under GAAP. Management believes that EBITDA provides relevant and useful information, which is widely used by analysts, investors and competitors in our industry as well as by our management. Management also believes that adjusting EBITDA for the effects of non-recurring transactions may provide insight into the nature of the core business. By providing these non-GAAP profitability measure, management intends to provide investors with a meaningful, consistent comparison of our profitability measures for the periods presented.

 

   

Three Months Ended

November 30, 2024

   

Three Months Ended

November 30, 2023

 

Net Loss attributable to CLS Holdings, Inc.

  $ (87,671 )   $ (1,302,272 )

Add:

               

Interest expense, net

    295,715       410,841  

Provision for taxes

    468,778       456,040  

Depreciation and amortization

    122,043       165,874  

EBITDA (1)

  $ 798,865     $ 269,517  

Less non-recurring gains and losses:

               

Gain on settlement of debt

  $ (949,793 )   $ -  

Employee retention tax credit

    (50,103 )     -  

Adjusted EBITDA (2)

  $ (201,031 )   $ 269,517  

 

   

Six Months Ended

November 30, 2024

   

Six Months Ended

November 30, 2023

 

Net Loss attributable to CLS Holdings, Inc.

  $ (908,834 )   $ (1,766,113 )

Add:

               

Interest expense, net

    455,118       868,313  

Provision for taxes

    993,674       933,564  

Depreciation and amortization

    256,530       332,748  

EBITDA (1)

  $ 796,788     $ 368,512  

Less non-recurring gains and losses:

               

Gain on settlement of debt

  $ (949,793 )   $ -  

Gain on settlement of accounts payable

    -       (4,375 )

Employee retention tax credit

    (50,103 )     (924,862 )

Adjusted EBITDA (2)

  $ (203,108 )   $ (560,725 )

 

 

(1)

Net loss plus interest, taxes, depreciation, and amortization.

 

(2)

EBITDA adjusted for non-recurring gains, losses, and impairments.

 

 

Liquidity and Capital Resources

 

Since our inception we have funded our operations and capital spending primarily through the issuance of debt and common stock. At November 30, 2024, we had cash of $592,584 and a working capital deficit of $13,116,227; at January 8, 2025, we had cash of $1,864,918. We generated cash flow from operating activities of $468,336 for the six months ended November 30, 2024, compared to $1,004,631 for the six months ended November 30, 2023. As of November 30, 2024, we had an accumulated deficit of $114,275,584. The Company’s auditors have included a going concern qualification in their audit report for the years ended May 31, 2024 and 2023.

 

During the past two years, we have been involved in a focused effort to reduce our debt burden through a combination of settlements, restructurings, principal payments, and conversions of debt to common stock. The following table illustrates the results of these efforts:

 

Principal balance of debt:

 

   

November 30,

2024

   

August 31,

2024

   

May 31,

2024

   

May 31,

2023

   

May 31,

2022

 

Convertible notes payable including related party

  $ 1,661,326     $ 3,985,481     $ 4,001,431     $ 7,606,102     $ 19,448,821  

Current portion

  $ 126,043     $ 375,025     $ 302,005     $ 3,853,051     $ 9,448,821  
                                         

Notes Payable and Debentures

  $ 163,600     $ 704,830     $ 741,052     $ 3,472,661     $ 4,375,000  

Current portion

  $ 128,898     $ 125,107     $ 139,345     $ 1,439,584     $ -  
                                         

Notes Payable, Related Party

  $ 2,180,484     $ 2,254,750     $ 2,067,023     $ -     $ -  

Current portion

  $ 1,514,362     $ 1,415,392     $ 988,472     $ -     $ -  
                                         

Total

  $ 4,005,410     $ 6,945,061     $ 6,809,506     $ 11,981,102     $ 23,823,821  

Current portion

  $ 1,769,303     $ 1,915,524     $ 1,429,822     $ 5,292,635     $ 19,448,821  

 

We intend to continue these efforts to further reduce our debt burden in the coming year. During the six months ended November 30, 2024, we raised $2,600,000 from the issuance of a note payable to a related party; $2,200,000 of this amount was converted to 56,847,545 shares of common stock during the period, and $400,000 remains on the balance sheet as a note payable at November 30, 2024. The $2,600,000 was used to retire debt in the aggregate principal amount of $2,868,282 in September 2024. We believe we have resources in place with existing and prospective lenders to continue to reduce our debt burden, though there can be no guarantee that this will be the case.

 

Our working capital deficit is due primarily to accruals for taxes payable under Section 280E of the Internal Revenue Code in the amount of $9,888,537 and $8,899,863 at November 30, 2024. It is the Company’s position that these taxes will not ultimately be owed. Removing this amount from the calculation of net working capital results in a working capital deficit of $3,227,690 at November 30, 2024.

 

The Company continues to generate positive cash flow from operating activities, which were $468,336 for the six months ended November 30, 2024 compared to $1,004,631 for the six months ended November 30, 2023. We intend to continue to focus on operational activities in order to further improve our cash flow.

 

We have one potential capital expenditure project planned for fiscal 2025, which is our proposed 3,700 square foot cannabis consumption lounge and 300 square foot outdoor patio area to be attached to the Oasis dispensary. We expect this project to require a capital expenditure in the range of $500,000 to $1,000,000, depending upon various buildout decisions.

 

We believe the resources are available to execute our business plan in the coming year from existing and prospective investors and from internally generated cash flow, though there is no guarantee that this will be the case.

 

Going Concern

 

Our financial statements were prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. With the exception of the first quarter of fiscal 2022, we have incurred losses from operations since inception, and have an accumulated deficit of $114,275,584 as of November 30, 2024, compared to $113,367,050 as of May 31, 2024. We had a working capital deficit of $13,116,227 as of November 30, 2024, compared to a working capital deficit of $10,928,252 as of May 31, 2024. The report of our independent auditors for the year ended May 31, 2024 contained a going concern qualification.

 

 

Our ability to continue as a going concern must be considered in light of the problems, expenses, and complications frequently encountered by early-stage companies.

 

Our ability to continue as a going concern is dependent on our ability to generate sufficient cash from operations to meet our cash needs and finance our ongoing operations. There can be no assurance that cash generated by our future operations will be adequate to meet our needs.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Critical Accounting Estimates

 

Management uses various estimates and assumptions in preparing our financial statements in accordance with generally accepted accounting principles. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Accounting estimates that are the most important to the presentation of our results of operations and financial condition, and which require the greatest use of judgment by management, are designated as our critical accounting estimates. We have the following critical accounting estimates:

 

 

Estimates and assumptions regarding the deductibility of expenses for purposes of Section 280E of the Internal Revenue Code: Management evaluates the expenses of its manufacturing and retail operations and makes certain judgments regarding the deductibility of various expenses under Section 280E of the Internal Revenue Code based on its interpretation of this regulation and its subjective assumptions about the categorization of these expenses.

 

 

 

 

Estimates and assumptions used in the valuation of derivative liabilities: Management utilizes a lattice model to estimate the fair value of derivative liabilities. The model includes subjective assumptions that can materially affect the fair value estimates.

 

 

 

 

Estimates and assumptions used in the valuation of intangible assets. In order to value our intangible assets, management prepares multi-year projections of revenue, costs of goods sold, gross margin, operating expenses, taxes and after tax margins relating to the operations associated with the intangible assets being valued. These projections are based on the estimates of management at the time they are prepared and include subjective assumptions regarding industry growth and other matters.

 

Recently Issued Accounting Standards

 

Accounting standards promulgated by the Financial Accounting Standards Board (the “FASB”) are subject to change. Changes in such standards may have an impact on our future financial statements. The following are a summary of recent accounting developments.

 

In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible Preferred Stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on June 1, 2024, including interim periods within such fiscal year. Adoption is either a modified retrospective method or a fully retrospective method of transition. We do not expect the implementation of this standard to have a material effect on our consolidated financial statements.

 

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

 

 

Item 3. Quantitative and Qualitative Disclosure about Market Risk.

 

This item is not applicable as we are currently considered a smaller reporting company.

 

Item 4. Controls and Procedures.

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit pursuant to the requirements of the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, among other things, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Securities Exchange Act is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate, to allow timely decisions regarding required disclosure.

 

Evaluation of Disclosure Controls and Procedures

 

Andrew Glashow, our Chief Executive Officer, and Principal Financial and Accounting Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. The Company believes it now has an adequate number of trained personnel to resolve any segregation of duties deficiencies. Based on the evaluation, Mr. Glashow concluded that:

 

 

We do not have an independent body to oversee our internal controls over financial reporting due to our limited resources.

 

We plan to rectify these weaknesses by hiring additional accounting personnel once we have additional resources to do so.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

PART II OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors.

 

The Effects of Climate Change Could Adversely Affect the Quantity and Quality of Our Crops and the Cost and Availability of Energy to Our Dispensary Operations.

 

The effect of climate change is causing an increase in the cost of electricity to operate our dispensary operation and if temperatures remain high, could result in rationing of electricity, which could necessitate a reduction in operating hours at our dispensary.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

None.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

 

31.1

Certification by the Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

32.1

Certification by the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

101.INS

Inline XBRL Instance Document

 

 

101.SCH

Inline XBRL Taxonomy Extension Schema

 

 

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase

 

 

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase

 

 

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase

 

 

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase

 

 

104

Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

CLS HOLDINGS USA, INC.

 

 

 

 

 

Date: January 10, 2025

By:

/s/ Andrew Glashow

 

 

 

Andrew Glashow

Chairman of the Board of Directors and Chief Executive Officer

 

 

(Principal Executive, Financial and Accounting Officer)

 

 

 

 

 

39
http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember false --05-31 Q2 2025 0001522222 0001522222 2024-06-01 2024-11-30 0001522222 2025-01-08 0001522222 2024-11-30 0001522222 2024-05-31 0001522222 us-gaap:NonrelatedPartyMember 2024-11-30 0001522222 us-gaap:NonrelatedPartyMember 2024-05-31 0001522222 us-gaap:RelatedPartyMember 2024-11-30 0001522222 us-gaap:RelatedPartyMember 2024-05-31 0001522222 2024-09-01 2024-11-30 0001522222 2023-09-01 2023-11-30 0001522222 2023-06-01 2023-11-30 0001522222 us-gaap:CommonStockMember 2023-08-31 0001522222 us-gaap:AdditionalPaidInCapitalMember 2023-08-31 0001522222 clsh:StockPayableMember 2023-08-31 0001522222 us-gaap:RetainedEarningsMember 2023-08-31 0001522222 us-gaap:NoncontrollingInterestMember 2023-08-31 0001522222 2023-08-31 0001522222 us-gaap:AdditionalPaidInCapitalMember 2023-09-01 2023-11-30 0001522222 us-gaap:RetainedEarningsMember 2023-09-01 2023-11-30 0001522222 us-gaap:NoncontrollingInterestMember 2023-09-01 2023-11-30 0001522222 us-gaap:CommonStockMember 2023-11-30 0001522222 us-gaap:AdditionalPaidInCapitalMember 2023-11-30 0001522222 clsh:StockPayableMember 2023-11-30 0001522222 us-gaap:RetainedEarningsMember 2023-11-30 0001522222 us-gaap:NoncontrollingInterestMember 2023-11-30 0001522222 2023-11-30 0001522222 us-gaap:CommonStockMember 2023-05-31 0001522222 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001522222 clsh:StockPayableMember 2023-05-31 0001522222 us-gaap:RetainedEarningsMember 2023-05-31 0001522222 us-gaap:NoncontrollingInterestMember 2023-05-31 0001522222 2023-05-31 0001522222 us-gaap:AdditionalPaidInCapitalMember 2023-06-01 2023-11-30 0001522222 us-gaap:RetainedEarningsMember 2023-06-01 2023-11-30 0001522222 us-gaap:NoncontrollingInterestMember 2023-06-01 2023-11-30 0001522222 us-gaap:CommonStockMember 2024-08-31 0001522222 us-gaap:AdditionalPaidInCapitalMember 2024-08-31 0001522222 clsh:StockPayableMember 2024-08-31 0001522222 us-gaap:RetainedEarningsMember 2024-08-31 0001522222 us-gaap:NoncontrollingInterestMember 2024-08-31 0001522222 2024-08-31 0001522222 us-gaap:CommonStockMember 2024-09-01 2024-11-30 0001522222 us-gaap:AdditionalPaidInCapitalMember 2024-09-01 2024-11-30 0001522222 us-gaap:RetainedEarningsMember 2024-09-01 2024-11-30 0001522222 us-gaap:CommonStockMember 2024-11-30 0001522222 us-gaap:AdditionalPaidInCapitalMember 2024-11-30 0001522222 clsh:StockPayableMember 2024-11-30 0001522222 us-gaap:RetainedEarningsMember 2024-11-30 0001522222 us-gaap:NoncontrollingInterestMember 2024-11-30 0001522222 us-gaap:CommonStockMember 2024-05-31 0001522222 us-gaap:AdditionalPaidInCapitalMember 2024-05-31 0001522222 clsh:StockPayableMember 2024-05-31 0001522222 us-gaap:RetainedEarningsMember 2024-05-31 0001522222 us-gaap:NoncontrollingInterestMember 2024-05-31 0001522222 us-gaap:CommonStockMember 2024-06-01 2024-11-30 0001522222 us-gaap:AdditionalPaidInCapitalMember 2024-06-01 2024-11-30 0001522222 us-gaap:RetainedEarningsMember 2024-06-01 2024-11-30 0001522222 us-gaap:NonrelatedPartyMember 2024-06-01 2024-11-30 0001522222 us-gaap:NonrelatedPartyMember 2023-06-01 2023-11-30 0001522222 us-gaap:RelatedPartyMember 2024-06-01 2024-11-30 0001522222 us-gaap:RelatedPartyMember 2023-06-01 2023-11-30 0001522222 clsh:CLSCBDMember 2024-11-30 0001522222 clsh:KealiiOkamaluLLCMember 2024-11-30 0001522222 clsh:KealiiOkamaluLLCMember 2024-11-30 0001522222 us-gaap:WarrantMember 2024-06-01 2024-11-30 0001522222 us-gaap:ConvertibleDebtSecuritiesMember 2024-06-01 2024-11-30 0001522222 us-gaap:StockOptionMember 2024-06-01 2024-11-30 0001522222 clsh:StockPayableMember 2024-06-01 2024-11-30 0001522222 us-gaap:WarrantMember 2023-06-01 2023-11-30 0001522222 us-gaap:ConvertibleDebtSecuritiesMember 2023-06-01 2023-11-30 0001522222 clsh:StockPayableMember 2023-06-01 2023-11-30 0001522222 clsh:EstimatedUsefulLIfeMember 2024-06-01 2024-11-30 0001522222 srt:MinimumMember us-gaap:OfficeEquipmentMember 2024-11-30 0001522222 srt:MaximumMember us-gaap:OfficeEquipmentMember 2024-11-30 0001522222 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2024-11-30 0001522222 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2024-11-30 0001522222 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-11-30 0001522222 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-11-30 0001522222 us-gaap:LeaseholdImprovementsMember 2024-11-30 0001522222 clsh:CannabisDispensaryMember 2024-09-01 2024-11-30 0001522222 clsh:CannabisDispensaryMember 2023-09-01 2023-11-30 0001522222 clsh:CannabisProductionMember 2024-09-01 2024-11-30 0001522222 clsh:CannabisProductionMember 2023-09-01 2023-11-30 0001522222 clsh:CannabisDispensaryMember 2024-06-01 2024-11-30 0001522222 clsh:CannabisDispensaryMember 2023-06-01 2023-11-30 0001522222 clsh:CannabisProductionMember 2024-06-01 2024-11-30 0001522222 clsh:CannabisProductionMember 2023-06-01 2023-11-30 0001522222 us-gaap:ComputerEquipmentMember 2024-11-30 0001522222 us-gaap:ComputerEquipmentMember 2024-05-31 0001522222 us-gaap:FurnitureAndFixturesMember 2024-11-30 0001522222 us-gaap:FurnitureAndFixturesMember 2024-05-31 0001522222 us-gaap:MachineryAndEquipmentMember 2024-11-30 0001522222 us-gaap:MachineryAndEquipmentMember 2024-05-31 0001522222 us-gaap:LeaseholdImprovementsMember 2024-05-31 0001522222 srt:MinimumMember 2024-08-31 0001522222 srt:MaximumMember 2024-08-31 0001522222 2019-05-31 2024-08-31 0001522222 2019-05-31 0001522222 2023-06-01 2024-05-31 0001522222 2019-06-01 2024-11-30 0001522222 us-gaap:BuildingMember 2024-11-30 0001522222 us-gaap:LandMember 2024-11-30 0001522222 us-gaap:OfficeEquipmentMember 2024-11-30 0001522222 us-gaap:CustomerRelationshipsMember 2024-11-30 0001522222 us-gaap:CustomerRelationshipsMember 2024-06-01 2024-11-30 0001522222 us-gaap:TrademarksAndTradeNamesMember 2024-11-30 0001522222 us-gaap:TrademarksAndTradeNamesMember 2024-06-01 2024-11-30 0001522222 us-gaap:InternetDomainNamesMember 2024-11-30 0001522222 us-gaap:InternetDomainNamesMember 2024-06-01 2024-11-30 0001522222 us-gaap:CustomerRelationshipsMember 2024-05-31 0001522222 us-gaap:CustomerRelationshipsMember 2023-06-01 2024-05-31 0001522222 us-gaap:TrademarksAndTradeNamesMember 2024-05-31 0001522222 us-gaap:TrademarksAndTradeNamesMember 2023-06-01 2024-05-31 0001522222 us-gaap:InternetDomainNamesMember 2024-05-31 0001522222 us-gaap:InternetDomainNamesMember 2023-06-01 2024-05-31 0001522222 clsh:Debenture2Member us-gaap:NotesPayableOtherPayablesMember 2024-11-30 0001522222 clsh:Debenture2Member us-gaap:NotesPayableOtherPayablesMember 2024-05-31 0001522222 clsh:Debenture2Member us-gaap:NotesPayableOtherPayablesMember 2021-12-21 0001522222 clsh:Debenture2Member us-gaap:NotesPayableOtherPayablesMember 2021-12-21 2021-12-21 0001522222 clsh:Debenture2Member us-gaap:NotesPayableOtherPayablesMember 2024-06-01 2024-11-30 0001522222 clsh:Debenture2Member us-gaap:NotesPayableOtherPayablesMember 2012-12-21 0001522222 clsh:Debenture2Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001522222 clsh:Debenture2Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 2023-12-31 0001522222 clsh:Debenture2Member us-gaap:NotesPayableOtherPayablesMember 2024-09-01 2024-11-30 0001522222 clsh:Debenture6Member us-gaap:NotesPayableOtherPayablesMember 2024-11-30 0001522222 clsh:Debenture6Member us-gaap:NotesPayableOtherPayablesMember 2024-05-31 0001522222 clsh:Debenture6Member us-gaap:NotesPayableOtherPayablesMember 2022-01-04 0001522222 clsh:Debenture6Member us-gaap:NotesPayableOtherPayablesMember 2022-01-04 2022-01-04 0001522222 clsh:Debenture6Member us-gaap:NotesPayableOtherPayablesMember 2024-06-01 2024-11-30 0001522222 clsh:Debenture6Member us-gaap:NotesPayableOtherPayablesMember 2023-06-01 2024-05-31 0001522222 clsh:Debenture6Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001522222 clsh:Debenture6Member us-gaap:NotesPayableOtherPayablesMember 2024-09-01 2024-11-30 0001522222 clsh:Debenture6Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 2023-12-31 0001522222 clsh:PN6Member us-gaap:NotesPayableOtherPayablesMember 2024-11-30 0001522222 clsh:PN6Member us-gaap:NotesPayableOtherPayablesMember 2024-05-31 0001522222 clsh:PN6Member us-gaap:NotesPayableOtherPayablesMember 2024-02-22 0001522222 clsh:PN6Member us-gaap:NotesPayableOtherPayablesMember 2024-03-31 2024-03-31 0001522222 clsh:PN6Member us-gaap:NotesPayableOtherPayablesMember 2024-09-01 2024-11-30 0001522222 clsh:PN6Member us-gaap:NotesPayableOtherPayablesMember 2024-06-01 2024-11-30 0001522222 clsh:PN6Member us-gaap:NotesPayableOtherPayablesMember us-gaap:InterestExpenseMember 2024-09-01 2024-11-30 0001522222 clsh:PN6Member us-gaap:NotesPayableOtherPayablesMember us-gaap:InterestExpenseMember 2024-06-01 2024-11-30 0001522222 us-gaap:NotesPayableOtherPayablesMember 2024-11-30 0001522222 us-gaap:NotesPayableOtherPayablesMember 2024-05-31 0001522222 us-gaap:NotesPayableOtherPayablesMember us-gaap:NonrelatedPartyMember 2024-11-30 0001522222 us-gaap:NotesPayableOtherPayablesMember us-gaap:NonrelatedPartyMember 2024-05-31 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2024-11-30 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2024-05-31 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2018-10-10 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2018-10-10 2018-10-10 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2021-04-15 2021-04-15 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2022-09-15 2022-09-15 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2018-10-31 2018-10-31 0001522222 clsh:PrincipalMember clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2022-09-15 2022-09-15 0001522222 clsh:NavyCapitalDebenture2Member clsh:ConversionOptionsMember us-gaap:ConvertibleDebtMember 2023-09-15 2023-09-15 0001522222 clsh:NavyCapitalDebenture2Member clsh:ConversionOptionsMember us-gaap:ConvertibleDebtMember 2023-12-29 2023-12-29 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2024-06-01 2024-11-30 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2023-06-01 2024-05-31 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2024-09-01 2024-11-30 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:NoteWarrantMember us-gaap:ConvertibleDebtMember 2023-09-15 2023-09-15 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember 2023-12-29 2023-12-29 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember us-gaap:InterestExpenseMember 2024-09-01 2024-11-30 0001522222 clsh:NavyCapitalDebenture2Member us-gaap:ConvertibleDebtMember us-gaap:InterestExpenseMember 2024-06-01 2024-11-30 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2024-11-30 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2024-05-31 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2018-12-12 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2023-12-28 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2024-01-04 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2018-12-12 2018-12-12 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2022-09-15 2022-09-15 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2021-03-21 2021-03-21 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2020-06-01 2021-05-31 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2021-06-01 2022-05-31 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2019-09-01 2019-11-30 0001522222 clsh:CanaccordDebenturesMember clsh:ConversionOptionsMember us-gaap:ConvertibleDebtMember 2023-09-15 2023-09-15 0001522222 clsh:CanaccordDebenturesMember us-gaap:NoteWarrantMember us-gaap:ConvertibleDebtMember 2023-09-15 2023-09-15 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2023-12-28 2023-12-28 0001522222 clsh:AccruedInterestMember clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2023-12-28 2023-12-28 0001522222 clsh:PrincipalMember clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2024-01-04 2024-01-04 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2024-01-04 2024-01-04 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2024-09-01 2024-11-30 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2024-06-01 2024-11-30 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2024-12-27 0001522222 clsh:CanaccordDebenturesMember us-gaap:ConvertibleDebtMember 2024-12-27 2024-12-27 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2024-11-30 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2024-05-31 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2018-10-31 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2018-10-31 2018-10-31 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2020-06-01 2021-05-31 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2023-06-01 2024-05-31 0001522222 clsh:PrincipalMember clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2023-06-01 2024-05-31 0001522222 clsh:AccruedInterestMember clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2022-09-15 2022-09-15 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2023-12-29 2023-12-29 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2022-09-15 2022-09-15 0001522222 clsh:USConvertibleDebenture1Member us-gaap:NoteWarrantMember us-gaap:ConvertibleDebtMember 2022-06-01 2023-05-31 0001522222 clsh:USConvertibleDebenture1Member us-gaap:NoteWarrantMember us-gaap:ConvertibleDebtMember 2023-06-01 2024-05-31 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2023-12-29 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2021-04-15 2021-04-15 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2019-07-26 2019-07-26 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2018-10-18 2018-10-18 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2024-09-01 2024-11-30 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember 2024-06-01 2024-11-30 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember us-gaap:InterestExpenseMember 2024-09-01 2024-11-30 0001522222 clsh:USConvertibleDebenture1Member us-gaap:ConvertibleDebtMember us-gaap:InterestExpenseMember 2024-06-01 2024-11-30 0001522222 clsh:PN1Member us-gaap:RelatedPartyMember 2024-11-30 0001522222 clsh:PN1Member us-gaap:RelatedPartyMember 2024-05-31 0001522222 clsh:PN1Member us-gaap:RelatedPartyMember 2024-01-02 0001522222 clsh:PN1Member us-gaap:RelatedPartyMember 2024-02-29 2024-02-29 0001522222 clsh:PN1Member us-gaap:RelatedPartyMember 2024-09-01 2024-11-30 0001522222 clsh:PN1Member us-gaap:RelatedPartyMember 2024-06-01 2024-11-30 0001522222 clsh:PN2Member us-gaap:RelatedPartyMember 2024-11-30 0001522222 clsh:PN2Member us-gaap:RelatedPartyMember 2024-05-31 0001522222 clsh:PN2Member us-gaap:RelatedPartyMember 2024-01-02 0001522222 clsh:PN2Member us-gaap:RelatedPartyMember 2024-02-29 2024-02-29 0001522222 clsh:PN2Member us-gaap:RelatedPartyMember 2024-09-01 2024-11-30 0001522222 clsh:PN2Member us-gaap:RelatedPartyMember 2024-06-01 2024-11-30 0001522222 clsh:PN3Member us-gaap:RelatedPartyMember 2024-11-30 0001522222 clsh:PN3Member us-gaap:RelatedPartyMember 2024-05-31 0001522222 clsh:PN3Member us-gaap:RelatedPartyMember 2024-02-22 0001522222 clsh:PN3Member us-gaap:RelatedPartyMember 2024-03-31 2024-03-31 0001522222 clsh:PN3Member us-gaap:RelatedPartyMember 2024-09-01 2024-11-30 0001522222 clsh:PN3Member us-gaap:RelatedPartyMember 2024-06-01 2024-11-30 0001522222 clsh:PN4Member us-gaap:RelatedPartyMember 2024-11-30 0001522222 clsh:PN4Member us-gaap:RelatedPartyMember 2024-05-31 0001522222 clsh:PN4Member us-gaap:RelatedPartyMember 2024-02-22 0001522222 clsh:PN4Member us-gaap:RelatedPartyMember 2024-03-31 2024-03-31 0001522222 clsh:PN4Member us-gaap:RelatedPartyMember 2024-09-01 2024-11-30 0001522222 clsh:PN4Member us-gaap:RelatedPartyMember 2024-06-01 2024-11-30 0001522222 clsh:PN5Member us-gaap:RelatedPartyMember 2024-11-30 0001522222 clsh:PN5Member us-gaap:RelatedPartyMember 2024-05-31 0001522222 clsh:PN5Member us-gaap:RelatedPartyMember 2024-02-22 0001522222 clsh:PN5Member us-gaap:RelatedPartyMember 2024-03-31 2024-03-31 0001522222 clsh:PN5Member us-gaap:RelatedPartyMember 2024-09-01 2024-11-30 0001522222 clsh:PN5Member us-gaap:RelatedPartyMember 2024-06-01 2024-11-30 0001522222 clsh:PN7Member us-gaap:RelatedPartyMember 2024-11-30 0001522222 clsh:PN7Member us-gaap:RelatedPartyMember 2024-05-31 0001522222 clsh:PN7Member us-gaap:RelatedPartyMember 2024-03-06 0001522222 clsh:PN7Member us-gaap:RelatedPartyMember 2024-03-29 2024-03-29 0001522222 clsh:PN7Member us-gaap:RelatedPartyMember 2024-09-01 2024-11-30 0001522222 clsh:PN7Member us-gaap:RelatedPartyMember 2024-06-01 2024-11-30 0001522222 clsh:PN7Member us-gaap:RelatedPartyMember 2024-03-06 2024-03-06 0001522222 clsh:PN8Member us-gaap:RelatedPartyMember 2024-11-30 0001522222 clsh:PN8Member us-gaap:RelatedPartyMember 2024-05-31 0001522222 clsh:PN8Member us-gaap:RelatedPartyMember 2024-04-30 0001522222 clsh:PN8Member us-gaap:RelatedPartyMember 2024-04-30 2024-04-30 0001522222 clsh:PN8Member us-gaap:RelatedPartyMember 2024-09-01 2024-11-30 0001522222 clsh:PN8Member us-gaap:RelatedPartyMember 2024-06-01 2024-11-30 0001522222 clsh:PN9Member us-gaap:RelatedPartyMember 2024-11-30 0001522222 clsh:PN9Member us-gaap:RelatedPartyMember 2024-05-31 0001522222 clsh:PN9Member us-gaap:RelatedPartyMember 2024-08-28 0001522222 clsh:PN9Member us-gaap:RelatedPartyMember 2024-08-30 2024-08-30 0001522222 clsh:PN9Member us-gaap:RelatedPartyMember 2024-08-30 0001522222 clsh:PN9Member us-gaap:RelatedPartyMember 2024-10-30 0001522222 clsh:PN10Member us-gaap:RelatedPartyMember 2024-11-30 0001522222 clsh:PN10Member us-gaap:RelatedPartyMember 2024-05-31 0001522222 clsh:PN10Member us-gaap:RelatedPartyMember 2024-10-15 0001522222 clsh:PN10Member us-gaap:RelatedPartyMember 2024-10-15 2024-10-15 0001522222 clsh:PN10Member us-gaap:RelatedPartyMember 2024-09-01 2024-11-30 0001522222 clsh:PN10Member us-gaap:RelatedPartyMember 2024-06-01 2024-11-30 0001522222 clsh:FinanceLease1Member 2024-11-30 0001522222 clsh:FinanceLease1Member 2024-05-31 0001522222 clsh:FinanceLease1Member 2022-03-14 0001522222 clsh:FinanceLease1Member 2022-03-14 2022-03-14 0001522222 clsh:FinanceLease1Member 2024-09-01 2024-11-30 0001522222 clsh:FinanceLease1Member 2024-06-01 2024-11-30 0001522222 clsh:FinanceLease2Member 2024-11-30 0001522222 clsh:FinanceLease2Member 2024-05-31 0001522222 clsh:FinanceLease2Member 2022-06-20 0001522222 clsh:FinanceLease2Member 2022-06-20 2022-06-20 0001522222 clsh:FinanceLease2Member 2024-09-01 2024-11-30 0001522222 clsh:FinanceLease2Member 2024-06-01 2024-11-30 0001522222 2024-08-30 2024-08-30 0001522222 2024-09-10 2024-09-10 0001522222 2024-09-10 0001522222 srt:DirectorMember 2024-11-01 2024-11-01 0001522222 srt:DirectorMember 2024-11-01 0001522222 srt:DirectorMember 2024-11-30 0001522222 clsh:CanaccordDebenturesMember 2024-06-01 2024-11-30 0001522222 us-gaap:EmployeeStockOptionMember 2023-09-01 2023-11-30 0001522222 clsh:WarrantsExercisableAt040Member srt:MinimumMember 2024-11-30 0001522222 clsh:WarrantsExercisableAt040Member srt:MaximumMember 2024-11-30 0001522222 clsh:WarrantsExercisableAt040Member 2024-11-30 0001522222 clsh:WarrantsExercisableAt040Member 2024-06-01 2024-11-30 0001522222 clsh:PN9Member 2024-08-28 0001522222 2024-08-28 2024-08-28 0001522222 us-gaap:WarrantMember 2024-06-01 2024-11-30 0001522222 clsh:FormerOfficerMember 2024-11-30 0001522222 clsh:FormerOfficerMember 2024-05-31 0001522222 clsh:Director1Member 2024-09-01 2024-11-30 0001522222 clsh:Director2Member 2024-09-01 2024-11-30 0001522222 srt:DirectorMember 2024-09-01 2024-11-30 0001522222 clsh:ConsultingFeesMember srt:DirectorMember 2024-09-01 2024-11-30 0001522222 clsh:Director1Member 2024-06-01 2024-11-30 0001522222 clsh:Director2Member 2024-06-01 2024-11-30 0001522222 srt:DirectorMember 2024-06-01 2024-11-30 0001522222 clsh:ConsultingFeesMember srt:DirectorMember 2024-06-01 2024-11-30 0001522222 clsh:PN9Member 2024-08-30 0001522222 clsh:NavyCapitalDebenture1Member us-gaap:RelatedPartyMember 2024-08-28 2024-08-28 0001522222 clsh:LasVegasNV1Member us-gaap:BuildingMember 2019-02-28 0001522222 srt:MinimumMember clsh:LasVegasNV1Member us-gaap:BuildingMember 2019-02-01 2019-02-28 0001522222 clsh:LasVegasNV1Member us-gaap:BuildingMember 2020-02-01 2020-02-29 0001522222 clsh:LasVegasNV1Member us-gaap:BuildingMember 2022-09-01 2022-09-01 0001522222 clsh:LasVegasNV2Member us-gaap:BuildingMember 2018-01-31 0001522222 srt:MinimumMember clsh:LasVegasNV2Member us-gaap:BuildingAndBuildingImprovementsMember 2018-01-01 2018-01-31 0001522222 clsh:LasVegasNV2Member us-gaap:BuildingAndBuildingImprovementsMember 2020-02-01 2020-02-29 0001522222 clsh:LasVegasNV2Member us-gaap:BuildingAndBuildingImprovementsMember 2024-06-01 2024-11-30 0001522222 clsh:LasVegasNV3Member us-gaap:BuildingMember 2019-02-28 0001522222 srt:MinimumMember clsh:LasVegasNV3Member us-gaap:BuildingMember 2019-02-01 2019-02-28 0001522222 clsh:LasVegasNV3Member us-gaap:BuildingMember 2019-02-01 2019-02-28 0001522222 clsh:LasVegasNV3Member us-gaap:BuildingMember 2020-02-01 2020-02-29 0001522222 clsh:LasVegasNV3Member us-gaap:BuildingMember 2024-06-01 2024-11-30 0001522222 clsh:LasVegasNV4Member us-gaap:BuildingMember 2020-02-29 0001522222 srt:MinimumMember clsh:LasVegasNV4Member us-gaap:BuildingMember 2016-01-01 2020-02-29 0001522222 srt:MaximumMember clsh:LasVegasNV4Member us-gaap:BuildingMember 2020-01-01 2020-03-31 0001522222 srt:MinimumMember clsh:LasVegasNV4Member clsh:RentForAprilMayAndJune2020Member us-gaap:BuildingMember 2020-04-01 2020-06-30 0001522222 srt:MinimumMember clsh:LasVegasNV4Member clsh:RentForMarch2021ThroughFebruary2022Member us-gaap:BuildingMember 2021-03-01 2022-02-28 0001522222 srt:MinimumMember clsh:LasVegasNV4Member clsh:RentForMarch2022ThroughFebruary2023Member us-gaap:BuildingMember 2022-03-01 2023-02-28 0001522222 srt:MinimumMember clsh:LasVegasNV4Member clsh:RentForMarch2023ThroughFebruary2024Member us-gaap:BuildingMember 2023-03-01 2024-02-29 0001522222 srt:MinimumMember clsh:LasVegasNV4Member clsh:RentForMarch2024ThroughFebruary2025Member us-gaap:BuildingMember 2024-03-01 2025-02-28 0001522222 srt:MinimumMember clsh:LasVegasNV4Member clsh:RentForMarch2025ThroughFebruary2026Member us-gaap:BuildingMember 2025-03-01 2026-02-28 0001522222 clsh:LasVegasNV5Member 2023-10-31 0001522222 clsh:LasVegasNV5Member us-gaap:BuildingMember 2023-10-31 0001522222 srt:MinimumMember clsh:LasVegasNV5Member us-gaap:BuildingMember 2023-10-01 2024-09-30 0001522222 srt:MinimumMember clsh:LasVegasNV5Member us-gaap:BuildingMember 2024-10-01 2025-09-30 0001522222 srt:MinimumMember clsh:LasVegasNV5Member us-gaap:BuildingMember 2025-10-01 2026-09-30 0001522222 srt:MinimumMember clsh:LasVegasNV5Member us-gaap:BuildingMember 2026-10-01 2027-09-30 0001522222 srt:MinimumMember clsh:LasVegasNV5Member us-gaap:BuildingMember 2027-10-01 2028-09-30 0001522222 us-gaap:BuildingMember 2017-04-17 0001522222 us-gaap:BuildingMember 2027-04-17 0001522222 clsh:DepositMember 2018-06-01 2019-02-28 0001522222 us-gaap:OtherExpenseMember 2018-06-01 2019-02-28 0001522222 clsh:RentExpenseMember 2018-06-01 2019-02-28 0001522222 clsh:RemainingAmountsDueUnderLeaseMember 2018-06-01 2019-02-28 0001522222 clsh:CanaccordDebenturesMember us-gaap:SubsequentEventMember 2024-12-27 0001522222 clsh:CanaccordDebenturesMember us-gaap:SubsequentEventMember 2024-12-27 2024-12-27 0001522222 us-gaap:SubsequentEventMember 2024-12-27 0001522222 us-gaap:SubsequentEventMember 2024-12-27 2026-12-31 0001522222 us-gaap:SubsequentEventMember 2025-01-31 2026-12-31 0001522222 us-gaap:SubsequentEventMember 2025-01-07 0001522222 us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2025-01-07 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqft

EXHIBIT 31.1

 

CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Andrew Glashow, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of CLS Holdings USA, Inc.

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. As the registrant’s certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control for financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant is made known to me by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. As the registrant’s certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

 

 

January 10, 2025

 

/s/ Andrew Glashow

 

 

 

Andrew Glashow

Chairman of the Board of Directors and Chief Executive Officer

 

 

(Principal Executive, Financial and Accounting Officer)

 

 

EXHIBIT 32.1

 

Certification by the Principal Financial Officer Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

I, Andrew Glashow, certify pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the Quarterly Report on Form 10-Q of CLS Holdings USA, Inc. (the “Company”) for the quarter ended November 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

 

Date: January 10, 2025

 

/s/ Andrew Glashow

 

 

 

Andrew Glashow

Chairman of the Board of Directors and Chief Executive Officer

 

 

 

(Principal Executive, Financial and Accounting Officer)

 

 

A signed original copy of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 
v3.24.4
Cover - shares
6 Months Ended
Nov. 30, 2024
Jan. 08, 2025
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Period End Date Nov. 30, 2024  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q2  
Entity Information [Line Items]    
Entity Registrant Name CLS HOLDINGS USA, INC.  
Entity Central Index Key 0001522222  
Entity File Number 000-55546  
Entity Tax Identification Number 45-1352286  
Entity Incorporation, State or Country Code NV  
Current Fiscal Year End Date --05-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 516 S. 4th Street  
Entity Address, City or Town Las Vegas  
Entity Address, State or Province NV  
Entity Address, Postal Zip Code 89101  
Entity Phone Fax Numbers [Line Items]    
City Area Code 888  
Local Phone Number 359-4666  
Entity Listings [Line Items]    
Entity Common Stock, Shares Outstanding   164,734,517
v3.24.4
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Nov. 30, 2024
May 31, 2024
Current assets    
Cash and cash equivalents $ 592,584 $ 600,007
Accounts Receivable 1,152,082 682,894
Inventory 1,805,661 1,968,573
Prepaid expenses and other current assets 39,934 49,309
Total current assets 3,590,261 3,300,783
Property, plant and equipment, net of accumulated depreciation of $3,572,740 and $3,318,550 2,184,815 2,423,553
Right of use assets, operating leases 1,385,830 1,475,351
Intangible assets, net of accumulated amortization of $351,824 and $348,015 8,327 9,978
Goodwill 557,896 557,896
Other assets 157,500 157,500
Total assets 7,884,629 7,925,061
Current liabilities    
Accounts payable and accrued liabilities 4,400,037 3,356,059
Accrued interest 15,600 3,600
Due to related party 40,000 0
Lease liability - operating leases, current 484,601 443,467
Lease liability - financing leases, current 108,410 96,224
Taxes Payable 9,888,537 8,899,863
Convertible notes payable - current 126,043 302,005
Total current liabilities 16,706,488 14,229,035
Noncurrent liabilities    
Lease liability - operating leases, non-current 1,188,793 1,318,644
Lease liability - financing leases, non-current 39,899 100,252
Convertible notes payable, non-current 1,535,283 3,699,426
Total Liabilities 20,171,287 20,833,859
Commitments and contingencies 0 0
Stockholder's deficit    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued 0 0
Common stock, $0.0001 par value; 345,000,000 shares authorized; 164,734,517 and 124,500,873 shares issued and outstanding at November 30, 2024 and May 31, 2024, respectively 16,474 12,450
Additional paid-in capital 103,046,249 101,519,599
Common stock subscribed 65,702 65,702
Accumulated deficit (114,275,584) (113,367,050)
Stockholder's deficit attributable to CLS Holdings, Inc. (11,147,159) (11,769,299)
Non-controlling interest (1,139,499) (1,139,499)
Total stockholder's deficit (12,286,658) (12,908,798)
Total liabilities and stockholders' deficit 7,884,629 7,925,061
Nonrelated Party [Member]    
Current liabilities    
Notes payable, current 128,898 139,345
Convertible notes payable - current 126,043 302,005
Noncurrent liabilities    
Notes payable, non-current 34,702 407,951
Convertible notes payable, non-current 1,535,283 3,699,426
Related Party [Member]    
Current liabilities    
Due to related party 40,000  
Notes payable, current 1,514,362 988,472
Noncurrent liabilities    
Notes payable, non-current $ 666,122 $ 1,078,551
v3.24.4
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)
Nov. 30, 2024
May 31, 2024
Statement of Financial Position [Abstract]    
Property, plant and equipment, accumulated depreciation (in Dollars) $ 3,572,740 $ 3,318,550
Intangible assets, accumulated amortization (in Dollars) 351,824 348,015
Notes payable, non-current, discount (in Dollars) $ 0 $ 193,756
Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 345,000,000 345,000,000
Common stock, shares issued 164,734,517 124,500,873
Common stock, shares outstanding 164,734,517 124,500,873
v3.24.4
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
Income Statement [Abstract]        
Revenue $ 4,161,270 $ 5,197,214 $ 8,966,435 $ 10,311,741
Cost of goods sold 2,389,245 3,025,595 5,146,141 5,866,196
Gross margin 1,772,025 2,171,619 3,820,294 4,445,545
Selling, general and administrative expenses 2,095,099 2,606,918 4,279,932 5,336,818
Total operating expenses 2,095,099 2,606,918 4,279,932 5,336,818
Operating income (loss) (323,074) (435,299) (459,638) (891,273)
Other (income) expense:        
Interest expense, net 295,715 410,841 455,118 868,313
Employee retention tax credit income (50,103) 0 (50,103) (924,862)
(Gain) on settlement of debt (949,793) 0 (949,793) 0
(Gain) on settlement of accounts payable 0 0 0 (4,375)
Total other (income) expense (704,181) 410,841 (544,778) (60,924)
Income (Loss) before income taxes 381,107 (846,140) 85,140 (830,349)
Provision for income tax (468,778) (456,040) (993,674) (933,564)
Net loss (87,671) (1,302,180) (908,534) (1,763,913)
Non-controlling interest 0 (92) 0 (2,200)
Net loss attributable to CLS Holdings, Inc. $ (87,671) $ (1,302,272) $ (908,534) $ (1,766,113)
Net loss per share - basic (in Dollars per share) $ 0 $ (0.02) $ (0.01) $ (0.02)
Net loss per share - diluted (in Dollars per share) $ 0 $ (0.02) $ (0.01) $ (0.02)
Weighted average shares outstanding - basic (in Shares) 167,203,078 72,543,141 146,045,945 72,543,141
Weighted average shares outstanding - diluted (in Shares) 167,203,078 72,543,141 146,045,945 72,543,141
v3.24.4
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Payable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Balance at May. 31, 2023 $ 7,255 $ 96,147,784 $ 65,702 $ (108,879,446) $ (1,141,867) $ (13,800,572)
Balance (in Shares) at May. 31, 2023 72,543,141          
Discount on convertible notes payable   62,400       62,400
Shares purchased from related party           0
Loss       (1,766,113) 2,200 (1,763,913)
Balance at Nov. 30, 2023 $ 7,255 96,210,184 65,702 (110,645,559) (1,139,667) (15,502,085)
Balance (in Shares) at Nov. 30, 2023 72,543,141          
Balance at Aug. 31, 2023 $ 7,255 96,147,784 65,702 (109,343,287) (1,139,759) (14,262,305)
Balance (in Shares) at Aug. 31, 2023 72,543,141          
Discount on convertible notes payable   62,400       62,400
Loss       (1,302,272) 92 (1,302,180)
Balance at Nov. 30, 2023 $ 7,255 96,210,184 65,702 (110,645,559) (1,139,667) (15,502,085)
Balance (in Shares) at Nov. 30, 2023 72,543,141          
Balance at May. 31, 2024 $ 12,450 101,519,599 65,702 (113,367,050) (1,139,499) (12,908,798)
Balance (in Shares) at May. 31, 2024 124,500,873          
Conversion of notes payable $ 5,685 2,194,315       2,200,000
Conversion of notes payable (in Shares) 56,847,545          
Shares purchased from related party $ (112) (39,888)       (40,000)
Shares purchased from related party (in Shares) (1,125,000)          
Shares and warrants cancelled in debt settlement $ (1,549) (679,961)       (681,510)
Shares and warrants cancelled in debt settlement (in Shares) (15,488,901)          
Amortization of employee stock options   52,184       52,184
Loss       (908,534)   (908,534)
Balance at Nov. 30, 2024 $ 16,474 103,046,249 65,702 (114,275,584) (1,139,499) (12,286,658)
Balance (in Shares) at Nov. 30, 2024 164,734,517          
Balance at Aug. 31, 2024 $ 18,135 103,742,716 65,702 (114,187,913) (1,139,499) (11,500,859)
Balance (in Shares) at Aug. 31, 2024 181,348,418          
Shares purchased from related party $ (112) (39,888)       (40,000)
Shares purchased from related party (in Shares) (1,125,000)          
Shares and warrants cancelled in debt settlement $ (1,549) (679,961)       (681,510)
Shares and warrants cancelled in debt settlement (in Shares) (15,488,901)          
Amortization of employee stock options   23,382       23,382
Loss       (87,671)   (87,671)
Balance at Nov. 30, 2024 $ 16,474 $ 103,046,249 $ 65,702 $ (114,275,584) $ (1,139,499) $ (12,286,658)
Balance (in Shares) at Nov. 30, 2024 164,734,517          
v3.24.4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended
Nov. 30, 2024
Nov. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) $ (908,534) $ (1,763,913)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 52,184 0
Amortization of debt discounts 193,756 335,999
Depreciation and amortization expense 256,530 332,748
Gain on settlement of accounts payable 0 (4,375)
Gain on settlement of debt (949,793) 0
Bad debt expense 0 393
Changes in assets and liabilities:    
Accounts receivable (469,188) (502,200)
Prepaid expenses and other current assets 9,375 78,765
Inventory 162,912 371,079
Right of use asset 209,922 186,424
Accounts payable and accrued expenses 1,043,978 1,000,336
Accrued interest 87,638 216,098
Deferred tax liability 988,674 933,564
Operating lease liability (209,118) (180,287)
Net cash used in operating activities 468,336 1,004,631
CASH FLOWS FROM INVESTING ACTIVITIES    
Payments to purchase property, plant and equipment (16,141) (44,248)
Payment for construction security deposit 0 (58,175)
Net cash used in investing activities (16,141) (102,423)
CASH FLOWS FROM FINANCING ACTIVITIES    
Cash received from the issuance of convertible notes payable 2,600,000 0
Cash received from issuance of note payable - related party 150,000 0
Principal payment on notes and cancellation of shares (2,600,000) 0
Principal payments on convertible notes payable (48,093) (100,000)
Proceeds of loan payable 0 960,000
Repayments of loan payable 0 (481,943)
Principal payments on finance leases (48,167) (41,931)
Net cash used in financing activities (459,618) (140,958)
Net increase in cash and cash equivalents (7,423) 761,250
Cash and cash equivalents at beginning of period 600,007 998,421
Cash and cash equivalents at end of period 592,584 1,759,671
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Interest paid 115,333 163,783
Income taxes paid 0 0
NONCASH INVESTING AND FINANCING ACTIVITIES:    
Common stock issued for conversion of convertible notes payable 2,200,000 0
Capitalized interest 75,638 0
Initial ROU asset and lease liability - operating 120,401 224,899
Discount on convertible note payable 0 62,400
Cancellation of shares held by related party 40,000 0
Nonrelated Party [Member]    
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on notes payable (76,819) (477,084)
Related Party [Member]    
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on notes payable $ (436,539) $ 0
v3.24.4
Nature of Business and Significant Accounting Policies
6 Months Ended
Nov. 30, 2024
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]

Note 1: Nature of Business and Significant Accounting Policies

 

Basis of Presentation

 

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in US dollars. The Company has adopted a fiscal year end of May 31st.

 

Principals of Consolidation

 

The accompanying consolidated financial statements include the accounts of CLS Holdings USA, Inc.; its direct and indirect wholly owned operating subsidiaries, CLS Nevada, Inc., (“CLS Nevada”), CLS Labs, Inc. (“CLS Labs”), CLS Labs Colorado, Inc. (“CLS Colorado”), CLS Massachusetts, Inc. (“CLS Massachusetts”), and Alternative Solutions, LLC (“Alternative Solutions”); and wholly owned inactive subsidiaries CLS Labs Colorado, Inc. (“CLS Colorado”) and CLS Massachusetts, Inc. (“CLS Massachusetts”). Alternative Solutions is the sole owner of the following three entities (collectively, the “Oasis LLCs”): Serenity Wellness Center, LLC (“Serenity Wellness Center”); Serenity Wellness Products, LLC (“Serenity Wellness Products”); and Serenity Wellness Growers, LLC (“Serenity Wellness Growers”). The accompanying consolidated financial statements also include the accounts of CLS CBD in which the company owns a 95% ownership interest and a variable interest entity, Kealii Okamalu, LLC (“Kealii Okamalu”), in which the Company owns a 50% interest. All material intercompany transactions have been eliminated upon consolidation of these entities.

 

Nature of Business

 

CLS Holdings USA, Inc. (the “Company”) was originally incorporated as Adelt Design, Inc. (“Adelt”) on March 31, 2011 to manufacture and market carpet binding art. Production and marketing of carpet binding art never commenced.

 

We currently operate a retail marijuana dispensary within walking distance to the Las Vegas Strip and a small-scale cultivation facility, as well as a product manufacturing facility and a wholesale distribution operation in North Las Vegas. The vertically integrated business model drives strong margins to the bottom line on a portion of sales at the dispensary.

 

Our retail dispensary is a single location operation in Nevada and occupies over 5,000 square feet. This location, which is easily accessible by tourists, is currently open 19.5 hours per day for walk-in service. Curbside and in store express pick up is available between the hours of 8:00 AM and 12:00 AM. Oasis dispensary also delivers cannabis to residents between the hours of 8:00 AM and 10:00 PM. The central location provides logistical convenience for delivery to all parts of the Las Vegas valley.

 

Our wholesale operations, which occupies approximately 10,000 square feet of a 22,000 square foot warehouse, began sales to third parties in August 2017 and completed construction and received a certificate of occupancy for its state-of-the-art extraction facility in December of 2019. We have made sales to over 88 external customers as of November 30, 2024. Our existing product line includes vaporizers, tinctures, ethanol produced THC distillate, and live and cured hydrocarbon concentrates. At present, the City Trees cultivation facility only grows breeding stock to preserve valuable genetics and does not offer its crops for sale or processing. As a result, all raw materials for manufacturing are sourced from third parties.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Reclassification

 

Certain reclassifications, not affecting previously reported net income or cash flows, have been made to the previously issued financial statements to conform to the current period presentation.

 

Cash, Cash Equivalents, and Restricted Cash

 

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. The Company had cash and cash equivalents of $592,584 and $600,007 as of November 30, 2024 and May 31, 2024, respectively.

 

Allowance for Doubtful Accounts

 

The Company generates the majority of its revenues and corresponding accounts receivable from the sale of cannabis, and cannabis related products. The Company evaluates the collectability of its accounts receivable considering a combination of factors. In circumstances where it is aware of a specific customer’s inability to meet its financial obligations to it, the Company records a specific reserve for bad debts against amounts due in order to reduce the net recognized receivable to the amount it reasonably believes will be collected. For all other customers, the Company recognizes reserves for bad debts based on past write-off experience and the length of time the receivables are past due. The Company had bad debt expense of $0 and $93 during the three months ended November 30, 2024 and 2023.

 

Inventory

 

Inventories are stated at the lower of cost or market. Cost is determined using a perpetual inventory system whereby costs are determined by acquisition costs of individual items included in inventory. Market is determined based on net realizable value. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable values. Our cannabis products consist of prepackaged purchased goods ready for resale, along with produced tinctures and extracts developed under our production license.

 

Property, Plant and Equipment

 

Property and equipment is recorded at the lower of cost or estimated net recoverable amount, and is depreciated using the straight-line method over its estimated useful life. Property acquired in a business combination is recorded at estimated initial fair value. Property, plant, and equipment are depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based upon the following life expectancy:

 

 

 

Years

 

Office equipment

 

 

3 to 5

 

Furniture & fixtures

 

 

3 to 7

 

Machinery & equipment

 

 

3 to 10

 

Leasehold improvements

 

Term of lease

 

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated, and any resulting gain or loss is reflected in operations.

 

Long-Lived Assets

 

The Company reviews its property and equipment and any identifiable intangibles including goodwill for impairment on an annual basis utilizing the guidance set forth in the Statement of Financial Accounting Standards Board ASC 350 “Intangibles – Goodwill and Other” and ASC 360 “Property, Plant, and Equipment.” At November 30, 2024, the net carrying value of goodwill on the Company’s balance sheet remained at $557,896.

 

Employee Retention Tax Credit

 

Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), the Company was eligible for a refundable employee retention tax credit (the “ERTC”), subject to certain criteria. As ERTCs are not within the scope of ASC 740, Income Taxes, the Company has chosen to account for the ERTCs by analogizing to the International Standard IAS 20, Accounting/or Government Grants and Disclosure of Government Assistance (“IAS 20”). In accordance with IAS 20, an entity recognizes government grants only when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. During the three months ended November 30, 2024 and 2023, the Company received an aggregate of $50,103 and $0, respectively, and during the six months ended November 30, 2024 and 2023, the Company received an aggregate of $50,103 and $924,862, respectively; these amounts were accounted for as other income on the Company’s condensed consolidated statement of operations.

 

Comprehensive Income

 

ASC 220-10-15 “Reporting Comprehensive Income,” establishes standards for reporting and displaying of comprehensive income, its components and accumulated balances. Comprehensive income is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220-10-15 requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The Company does not have any items of comprehensive income in any of the periods presented.

 

Non-Controlling Interests

 

The Company reports “non-controlling interest in subsidiary” as a component of equity, separate from parent’s equity, on the Consolidated Balance Sheets. In addition, the Company’s Consolidated Statements of Operations includes “net income (loss) attributable to non-controlling interest.” There was no non-controlling interest reported during the three and six months ended November 30, 2024. During the three and six months ended November 30, 2023, the Company reported a non-controlling interest in the amount of $(92) and ($2,200), respectively, representing 50% of the income (loss) incurred by its partially owned subsidiary, Kealii Okamalu.

 

Variable Interest Entities

 

The Company’s consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and variable interest entities (“VIE”), where the Company is the primary beneficiary under the provisions of ASC 810, Consolidation (“ASC 810”). A VIE must be consolidated by its primary beneficiary when, along with its affiliates and agents, the primary beneficiary has both: (i) the power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) the obligation to absorb losses or the right to receive the benefits of the VIE that could potentially be significant to the VIE. The Company reconsiders whether an entity is still a VIE only upon certain triggering events and continually assesses its consolidated VIEs to determine if it continues to be the primary beneficiary.

 

Concentrations of Credit Risk

 

The Company maintains its cash in bank deposit accounts and other accounts, the balances of which at times may be uninsured or exceed federally insured limits. From time to time, some of the Company’s funds are also held by escrow agents; these funds may not be federally insured. The Company continually monitors its banking relationships and consequently has not experienced any losses in such accounts.

 

Advertising and Marketing Costs

 

All costs associated with advertising and promoting products are expensed as incurred. Total recognized advertising and marketing expenses were $96,709 and $103,448 for the three months ended November 30, 2024 and 2023, respectively, and $174,710 and $227,059 for the six months ended November 30, 2024 and 2023, respectively.

 

Research and Development

 

Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $281 and $431 for the three months ended November 30, 2024 and 2023, respectively, and $421 and $1,887 for the six months ended November 30, 2024 and 2023, respectively.

 

Fair Value of Financial Instruments

 

Pursuant to Accounting Standards Codification (“ASC”) No. 825–- Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheets. The carrying amounts of the Company’s cash and cash equivalents, notes receivable, convertible notes payable, accounts payable and accrued expenses, none of which is held for trading, approximate their estimated fair values due to the short-term maturities of those financial instruments.

 

A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

 

Level 1–- Quoted prices in active markets for identical assets or liabilities.

 

Level 2–- Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

 

Level 3–- Significant unobservable inputs that cannot be corroborated by market data.

 

Revenue Recognition

 

Revenue from the sale of cannabis products is recognized by Oasis at the point of sale, at which time payment is received, the product is delivered, and the Company’s performance obligation has been met. Management estimates an allowance for sales returns.

 

The Company also recognizes revenue from Serenity Wellness Products LLC and Serenity Wellness Growers LLC, d/b/a City Trees (“City Trees”). City Trees recognizes revenue from the sale of the following cannabis products and services to licensed dispensaries, cultivators and distributors within the State of Nevada:

 

 

Premium organic medical cannabis sold wholesale to licensed retailers

 

 

 

 

Recreational marijuana cannabis products sold wholesale to licensed distributors and retailers

 

 

 

 

Extraction products such as oils and waxes derived from in-house cannabis production

 

 

 

 

Processing and extraction services for licensed medical cannabis cultivators in Nevada

 

 

 

 

High quality cannabis strains in the form of vegetative cuttings for sale to licensed medical cannabis cultivators in Nevada

 

Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from commercial sales of products and licensing agreements by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.

 

Disaggregation of Revenue

 

The following table represents a disaggregation of revenue for the three and six months ended November 30, 2024 and 2023:

 

   

For the Three

   

For the Three

 
   

Months Ended

   

Months Ended

 
   

November 30, 2024

   

November 30, 2023

 

Cannabis Dispensary

    2,706,856       3,104,064  

Cannabis Production

    1,454,414       2,093,150  
    $ 4,161,270     $ 5,197,214  

 

   

For the Six

   

For the Six

 
   

Months Ended

   

Months Ended

 
   

November 30, 2024

   

November 30, 2023

 

Cannabis Dispensary

    5,773,932       6,412,606  

Cannabis Production

    3,192,503       3,899,135  
    $ 8,966,435     $ 10,311,741  

 

Basic and Diluted Earnings or Loss Per Share

 

Basic net earnings per share is based on the weighted average number of shares outstanding during the period, while fully diluted net earnings per share is based on the weighted average number of shares of common stock and potentially dilutive securities assumed to be outstanding during the period using the treasury stock method. Potentially dilutive securities consist of options and warrants to purchase common stock, and convertible debt. Basic and diluted net loss per share are computed based on the weighted average number of shares of common stock outstanding during the period. At November 30, 2024 and 2023, the Company had the following potentially dilutive instruments outstanding: at November 30, 2024, a total of 46,300,414 shares (14,549,685 issuable upon the exercise of warrants, 23,733,229 issuable upon the conversion of convertible notes payable and accrued interest, 8,000,000 shares issuable upon the conversion of stock options, and 17,500 in stock to be issued); and at November 30, 2023, a total of 73,715,637 shares (21,181,449 issuable upon the exercise of warrants, 52,516,688 issuable upon the conversion of convertible notes payable and accrued interest, and 17,500 in stock to be issued).

 

The Company uses the treasury stock method to calculate the impact of outstanding stock options and warrants. Stock options and warrants for which the exercise price exceeds the average market price over the period have an anti-dilutive effect on earnings per common share and, accordingly, are excluded from the calculations.

 

A net loss causes all outstanding stock options and warrants to be anti-dilutive. As a result, the basic and dilutive losses per common share are the same for the three months ended November 30, 2024 and 2023. For the three months ended November 30, 2024 and 2023, the Company excluded from the calculation of fully diluted earnings per share the following instruments which were anti-dilutive: shares issuable pursuant to the conversion of notes payable and accrued interest, shares issuable pursuant to the exercise of warrants, and shares of common stock issuable.

 

Income Taxes

 

The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

 

Section 280E of the Internal Revenue Code, as amended, prohibits businesses from deducting certain expenses associated with trafficking controlled substances (within the meaning of Schedule I and II of the Controlled Substances Act). The IRS has invoked Section 280E in tax audits against various cannabis businesses in the U.S. that are permitted under applicable state laws. Although the IRS has issued a clarification allowing the deduction of certain expenses, the bulk of operating costs and general administrative costs are generally not permitted to be deducted. The operations of certain of the Company’s subsidiaries are subject to Section 280E. This results in permanent differences between ordinary and necessary business expenses deemed non-deductible under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income or loss.

 

Commitments and Contingencies

 

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims brought to such legal counsel’s attention as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

 

Recent Accounting Pronouncements

 

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

v3.24.4
Going Concern
6 Months Ended
Nov. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Substantial Doubt about Going Concern [Text Block]

Note 2: Going Concern

 

As shown in the accompanying financial statements, the Company has incurred net losses from operations resulting in an accumulated deficit of $114,275,584 as of November 30, 2024. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with revenues from operations.

v3.24.4
Accounts Receivable
6 Months Ended
Nov. 30, 2024
Receivables [Abstract]  
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

Note 3: Accounts Receivable

 

Accounts receivable was $1,152,082 and $682,894 at November 30, 2024 and May 31, 2024, respectively. The Company had bad debt expense of $0 and $93 during the three months ended November 30, 2024 and 2023. The Company had bad debt expense of $0 and $393 during the six months ended November 30, 2024 and 2023. No allowance for doubtful accounts was necessary during the three months ended November 30, 2024 and 2023.

v3.24.4
Inventory
6 Months Ended
Nov. 30, 2024
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block]

Note 4: Inventory

 

Inventory, consisting of material, overhead, labor, and manufacturing overhead, is stated at the lower of cost (first-in, first-out) or market, and consists of the following:

 

   

November 30,

   

May 31,

 
   

2024

   

2024

 

Raw materials

  $ 287,064     $ 386,803  

Finished goods

    1,518,597       1,581,770  

Total

  $ 1,805,661     $ 1,968,573  

 

Raw materials consist of cannabis plants and the materials that are used in our production process prior to being tested and packaged for consumption. Finished goods consist of pre-packaged materials previously purchased from other licensed cultivators and our manufactured edibles and extracts.

v3.24.4
Prepaid Expenses and Other Current Assets
6 Months Ended
Nov. 30, 2024
Disclosure Text Block Supplement [Abstract]  
Other Current Assets [Text Block]

Note 5: Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets consisted of the following at November 30, 2024 and May 31, 2024:

 

   

November 30,

   

May 31,

 
   

2024

   

2024

 

Prepaid license fees

    7,000       14,659  

Other prepaid expenses

    32,934       34,650  

Total

  $ 39,934     $ 49,309  

 

Prepaid expenses primarily of (i) annual license fees charged by the State of Nevada; (ii) insurance costs; (iii) supplies; (iv) rent; and (v) board fees.

v3.24.4
Property, Plant and Equipment
6 Months Ended
Nov. 30, 2024
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment Disclosure [Text Block]

Note 6: Property, Plant and Equipment

 

Property, plant and equipment consisted of the following at November 30, 2024 and May 31, 2024:

 

   

November 30,

2024

   

May 31,

2024

 

Office equipment

  $ 163,126     $ 163,126  

Furniture and fixtures

    149,478       148,358  

Machinery & Equipment

    2,522,795       2,519,455  

Leasehold improvements

    2,922,156       2,911,164  

Less: accumulated depreciation

    (3,572,740 )     (3,318,550 )

Property, plant, and equipment, net

  $ 2,184,815     $ 2,423,553  

 

The Company made payments in the amounts of $16,141 and $44,248 for property and equipment during the six months ended November 30, 2024 and 2023, respectively.

 

Depreciation expense totaled $121,219 and $158,497 for the three months ended November 30, 2024 and 2023, respectively. Depreciation expense totaled $254,880 and $317,250 for the six months ended November 30, 2024 and 2023, respectively.

v3.24.4
Right of Use Assets and Liabilities – Operating Leases
6 Months Ended
Nov. 30, 2024
Disclosure Text Block [Abstract]  
Lessee, Operating Leases [Text Block]

Note 7: Right of Use Assets and Liabilities Operating Leases

 

The Company has operating leases for offices and warehouses. The Company’s leases have remaining lease terms of 1 year to 10.5 years, some of which include options to extend.

 

The Company’s lease expense for the three months ended November 30, 2024 and 2023 was entirely comprised of operating leases and amounted to $140,612 and $123,408, respectively. The Company’s lease expense for the six months ended November 30, 2024 and 2023 was entirely comprised of operating leases and amounted to $278,097 and $257,611, respectively.

 

The Company’s right of use (“ROU”) asset amortization for the three months ended November 30, 2024 and 2023 was $106,422 and $89,736, respectively. The Company’s ROU asset amortization for the six months ended November 30, 2024 and 2023 was $209,922 and $186,424, respectively.

 

The Company has recorded total right of use assets of $4,384,520 and liabilities in the amount of $4,341,120 through November 30, 2024.

 

Right of use assets – operating leases are summarized below:

 

   

November 30,

2024

 

Amount at inception of leases

  $ 4,504,921  

Amount amortized

    (2,913,203 )

Prior Period Impairment of Quinn River Lease

    (205,888 )

Balance – November 30, 2024

  $ 1,385,830  

 

Operating lease liabilities are summarized below:

 

Amount at inception of leases

  $ 4,461,521  

Amount amortized

    (2,788,127 )

Balance – November 30, 2024

  $ 1,673,394  

 

Warehouse and offices

  $ 1,463,997  

Land

    205,888  

Office equipment

    3,509  

Balance – November 30, 2024

  $ 1,673,394  
         

Lease liability

  $ 1,673,394  

Less: current portion

    (484,601 )

Lease liability, non-current

  $ 1,188,793  

 

Maturity analysis under these lease agreements is as follows:

 

Twelve months ended November 30, 2025

  $ 676,970  

Twelve months ended November 30, 2026

    395,348  

Twelve months ended November 30, 2027

    321,828  

Twelve months ended November 30, 2028

    322,329  

Twelve months ended November 30, 2029

    263,561  

Thereafter

    155,779  

Total

  $ 2,135,815  

Less: Present value discount

    (462,421 )

Lease liability

  $ 1,673,394  
v3.24.4
Intangible Assets
6 Months Ended
Nov. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Disclosure [Text Block]

Note 8: Intangible Assets

 

Intangible assets consisted of the following at November 30, 2024 and May 31, 2024:

 

   

November 30, 2024

 
           

Accumulated

                 
   

Gross

   

Amortization

   

Impairment

   

Net

 

License & Customer Relations

  $ 110,000     $ (110,000 )     -       -  

Tradenames - Trademarks

    222,000       (222,000 )     -       -  

Domain Names

    28,151       (19,824 )     -       8,327  

Total

  $ 357,993     $ (351,824 )     -     $ 8,327  

 

   

May 31, 2024

 
           

Accumulated

                 
   

Gross

   

Amortization

   

Impairment

   

Net

 

License & Customer Relations

    110,000       (110,000 )     -       -  

Tradenames - Trademarks

    222,000       (222,000 )     -       -  

Domain Names

    25,993       (16,015 )     -       9,978  

Total

  $ 357,993     $ (348,015 )   $ -     $ 9,978  

 

Total amortization expense charged to operations for the three months ended November 30, 2024 and 2023 was $825 and $7,750, respectively. Total amortization expense charged to operations for the six months ended November 30, 2024 and 2023 was $1,651 and $15,501, respectively.

 

Remaining amortization expense for intangible assets as of November 30, 2024 is as follows:

2025

  $ 2,478  

2026

    3,304  

2027

    2,545  
    $ 8,327  
v3.24.4
Goodwill
6 Months Ended
Nov. 30, 2024
Disclosure Text Block Supplement [Abstract]  
Goodwill Disclosure [Text Block]

Note 9: Goodwill

 

Goodwill in the amount of $557,896 is carried on the Company’s balance sheet at November 30, 2024 and May 31, 2024 in connection with the acquisition of Alternative Solutions on June 27, 2018.

 

Goodwill Impairment Test

 

The Company assessed its intangible assets as of May 31, 2024 for purposes of determining if an impairment existed as set forth in ASC 350 – Intangibles – Goodwill and Other and ASC 360 – Property Plant and Equipment. Pursuant to ASC 360, the Company determined that the fair value of its intangible assets exceeded the carrying value of goodwill at May 31, 2024. As a result, no impairment was recorded. At November 30, 2024 and May 31, 2024, the net amount of goodwill on the Company’s balance sheet was $557,896.

v3.24.4
Other Assets
6 Months Ended
Nov. 30, 2024
Disclosure Text Block Supplement [Abstract]  
Other Assets Disclosure [Text Block]

Note 10: Other Assets

 

Other assets included the following as of November 30, 2024 and May 31, 2024:

 

   

November 30,

   

May 31,

 
   

2024

   

2024

 

Security deposits

    157,500       157,500  
    $ 157,500     $ 157,500  
v3.24.4
Accounts Payable and Accrued Liabilities
6 Months Ended
Nov. 30, 2024
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 11: Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consisted of the following at November 30, 2024 and May 31, 2024:

 

   

November 30,

2024

   

May 31,

2024

 

Trade accounts payable

  $ 3,708,509     $ 2,508,769  

Accrued payroll and payroll taxes

    313,275       313,296  

Accrued liabilities

    378,253       533,994  

Total

  $ 4,400,037     $ 3,356,059  
v3.24.4
Due to Related Party
6 Months Ended
Nov. 30, 2024
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]  
Other Liabilities Disclosure [Text Block]

Note 12: Due to Related Party

 

On November 1, 2024, the Company acquired and cancelled 1,125,000 shares of common stock from a board member at a cost of $40,000. These shares were valued at $0.0557 per shares, which was the closing price on the date of the cancellation; a gain in the amount of $22,663 was recorded on this transaction. The purchase price of $40,000 had not been paid at November 30, 2024.

v3.24.4
Notes Payable
6 Months Ended
Nov. 30, 2024
Notes Payable [Line Items]  
Debt Disclosure [Text Block]

Note 13: Notes Payable

 

   

November 30, 2024

   

May 31, 2024

 

Debenture 2

Debenture in the principal amount of $250,000 (the “Debenture 2”) dated December 21, 2021, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 2 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 75,758 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 2 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $10,428 on Debenture 2.

 

On May 31, 2023, the Debenture 2 was amended as follows: (1) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and Interest monthly through the maturity date.

 

On December 31, 2023, the Debenture 2 was amended as follows: The original issue discount in the amount of $187,000 was reduced to $37,500. A gain on extinguishment of debt in the amount of $111,807 was recognized in connection with this transaction, and a discount in the amount of $6,501 was recorded.

 

During the three and six months ended November 30, 2024, the Company amortized discounts on the Debenture 2 in the aggregate amount of $0 and $197, respectively. During the three and six months ended November 30, 2024, the Company made principal and interest payments in the amount of $0 and $17,917, respectively, on Debenture 2. As of November 30, 2024, Debenture 2 has been paid in full.

    -       17,917  

 

   

November 30, 2024

   

May 31, 2024

 

Debenture 6

Debenture in the principal amount of $500,000 (the “Debenture 6”) dated January 4, 2022, which bears interest, payable quarterly commencing nine months after issuance, at a rate of 15% per annum. Principal on Debenture 6 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 6 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,154 on Debenture 6. The Company recorded an original issue discount in the amount of $375,000 on Debenture 6.

 

On May 31, 2023, the Debenture 6 was amended as follows: (1) the maturity date was extended to October 31, 2024; (2) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and interest monthly through the maturity date.

 

On December 31, 2023, the Debenture 6 was amended as follows: The original issue discount in the amount of $375,000 was reduced to $75,000. A gain on extinguishment of debt in the amount of $402,370 was recognized in connection with this transaction, and a discount in the amount of $209,783 was recorded.

 

During the three months and six ended November 30, 2024, the Company amortized discounts in the amount of $183,263 and $193,560, respectively, on Debenture 6. During the three and six months ended November 30, 2024, the Company capitalized interest in the amount of $10,708 on Debenture 6. During the three months and six ended November 30, 2024, the Company made principal payments in the amount of $511,340 on Debenture 6 (see note 17). At November 30, 2024, all amounts due under Debenture 6 have been paid in full.

    -       500,632  
                 

Promissory Note 6 (PN 6)

PN6 in the principal amount of $250,000 (the “PN6”) dated February 22, 2024, which bears interest a rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $11,799 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments in the amount of $29,890 and $58,902, respectively, on PN6. During the three and six months ended November 30, 2024, the Company made interest payments on PN6 in the amount of $5,508 and $11,895, respectively.

    163,600       222,502  

Notes Payable

  $ 163,600     $ 741,052  

Less: Discount

    -       (193,756 )

Notes Payable, Net of Discount

  $ 163,600     $ 547,296  

 

   

November 30, 2024

   

May 31, 2024

 

Total Notes Payable, Current Portion

  $ 128,898     $ 139,345  

Total Notes Payable, Long-term Portion, net of discount

  $ 34,702     $ 407,951  
Related Party [Member]  
Notes Payable [Line Items]  
Debt Disclosure [Text Block]

Note 15: Notes Payable Related Party

 

   

November 30, 2024

   

May 31, 2024

 

Promissory Note 1 (APN1)

PN1 Debenture in the principal amount of $475,000 (the “PN1”) dated January 2, 2024, which bears interest at a rate of 12% per annum. Principal and interest payments are due monthly for 36 months in the amount $15,917 beginning February 29, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN1 in the amount of $36,142 and $71,221, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN1 in the amount of $11,610 and $24,284, respectively.

  $ 362,840     $ 434,061  
                 

Promissory Note 2 (PN2)

PN2 in the principal amount of $465,000 (the “PN2”) dated January 2, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 36 months in the amount $15,582 beginning February 29, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN2 in the amount of $35,382 and $69,722, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN2 in the amount of $11,366 and $23,773, respectively.

    355,201       424,923  
                 

Promissory Note 3 (PN3)

PN3 in the principal amount of $450,000 (the “PN3”) dated February 22, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $21,239 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN3 in the amount of $53,802 and $106,023, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN3 in the amount of $9,914 and $21,410, respectively.

    294,480       400,503  
                 

Promissory Note 4 (PN4)

PN4 in the principal amount of $300,000 (the “PN4”) dated February 22, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $14,159 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN4 in the amount of $35,868 and $70,682, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN4 in the amount of $6,609 and $14,274, respectively.

    196,320       267,002  
                 

Promissory Note 5 (PN5)

PN5 in the principal amount of $350,000 (the “PN5”) dated February 22, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $16,519 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN5 in the amount of $41,487 and $82,463, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN5 in the amount of $7,711 and $16,653, respectively.

    229,040       311,503  
                 

Promissory Note 7 (PN7)

PN7 in the principal amount of $100,000 (the “PN7”) dated March 6, 2024, which bears interest at the rate of 12% per annum. Interest only payments are due quarterly in the amount of $3,500 for four quarters beginning March 29, 2024. The loan is due on February 28, 2025. During the three and six months ended November 30, 2024, the Company made principal payments on PN7 in the amount of $0. During the three and six months ended November 30, 2024, the Company made interest payments on the PN7 in the amount of $3,500 and $7,000, respectively.

    100,000       100,000  
                 

Promissory Note 8 (PN8)

PN8 in the principal amount of $134,000 (the “PN8”) dated April 30, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $6,308 beginning May 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN8 in the amount of $15,664 and $30,867, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN8 in the amount of $3,529 and $6,979, respectively.

    98,164       129,031  

 

   

November 30, 2024

   

May 31, 2024

 

Promissory Note 9 (PN9)

PN9 in the principal amount of $2,600,000 (the “PN9”) dated August 28, 2024. Principal in the amount of $2,200,000 automatically converted into 56,847,545 shares of the Company’s common stock on August 30,2024; the remaining principal in the amount of $400,000 bears interest at the rate of 12% per annum and is due on August 28, 2025. The conversion of the $2,200,000 in principal was at the market price per share of $0.0387 on the date of the note, and no gain or loss was recognized on this transaction. See note 17. No interest was accrued on this note during the three months ended November 30, 2024. During the three and six months ended November 30, 2024, the Company accrued interest on the PN9 in the amount of $12,000.

    400,000       -  
                 

Promissory Note 10 (PN10)

PN10 in the principal amount of $150,000 (the “PN10”) dated October 15, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $7,061 beginning November 30, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN10 in the amount of $5,561. During the three and six months ended November 30, 2024, the Company made interest payments on the PN10 in the amount of $1,500.

    144,439       -  
                 

Total

  $ 2,180,484     $ 2,067,023  

 

   

November 30, 2024

   

May 31, 2024

 

Total Notes Payable – Related Party, Current Portion

  $ 1,514,362     $ 988,472  

Total Notes Payable – Related Party, Long Term Portion

  $ 666,122     $ 1,078,551  

 

Aggregate maturities of notes payable, convertible notes payable, and notes payable – related parties as of November 30, 2024 are as follows:

 

For the twelve months ended November 30,

 

2025

  $ 1,769,303  

2026

    866,804  

2027

    309,042  

2028

    1,060,261  

Total

  $ 4,005,410  
v3.24.4
Convertible Notes Payable
6 Months Ended
Nov. 30, 2024
Debt Disclosure [Abstract]  
Long-Term Debt [Text Block]

Note 14: Convertible Notes Payable

 

   

November 30, 2024

   

May 31, 2024

 

US Convertible Debenture 2 (Navy Capital Green Fund)

Convertible debenture in the principal amount of $1,000,000 (the “U.S. Convertible Debenture 2”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 2. The U.S. Convertible Debenture 2 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 2 was convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40.

 

On July 26, 2019, U.S. Convertible Debenture 2 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. convertible Debenture 2, the conversion price of U.S. Convertible Debenture 2 would be reduced to such issuance price, and the exercise price of the warrant issuable in connection with U.S. Convertible Debenture 2 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 2 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 2 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $813,724 on the U.S. Convertible Debenture 2.

 

On April 15, 2021, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $509,700 during the year ended May 31, 2021.

 

On September 15, 2022, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of debentures with a principal amount of $675,668 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $11,261 were converted to 2,410,279 shares of common stock and warrants to purchase 1,205,140 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $450,446 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $422,331 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $223,515 and $198,816, respectively.

 

On December 29, 2023, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) principal payments in the amount of $8,000 per month are due for 48 months beginning January 31, 2024, and a balloon payment in the amount of $235,658 will be due on January 31, 2028; (iv) accrued interest in the amount of $54,053 was added to the principal balance. A loss on extinguishment of debt in the amount of $344,036 was charged to operations in connection with this transaction. During the years ended May 31, 2024 and 2023, the Company accrued interest in the amounts of $37,526 and $27,717, on the U.S. Convertible Debenture 2, respectively. During the three and six months ended November 30, 2024, the Company made principal payments in the amount of $471,387 and $481,005, respectively, on the U.S. Convertible Debenture 2 (see note 17). During the three and six months ended November 30, 2024, the Company made interest payments in the amount of $6,381 on the U.S. Convertible Debenture 2. At November 30, 2024, all amounts due under U.S. Convertible Debenture 2 have been paid in full.

  $ -       481,005  

 

   

November 30, 2024

   

May 31, 2024

 

Canaccord Debentures

Convertible debentures payable in the aggregate principal amount of $12,012,000 (the “Canaccord Debentures”) dated December 12, 2018, which bear interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the Canaccord Debentures. The Canaccord Debentures were to mature on a date that was three years following issuance. The Canaccord Debentures were convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. The Canaccord Debentures have other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The Canaccord Debentures are unsecured obligations of the Company and rank pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. During the three months ended November 30, 2019, in two separate transactions, principal in the aggregate amount of $25,857 was converted into an aggregate of 8,081 shares of the Company’s common stock, and warrants to purchase 4,040 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement. No discount was recorded for the fair value of the warrants issued. Because the market price of the Company’s common stock was less than the conversion price on the date of issuance of the Canaccord Debentures, a discount was not recorded on the Canaccord Debentures.

 

On March 31, 2021, the Canaccord Debentures were amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; (ii) the maturity date was extended from December 12, 2021 to December 12, 2022; (iii) the mandatory conversion threshold was reduced from a daily volume weighted average trading price of greater than $4.80 per share to $2.40 per share for the preceding ten consecutive trading days; and (iv) the exercise price of the warrants issuable upon conversion was reduced from $4.40 to $1.60 and the expiration of the warrants extended until March 31, 2024. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $3,286,012 during the year ended May 31, 2021. During the year ended May 31, 2022, principal in the aggregate amount of $281,000 was converted into an aggregate of 234,167 shares of the Company’s common stock, and warrants to purchase 117,084 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement.

 

On September 15, 2022, the Canaccord Debentures were further amended as follows: (i) the conversion price of debentures with a principal amount of $7,965,278 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $132,755 were converted to 28,414,149 shares of common stock and warrants to purchase 14,207,075 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $52,53,873 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $4,547,660 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $2,623,852 and $1,923,808, respectively.

 

On December 28, 2023, the Canaccord Debentures were amended as follows: (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) the maturity date was extended to January 31, 2028; (iv) accrued interest in the amount of $186,111 was added to the principal balance and accrued interest in the amount of $465,012 was forgiven (v) Put Rights (the “Put Rights”) were granted to the debenture holders granting each debenture holder the right to require the Company to redeem all or any part of the debenture in cash at a redemption price of 60% of face value (a loss on extinguishment of debt in the amount of $1,727,071 was charged to operations in connection with this transaction); (vi) interest accruing through February 28, 2025 will be added to the principal balance rather than paid to debenture holders; (v) debenture holders were granted an additional put right in the event the Company’s cash available for debt service for any fiscal quarter exceeds $750,000, subject to pro ration, to require the Company to redeem all or any part of such debenture holder’s outstanding Canaccord Debentures in cash at a redemption price equal to the aggregate principal amount of the Canaccord Debentures being so redeemed, (vi) a provision that the Company shall redeem on the last day of each calendar month beginning March 31, 2025 a portion of the outstanding Canaccord Debentures less the amount of interest paid on such date was added; and (vii) subject to the receipt of regulatory approvals, a security interest in certain of the Company’s assets (such as licenses, inventory (including work in process), equipment (excluding equipment subject to purchase money financing) and contract rights (excluding investments in entities other than wholly owned subsidiaries)) to the holders of the Canaccord Debentures and to other holders of the Company’s debt, now or in the future, as the Company may elect was granted.

 

On January 4, 2024, debenture holders exercised Put Rights with regard to the Canaccord Debentures with a principal amount of $3,875,095, the Company made a cash payment to the debenture holders in the amount of $2,325,056 representing 60% of the principal amount of these debentures, and the principal amount of $1,550,039 representing 40% of the principal amount of these debentures was forgiven. The principal balance of the Canaccord Dentures subsequent to the January 4 Put Rights exercise was $1,544,231. Interest at the rate of 8.0% per annum on this amount will be capitalized monthly through February 28, 2025. Principal and interest payments in the amount of $28,522 will be due monthly beginning March 31, 2025 and continuing through December 31, 2027; on January 31, 2028 a balloon payment in the amount of $1,038,777 will be due. A gain on settlement of debt in the amount of $2,015,051 was recognized in connection with this transaction. During the three and six months ended November 30, 2024, the Company capitalized interest in the amounts of $32,788 and $64,930 on the Canaccord Debentures.

 

On December 27, 2024, the Company executed a Supplemental Indenture to amend that certain debenture indenture by and between the Company and Odyssey Trust Company, as Trustee, dated as of December 12, 2018, as supplemented March 31, 2021, as supplemented September 15, 2022, and as supplemented December 28, 2023, in order to amended the terms of its outstanding $1,378,778 principal amount unsecured convertible debentures Canaccord Debentures issued December 12, 2018 to provide the Company an option to redeem all outstanding Canaccord Debentures in cash at a redemption price equal to $600 per $1,000 principal amount of Canaccord Debentures; any accrued but unpaid interest through to and including the redemption date shall not be paid and shall be cancelled. See note 22.

    1,661,326       1,596,396  

 

   

November 30, 2024

   

May 31, 2024

 

US Convertible Debenture 1 (Navy Capital Green Co-Invest Fund)

Convertible debenture in the principal amount of $4,000,000 to a related party (the “U.S. Convertible Debenture 1”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 1. The U.S. Convertible Debenture 1 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 1 was convertible into units (the “Convertible Debenture Units”) at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. On July 26, 2019, U.S. Convertible Debenture 1 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. Convertible Debenture 1, the conversion price of U.S. Convertible Debenture 1 would be reduced to such issuance price, and the exercise price of the warrant Issuable in connection with U.S. Convertible Debenture 1 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 1 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 1 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $3,254,896 on the U.S. Convertible Debenture 1.

 

On April 15, 2021, the U.S. Convertible Debenture 1 was amended as follows: (i) the conversion price of the debenture was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $2,038,803 during the year ended May 31, 2021 in connection with the amendment.

 

On September 15, 2022, the U.S. Convertible Debenture 1 was further amended as follows: (i) the conversion price of debentures with a principal amount of $2,702,674 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $45,044 were converted to 9,641,118 shares of common stock and warrants to purchase 4,820,560 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $1,801,783 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $1,689,368 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $894,090 and $795,278, respectively.

 

On December 29, 2023, the U.S. Convertible Debenture 1 was amended as follows: (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) the maturity date was extended to January 31, 2028; (iv) accrued interest in the amount of $215,414 was added to the principal balance. A loss on extinguishment of debt in the amount of $1,376,083 was charged to operations in connection with this transaction. During the three and six months ended November 30, 2024, the Company made principal payments in the amount of $1,885,556 and $1,924,030, respectively, on the U.S. Convertible Debenture 1 (see note 17). During the three and six months ended November 30, 2024, the Company made interest payments in the amount of $25,226 on the U.S. Convertible Debenture 1. At November 30, 2024, all amounts due under U.S. Convertible Debenture 1 have been paid in full.

    -       1,924,030  
                 

Total Convertible Notes Payable

  $ 1,661,326     $ 4,001,431  

 

   

November 30, 2024

   

May 31, 2024

 

Total – Convertible Notes Payable, Current Portion

  $ 126,043     $ 302,005  

Total – Convertible Notes Payable, Long-term Portion

  $ 1,535,283     $ 3,699,426  
v3.24.4
Lease Liabilities - Financing Leases
6 Months Ended
Nov. 30, 2024
Disclosure Text Block [Abstract]  
Lessee, Finance Leases [Text Block]

Note 16: Lease Liabilities - Financing Leases

 

   

November 30, 2024

   

May 31, 2024

 

Financing lease obligation under a lease agreement for extraction equipment dated March 14, 2022 in the original amount of $359,900 payable in forty-eight monthly installments of $10,173 including interest at the rate of 15.89%. During the three and six months ended November 30, 2024, the Company made principal payments on this lease obligation in the amounts of $23,168 and $47,266, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on this lease obligation in the amounts of $6,421 and $13,772, respectively.

  $ 145,851     $ 193,117  
                 

Financing lease obligation under an agreement for equipment dated June 20, 2022 in the original amount of $12,400 payable in forty-eight monthly installments of $350 including interest at a rate of 15.78%. During the three and six months ended November 30, 2024, the Company made principal payments on this lease obligation in the amounts of $456 and $901, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on this lease obligation in the amounts of $69 and $149, respectively.

  $ 2,458       3,359  
                 

Total

  $ 148,309     $ 196,476  
                 

Current portion

  $ 108,410     $ 96,224  

Long-term maturities

    39,899       100,252  

Total

  $ 148,309     $ 196,476  

 

Aggregate maturities of lease liabilities – financing leases as of November 30, 2024 are as follows:

 

For the period ended November 30,

 

2025

  $ 108,410  

2026

    39,899  

Total

  $ 148,309  
v3.24.4
Stockholders’ Equity
6 Months Ended
Nov. 30, 2024
Stockholders' Equity Note [Abstract]  
Equity [Text Block]

Note 17: Stockholders Equity

 

The Company’s authorized capital stock consists of 345,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share.

 

Common stock transactions for the six months ended November 30, 2024

 

On August 30, 2024, the Company issued 56,847,545 shares of common stock pursuant to the conversion $2,200,000 of the principal amount of a note payable (see note 15). No gain or loss was recorded on this transaction as the conversion occurred according to the terms of the note.

 

On September 10, 2024, the Company settled three notes payable in the aggregate principal amount of $2,868,282 for a cash payment in the amount of $2,600,000. In addition, the noteholders returned for cancellation a total of 15,488,901 shares of the Company’s common stock and warrants to purchase 6,177,216 shares of the Company’s common stock. The cancelled shares were valued at the closing price of the Company’s common stock on the date of the cancellation, or $0.044 per share for a total value of $681,510. The warrants were valued at $4,136 using the Black-Sholes valuation model. A gain in the amount of $949,793 was recorded on this transaction. See note 18.

 

On November 1, 2024, the Company acquired and cancelled 1,125,000 shares of common stock from a board member at a cost of $40,000. These shares were valued at $0.0557 per shares, which was the closing price on the date of the cancellation; the amount of $22,663 was charged to additional paid-in capital on this related party transaction. The purchase price of $40,000 was unpaid at November 30, 2024. (see note 12)

 

Common stock transactions for the six months ended November 30, 2023

 

None.

 

Warrants

 

Warrants for the six months ended November 30, 2024:

 

The following table summarizes the significant terms of warrants outstanding at November 30, 2024. This table does not include the unit warrants. See Unit Warrants section below.

 

Range of

exercise

Prices

   

Number of

warrants

Outstanding

   

Weighted

average

remaining

contractual

life (years)

   

Weighted

average

exercise

price of

outstanding

Warrants

   

Number of

warrants

Exercisable

   

Weighted

average

exercise

price of

exercisable

Warrants

 
                                             
$ 0.40-0.4125       14,549,685       1.12     $ 0.40       14,549,685     $ 0.40  
          14,549,685       1.12     $ 0.40       14,549,685     $ 0.40  

 

Transactions involving warrants are summarized as follows. This table does not include the unit warrants. See Unit Warrants section below.

 

   

Number of

Shares

   

Weighted Average

Exercise Price

 

Warrants outstanding at May 31, 2023

    21,181,449     $ 0.40  

Granted

    -     $ -  

Exercised

    -     $ -  

Cancelled / Expired

    (454,548 )   $ 0.41  

Warrants outstanding at May 31, 2024

    20,726,901     $ 0.40  

Granted

               

Exercised

    -     $ -  

Cancelled / Expired

    (6,177,216 )   $ 0.40  

Warrants outstanding at November 30, 2024

    14,549,685     $ 0.40  

 

Stock Options

 

Stock options for the six months ended November 30, 2024

 

During the six months ended November 30, 2024, 41,667 options issued to the Company’s previous Chief Science Officer expired.

 

The following table summarizes the significant terms of options outstanding at November 30, 2024.

 

Range of

exercise

Prices

   

Number of

options

Outstanding

   

Weighted

average

remaining

contractual

life (years)

   

Weighted

average

exercise

price of

outstanding

Options

   

Number of

Options

Exercisable

   

Weighted

average

exercise

price of

exercisable

Option

 
                                             
$ 0.039       8,000,000       9.15     $ 0.039       2,520,832     $ 0.039  

 

Transactions involving options are summarized as follows.

 

   

Number of

Shares

   

Weighted Average

Exercise Price

 

Options outstanding at May 31, 2024

    8,041,667     $ 0.039  

Granted

    -     $ -  

Exercised

    -     $ -  

Cancelled / Expired

    (41,667 )   $ -  

Options outstanding at November 30, 2024

    8,000,000     $ 0.039  

 

The Company valued options using the Black-Scholes valuation model utilizing the following variables during the six months ended November 30, 2024:

 

   

November 30,

 
   

2024

 

Volatility

    269.44 %

Dividends

  $ -  

Risk-free interest rates

    3.8 %

Expected term (years)

    5.00  

 

Stock options for the three months ended November 30, 2023

 

None.

 

During the three and six months ended November 30, 2024, the Company charged $23,382 and $52,184, respectively, to stock-based compensation expense, in connection with the vesting of stock options. There were no comparable charges during the three and six months ended November 30, 2023.

 

The aggregate intrinsic value of options outstanding and exercisable at November 30, 2024 and 2023 was $16,637 and $0, respectively. Aggregate intrinsic value represents the difference between the fair value of the Company’s stock on the last day of the fiscal period, which was $0.045 as of November 30, 2024, and the exercise price multiplied by the number of options outstanding and exercisable.

v3.24.4
Gain on Settlement of Debt
6 Months Ended
Nov. 30, 2024
Gain On Settlement Of Debt Abstract  
Gain on Settlement of Debt [Text Block]

Note 18: Gain on Settlement of Debt

 

On August 28, 2024, the Company raised $2,600,000 in cash from the issuance of PN9. See note 13. On August 30, 2024, the Company issued 56,847,545 shares of common stock pursuant to the conversion $2,200,000 of the principal amount of a note payable (see note 15). No gain or loss was recorded on this transaction as the conversion occurred according to the terms of the note.

 

On September 10, 2024, the Company utilized the proceeds of PN9 to settle three notes payable in the aggregate principal amount of $2,868,282 for a cash payment in the amount of $2,600,000. See note 17. In addition, the noteholders returned for cancellation a total of 15,488,901 shares of the Company’s common stock and warrants to purchase 6,177,216 shares of the Company’s common stock. The cancelled shares were valued at the closing price of the Company’s common stock on the date of the cancellation, or $0.044 per share for a total value of $681,510. The warrants were valued at $4,136 using the Black-Sholes valuation model. A gain in the amount of $949,793 was recorded on this transaction.

 

The Company valued the warrants using the Black-Scholes valuation model utilizing the following variables during the six months ended November 30, 2024:

 

   

November 30,

 
   

2024

 

Volatility

    104.68 %

Dividends

  $ -  

Risk-free interest rates

    4.36 %

Expected term (years)

    1.05  
v3.24.4
Related Party Transactions
6 Months Ended
Nov. 30, 2024
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]

Note 19: Related Party Transactions

 

As of November 30, 2024 and May 31, 2024, the Company had accrued salary due to Michael Abrams, a former officer of the Company prior to his September 1, 2015 termination, in the amount of $16,250.

 

During the three months ended November 30, 2024, the Company made payments of $10,000 to one of its three directors and a payment of $5,000 to one director for their participation on the Board, for a total of $15,000. The Company also made a payment of $5,000 to one director for consulting fees. During the six months ended November 30, 2024, the Company made payments of $20,000 to one of its three and directors and $15,000 to one of its directors for their participation on the Board, for a total of $35,000; the Company also made a payment of $5,000 to one of its directors for consulting fees.

 

The Company’s CEO has waived his board fees for the period.

 

On November 1, 2024, the Company acquired and cancelled 1,125,000 shares of common stock from a board member at a cost of $40,000. These shares were valued at $0.0557 per shares, which was the closing price on the date of the cancellation. The amount of $22,663 was charged to additional paid-in capital on this transaction. The purchase price of $40,000 had not been paid at November 30, 2024.

 

On August 28, 2024 the Company issued PN9, a note payable to a related party, in the principal amount of $2,600,000. Principal in the amount of $2,200,000 automatically converted into 56,847,545 shares of the Company’s common stock on August 30,2024; the remaining principal in the amount of $400,000 bears interest at the rate of 12% per annum and matures on August 28, 2025. See note 15.

 

On October 15, 2024 the Company issued PN10, a note payable to a related party, in the principal amount of $150,000. Principal PN10 bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $7,061 beginning November 30, 2024. See note 15.

 

At November 30, 2024, there are nine related party notes outstanding with a total principal amount of $2,180,484. See note 15.

v3.24.4
Income Taxes
6 Months Ended
Nov. 30, 2024
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]

Note 20: Income Taxes

 

The following table summarizes the Company’s income tax accrued for the three months ended November 30, 2024 and 2023:

 

The Company accounts for income taxes under FASB ASC 740-10, which provides for an asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized based on anticipated future tax consequences, using currently enacted tax laws, attributed to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts calculated for income tax purposes.

 

The components of the income tax provision include:

 

   

Three Months Ended November 30,

 
   

2024

   

2023

 

Revenue

  $ 4,161,270     $ 5,197,214  

Directly attributable costs

    (1,928,995 )     (3,025,595 )

Deferred

    2,232,275       2,171,619  

Tax rate

    21 %     21 %

Tax expense

  $ 468,778     $ 456,040  

 

   

Six Months Ended November 30,

 
   

2024

   

2023

 

Revenue

  $ 8,966,435     $ 10,311,741  

Directly attributable costs

    (4,234,657 )     (5,866,196 )

Deferred

    4,731,778       4,445,545  

Tax rate

    21 %     21 %

Tax expense

  $ 993,674     $ 933,564  

 

Note: Change in uncertain tax position with all tax expense recorded in current year due to change in estimate. No prior year net operating loss was considered.

 

Due to the accrual of taxes related to Section 280E of the Internal Revenue Code, as amended, the Company has an uncertain tax accrual that is currently being expensed as a change in estimate. The Company has net operating losses that it believes are available to it to offset this expense; however, there can be no assurance under current interpretations of tax laws for cannabis companies that the Company will be allowed to use these net operating losses to offset Section 280E tax expenses.

 

During the three months ended November 30, 2024, the Company received a notification from the Internal Revenue Service (“IRS”) that the Company has been assessed the amount of $111,441, consisting of estimated tax owed of $71,959, penalties of $26,771, and interest of $12,711 for failure to file its tax return for the year ended May 31, 2022. The Company made a good faith payment to the IRS in the amount of $5,000 pursuant to this notice during the three months ended November 30, 2024. The accounting firm responsible for this tax filing on behalf of the Company has been terminated, and the Company is pursuing this firm for recovery of penalties and interest assessed.

v3.24.4
Commitments and Contingencies
6 Months Ended
Nov. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]

Note 21: Commitments and Contingencies

 

Legal Matters

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of the date of filing of this report, there were no pending or threatened lawsuits.

 

Lease Arrangements

 

The Company leases several facilities for office, warehouse, and retail space. Currently lease commitments are as follows:

 

 

A lease that commenced in February 2019 for 1,400 square feet of office space located at 1718 Industrial Road, Las Vegas, NV 89102, for a term of eighteen months, and for rent of $1,785 per month. In June 2020, this lease was extended to November 30, 2022, with the monthly rent increasing to $1,867 until September 2021, after which time it will be subject to annual increases of 3%. The lease was extended again on April 1, 2022, effective September 1, 2022 until November 30, 2024. The monthly rent increased on September 1, 2022 to $2,084. Effective September 1, 2024, the monthly rent was increased to $2,310, and the term of the lease was extended to November 30, 2029.

 

 

 

 

A lease that commenced January 2018 for 1,000 square feet of storefront space plus 5,900 square feet of warehouse space located at 1800 Industrial Road, Suites 102, 160, and 180, Las Vegas, NV 89102, for a term of five years and for initial base rent of $7,500 per month, with annual increases of 3%. In February 2020, this lease was extended to February 28, 2030 and the monthly rent was increased by $600. At November 30, 2024, the monthly rent on this lease was $10,679.

 

 

 

 

A lease that commenced in February 2019 for 2,504 square feet of office space located at 1800 Industrial Road, Suite 100, Las Vegas, NV 89102 for a term of eighteen months and for initial rent of $3,210 per month, with annual increases of 4%. In February 2020, this lease was extended to February 28, 2030, and the lease was modified to include annual rent increases of 3%. At November 30, 2024, the monthly rent on this lease was $3,758.

 

 

 

 

A lease that commenced in January 2016 for 22,000 square feet of warehouse space located at 203 E. Mayflower Avenue, North Las Vegas, NV 89030 for a term of five years and initial rent of $11,000 per month, which amount increased to $29,000 per month on January 1, 2020. In June 2020, this lease was extended to February 28, 2026, and the monthly rent was amended as follows: $25,000 for the months of April, May, and June 2020; $22,500 for the months of March 2021 through February 2022; $23,175 for the months of March 2022 through February 2023; 23,870 for the months of March 2023 through February 2024; $24,586 for the months of March 2024 through February 2025; and $25,323 for the months of March 2025 through February 2026.

 

 

 

 

A lease that commenced in October 2023 for 2,547 square feet of office space located at 516 S. 4th Street, Las Vegas, NV 89101 for a term of five years and initial rent of $5,083 per month through September 30, 2024. The monthly rent will increase to $5,236 for the months of October 2024 through September 2025; $5,393 for the months of October 2025 through September 2026; $5,554 for the months of October 2026 through September 2027; and $5,721 for the months of October 2027 through September 2028.

 

In connection with the Company’s planned Colorado operations, on April 17, 2015, pursuant to an Industrial Lease Agreement (the “Lease”), CLS Labs Colorado leased 14,392 square feet of warehouse and office space (the “Leased Real Property”) in a building in Denver, Colorado where certain intended activities, including growing, extraction, conversion, assembly and packaging of cannabis and other plant materials, are permitted by and in compliance with state, city and local laws, rules, ordinances and regulations. The Lease had an initial term of seventy-two (72) months and provided CLS Labs Colorado with two options to extend the term of the lease by up to an aggregate of ten (10) additional years. In August 2017, as a result of the Company’s decision to suspend its proposed operations in Colorado, CLS Labs Colorado asked its landlord to be relieved from its obligations under the Lease.

 

In August 2017, the Company’s Colorado subsidiary received a demand letter from its Colorado landlord requesting the forfeiture of the $50,000 security deposit, $10,000 in expenses, $15,699 in remaining rent due under the lease agreement and $30,000 to buy out the remaining amounts due under the lease. The $50,000 security deposit was forfeited to the Landlord and the Landlord has made no additional demands for payment or attempts at collection since August of 2017. These expenses, which are a liability of the Company’s Colorado subsidiary, have been accrued on the balance sheet as of November 30, 2024.

v3.24.4
Subsequent Events
6 Months Ended
Nov. 30, 2024
Subsequent Events [Abstract]  
Subsequent Events [Text Block]

Note 22: Subsequent Events

 

Termination of Chief Operating Officer

 

On December 17, 2024, the Company terminated the employment of Joseph Ramalho, its Chief Operating Officer. 

 

Amendments to Convertible Debentures 

 

On December 27, 2024, the Company executed a Supplemental Indenture to amend that certain debenture indenture by and between the Company and Odyssey Trust Company, as Trustee, dated as of December 12, 2018, as supplemented March 31, 2021, as supplemented September 15, 2022, and as supplemented December 28, 2023 (collectively, the “Debenture Indenture”), in order to amended the terms of its outstanding $1,378,778 principal amount unsecured convertible debentures (the “December Debentures”) issued December 12, 2018 to provide the Company an option to redeem all outstanding December Debentures in cash at a redemption price equal to $600 per $1,000 principal amount of December Debentures; any accrued but unpaid interest through to and including the redemption date shall not be paid and shall be cancelled. See note 14.

 

Secured Promissory Notes

 

On January 7, 2025, the Company entered into four secured promissory notes in the aggregate amount of $1,000,000.  These notes bear interest at the rate of 12%, are payable in 24 equal monthly installments beginning January 31, 2025, and are due on December 31, 2026.  Three of these notes with an aggregate principal amount of $900,000 are payable to related parties.

v3.24.4
Pay vs Performance Disclosure - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
Pay vs Performance Disclosure        
Net Income (Loss) $ (87,671) $ (1,302,272) $ (908,534) $ (1,766,113)
v3.24.4
Insider Trading Arrangements
3 Months Ended
Nov. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.4
Accounting Policies, by Policy (Policies)
6 Months Ended
Nov. 30, 2024
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in US dollars. The Company has adopted a fiscal year end of May 31st.

Consolidation, Policy [Policy Text Block]

Principals of Consolidation

The accompanying consolidated financial statements include the accounts of CLS Holdings USA, Inc.; its direct and indirect wholly owned operating subsidiaries, CLS Nevada, Inc., (“CLS Nevada”), CLS Labs, Inc. (“CLS Labs”), CLS Labs Colorado, Inc. (“CLS Colorado”), CLS Massachusetts, Inc. (“CLS Massachusetts”), and Alternative Solutions, LLC (“Alternative Solutions”); and wholly owned inactive subsidiaries CLS Labs Colorado, Inc. (“CLS Colorado”) and CLS Massachusetts, Inc. (“CLS Massachusetts”). Alternative Solutions is the sole owner of the following three entities (collectively, the “Oasis LLCs”): Serenity Wellness Center, LLC (“Serenity Wellness Center”); Serenity Wellness Products, LLC (“Serenity Wellness Products”); and Serenity Wellness Growers, LLC (“Serenity Wellness Growers”). The accompanying consolidated financial statements also include the accounts of CLS CBD in which the company owns a 95% ownership interest and a variable interest entity, Kealii Okamalu, LLC (“Kealii Okamalu”), in which the Company owns a 50% interest. All material intercompany transactions have been eliminated upon consolidation of these entities.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassification

Certain reclassifications, not affecting previously reported net income or cash flows, have been made to the previously issued financial statements to conform to the current period presentation.

 

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash, Cash Equivalents, and Restricted Cash

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. The Company had cash and cash equivalents of $592,584 and $600,007 as of November 30, 2024 and May 31, 2024, respectively.

Accounts Receivable [Policy Text Block]

Allowance for Doubtful Accounts

The Company generates the majority of its revenues and corresponding accounts receivable from the sale of cannabis, and cannabis related products. The Company evaluates the collectability of its accounts receivable considering a combination of factors. In circumstances where it is aware of a specific customer’s inability to meet its financial obligations to it, the Company records a specific reserve for bad debts against amounts due in order to reduce the net recognized receivable to the amount it reasonably believes will be collected. For all other customers, the Company recognizes reserves for bad debts based on past write-off experience and the length of time the receivables are past due. The Company had bad debt expense of $0 and $93 during the three months ended November 30, 2024 and 2023.

Inventory, Policy [Policy Text Block]

Inventory

Inventories are stated at the lower of cost or market. Cost is determined using a perpetual inventory system whereby costs are determined by acquisition costs of individual items included in inventory. Market is determined based on net realizable value. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable values. Our cannabis products consist of prepackaged purchased goods ready for resale, along with produced tinctures and extracts developed under our production license.

Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

Property and equipment is recorded at the lower of cost or estimated net recoverable amount, and is depreciated using the straight-line method over its estimated useful life. Property acquired in a business combination is recorded at estimated initial fair value. Property, plant, and equipment are depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based upon the following life expectancy:

 

 

Years

 

Office equipment

 

 

3 to 5

 

Furniture & fixtures

 

 

3 to 7

 

Machinery & equipment

 

 

3 to 10

 

Leasehold improvements

 

Term of lease

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated, and any resulting gain or loss is reflected in operations.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-Lived Assets

The Company reviews its property and equipment and any identifiable intangibles including goodwill for impairment on an annual basis utilizing the guidance set forth in the Statement of Financial Accounting Standards Board ASC 350 “Intangibles – Goodwill and Other” and ASC 360 “Property, Plant, and Equipment.” At November 30, 2024, the net carrying value of goodwill on the Company’s balance sheet remained at $557,896.

Employee Retention Tax Credit , Policy [Policy Text Block]

Employee Retention Tax Credit

Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), the Company was eligible for a refundable employee retention tax credit (the “ERTC”), subject to certain criteria. As ERTCs are not within the scope of ASC 740, Income Taxes, the Company has chosen to account for the ERTCs by analogizing to the International Standard IAS 20, Accounting/or Government Grants and Disclosure of Government Assistance (“IAS 20”). In accordance with IAS 20, an entity recognizes government grants only when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. During the three months ended November 30, 2024 and 2023, the Company received an aggregate of $50,103 and $0, respectively, and during the six months ended November 30, 2024 and 2023, the Company received an aggregate of $50,103 and $924,862, respectively; these amounts were accounted for as other income on the Company’s condensed consolidated statement of operations.

 

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income

ASC 220-10-15 “Reporting Comprehensive Income,” establishes standards for reporting and displaying of comprehensive income, its components and accumulated balances. Comprehensive income is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220-10-15 requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The Company does not have any items of comprehensive income in any of the periods presented.

Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]

Non-Controlling Interests

The Company reports “non-controlling interest in subsidiary” as a component of equity, separate from parent’s equity, on the Consolidated Balance Sheets. In addition, the Company’s Consolidated Statements of Operations includes “net income (loss) attributable to non-controlling interest.” There was no non-controlling interest reported during the three and six months ended November 30, 2024. During the three and six months ended November 30, 2023, the Company reported a non-controlling interest in the amount of $(92) and ($2,200), respectively, representing 50% of the income (loss) incurred by its partially owned subsidiary, Kealii Okamalu.

Consolidation, Variable Interest Entity, Policy [Policy Text Block]

Variable Interest Entities

The Company’s consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and variable interest entities (“VIE”), where the Company is the primary beneficiary under the provisions of ASC 810, Consolidation (“ASC 810”). A VIE must be consolidated by its primary beneficiary when, along with its affiliates and agents, the primary beneficiary has both: (i) the power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) the obligation to absorb losses or the right to receive the benefits of the VIE that could potentially be significant to the VIE. The Company reconsiders whether an entity is still a VIE only upon certain triggering events and continually assesses its consolidated VIEs to determine if it continues to be the primary beneficiary.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations of Credit Risk

The Company maintains its cash in bank deposit accounts and other accounts, the balances of which at times may be uninsured or exceed federally insured limits. From time to time, some of the Company’s funds are also held by escrow agents; these funds may not be federally insured. The Company continually monitors its banking relationships and consequently has not experienced any losses in such accounts.

Advertising Cost [Policy Text Block]

Advertising and Marketing Costs

All costs associated with advertising and promoting products are expensed as incurred. Total recognized advertising and marketing expenses were $96,709 and $103,448 for the three months ended November 30, 2024 and 2023, respectively, and $174,710 and $227,059 for the six months ended November 30, 2024 and 2023, respectively.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $281 and $431 for the three months ended November 30, 2024 and 2023, respectively, and $421 and $1,887 for the six months ended November 30, 2024 and 2023, respectively.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Pursuant to Accounting Standards Codification (“ASC”) No. 825–- Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheets. The carrying amounts of the Company’s cash and cash equivalents, notes receivable, convertible notes payable, accounts payable and accrued expenses, none of which is held for trading, approximate their estimated fair values due to the short-term maturities of those financial instruments.

 

A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

Level 1–- Quoted prices in active markets for identical assets or liabilities.

Level 2–- Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

Level 3–- Significant unobservable inputs that cannot be corroborated by market data.

Revenue [Policy Text Block]

Revenue Recognition

Revenue from the sale of cannabis products is recognized by Oasis at the point of sale, at which time payment is received, the product is delivered, and the Company’s performance obligation has been met. Management estimates an allowance for sales returns.

The Company also recognizes revenue from Serenity Wellness Products LLC and Serenity Wellness Growers LLC, d/b/a City Trees (“City Trees”). City Trees recognizes revenue from the sale of the following cannabis products and services to licensed dispensaries, cultivators and distributors within the State of Nevada:

 

Premium organic medical cannabis sold wholesale to licensed retailers

 

 

 

 

Recreational marijuana cannabis products sold wholesale to licensed distributors and retailers

 

 

 

 

Extraction products such as oils and waxes derived from in-house cannabis production

 

 

 

 

Processing and extraction services for licensed medical cannabis cultivators in Nevada

 

 

 

 

High quality cannabis strains in the form of vegetative cuttings for sale to licensed medical cannabis cultivators in Nevada

Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from commercial sales of products and licensing agreements by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.

Long-Duration Contracts Revenue Recognition, Policy [Policy Text Block]

Disaggregation of Revenue

The following table represents a disaggregation of revenue for the three and six months ended November 30, 2024 and 2023:

   

For the Three

   

For the Three

 
   

Months Ended

   

Months Ended

 
   

November 30, 2024

   

November 30, 2023

 

Cannabis Dispensary

    2,706,856       3,104,064  

Cannabis Production

    1,454,414       2,093,150  
    $ 4,161,270     $ 5,197,214  
   

For the Six

   

For the Six

 
   

Months Ended

   

Months Ended

 
   

November 30, 2024

   

November 30, 2023

 

Cannabis Dispensary

    5,773,932       6,412,606  

Cannabis Production

    3,192,503       3,899,135  
    $ 8,966,435     $ 10,311,741  

 

Earnings Per Share, Policy [Policy Text Block]

Basic and Diluted Earnings or Loss Per Share

Basic net earnings per share is based on the weighted average number of shares outstanding during the period, while fully diluted net earnings per share is based on the weighted average number of shares of common stock and potentially dilutive securities assumed to be outstanding during the period using the treasury stock method. Potentially dilutive securities consist of options and warrants to purchase common stock, and convertible debt. Basic and diluted net loss per share are computed based on the weighted average number of shares of common stock outstanding during the period. At November 30, 2024 and 2023, the Company had the following potentially dilutive instruments outstanding: at November 30, 2024, a total of 46,300,414 shares (14,549,685 issuable upon the exercise of warrants, 23,733,229 issuable upon the conversion of convertible notes payable and accrued interest, 8,000,000 shares issuable upon the conversion of stock options, and 17,500 in stock to be issued); and at November 30, 2023, a total of 73,715,637 shares (21,181,449 issuable upon the exercise of warrants, 52,516,688 issuable upon the conversion of convertible notes payable and accrued interest, and 17,500 in stock to be issued).

The Company uses the treasury stock method to calculate the impact of outstanding stock options and warrants. Stock options and warrants for which the exercise price exceeds the average market price over the period have an anti-dilutive effect on earnings per common share and, accordingly, are excluded from the calculations.

A net loss causes all outstanding stock options and warrants to be anti-dilutive. As a result, the basic and dilutive losses per common share are the same for the three months ended November 30, 2024 and 2023. For the three months ended November 30, 2024 and 2023, the Company excluded from the calculation of fully diluted earnings per share the following instruments which were anti-dilutive: shares issuable pursuant to the conversion of notes payable and accrued interest, shares issuable pursuant to the exercise of warrants, and shares of common stock issuable.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

Section 280E of the Internal Revenue Code, as amended, prohibits businesses from deducting certain expenses associated with trafficking controlled substances (within the meaning of Schedule I and II of the Controlled Substances Act). The IRS has invoked Section 280E in tax audits against various cannabis businesses in the U.S. that are permitted under applicable state laws. Although the IRS has issued a clarification allowing the deduction of certain expenses, the bulk of operating costs and general administrative costs are generally not permitted to be deducted. The operations of certain of the Company’s subsidiaries are subject to Section 280E. This results in permanent differences between ordinary and necessary business expenses deemed non-deductible under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income or loss.

Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims brought to such legal counsel’s attention as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

 

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

v3.24.4
Nature of Business and Significant Accounting Policies (Tables)
6 Months Ended
Nov. 30, 2024
Nature of Business and Significant Accounting Policies (Tables) [Line Items]  
Property, Plant and Equipment [Table Text Block] Property, plant and equipment consisted of the following at November 30, 2024 and May 31, 2024:
   

November 30,

2024

   

May 31,

2024

 

Office equipment

  $ 163,126     $ 163,126  

Furniture and fixtures

    149,478       148,358  

Machinery & Equipment

    2,522,795       2,519,455  

Leasehold improvements

    2,922,156       2,911,164  

Less: accumulated depreciation

    (3,572,740 )     (3,318,550 )

Property, plant, and equipment, net

  $ 2,184,815     $ 2,423,553  
Disaggregation of Revenue [Table Text Block] The following table represents a disaggregation of revenue for the three and six months ended November 30, 2024 and 2023:
   

For the Three

   

For the Three

 
   

Months Ended

   

Months Ended

 
   

November 30, 2024

   

November 30, 2023

 

Cannabis Dispensary

    2,706,856       3,104,064  

Cannabis Production

    1,454,414       2,093,150  
    $ 4,161,270     $ 5,197,214  
   

For the Six

   

For the Six

 
   

Months Ended

   

Months Ended

 
   

November 30, 2024

   

November 30, 2023

 

Cannabis Dispensary

    5,773,932       6,412,606  

Cannabis Production

    3,192,503       3,899,135  
    $ 8,966,435     $ 10,311,741  

 

Estimated Useful LIfe [Member]  
Nature of Business and Significant Accounting Policies (Tables) [Line Items]  
Property, Plant and Equipment [Table Text Block] Property and equipment is recorded at the lower of cost or estimated net recoverable amount, and is depreciated using the straight-line method over its estimated useful life. Property acquired in a business combination is recorded at estimated initial fair value. Property, plant, and equipment are depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based upon the following life expectancy:

 

 

Years

 

Office equipment

 

 

3 to 5

 

Furniture & fixtures

 

 

3 to 7

 

Machinery & equipment

 

 

3 to 10

 

Leasehold improvements

 

Term of lease

 

v3.24.4
Inventory (Tables)
6 Months Ended
Nov. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current [Table Text Block] Inventory, consisting of material, overhead, labor, and manufacturing overhead, is stated at the lower of cost (first-in, first-out) or market, and consists of the following:
   

November 30,

   

May 31,

 
   

2024

   

2024

 

Raw materials

  $ 287,064     $ 386,803  

Finished goods

    1,518,597       1,581,770  

Total

  $ 1,805,661     $ 1,968,573  
v3.24.4
Prepaid Expenses and Other Current Assets (Tables)
6 Months Ended
Nov. 30, 2024
Disclosure Text Block Supplement [Abstract]  
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Prepaid expenses and other current assets consisted of the following at November 30, 2024 and May 31, 2024:
   

November 30,

   

May 31,

 
   

2024

   

2024

 

Prepaid license fees

    7,000       14,659  

Other prepaid expenses

    32,934       34,650  

Total

  $ 39,934     $ 49,309  
v3.24.4
Property, Plant and Equipment (Tables)
6 Months Ended
Nov. 30, 2024
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment [Table Text Block] Property, plant and equipment consisted of the following at November 30, 2024 and May 31, 2024:
   

November 30,

2024

   

May 31,

2024

 

Office equipment

  $ 163,126     $ 163,126  

Furniture and fixtures

    149,478       148,358  

Machinery & Equipment

    2,522,795       2,519,455  

Leasehold improvements

    2,922,156       2,911,164  

Less: accumulated depreciation

    (3,572,740 )     (3,318,550 )

Property, plant, and equipment, net

  $ 2,184,815     $ 2,423,553  
v3.24.4
Right of Use Assets and Liabilities – Operating Leases (Tables)
6 Months Ended
Nov. 30, 2024
Disclosure Text Block [Abstract]  
Lease, Cost [Table Text Block] Right of use assets – operating leases are summarized below:
   

November 30,

2024

 

Amount at inception of leases

  $ 4,504,921  

Amount amortized

    (2,913,203 )

Prior Period Impairment of Quinn River Lease

    (205,888 )

Balance – November 30, 2024

  $ 1,385,830  
Operating lease liabilities are summarized below:

Amount at inception of leases

  $ 4,461,521  

Amount amortized

    (2,788,127 )

Balance – November 30, 2024

  $ 1,673,394  

Warehouse and offices

  $ 1,463,997  

Land

    205,888  

Office equipment

    3,509  

Balance – November 30, 2024

  $ 1,673,394  
         

Lease liability

  $ 1,673,394  

Less: current portion

    (484,601 )

Lease liability, non-current

  $ 1,188,793  

 

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Maturity analysis under these lease agreements is as follows:

Twelve months ended November 30, 2025

  $ 676,970  

Twelve months ended November 30, 2026

    395,348  

Twelve months ended November 30, 2027

    321,828  

Twelve months ended November 30, 2028

    322,329  

Twelve months ended November 30, 2029

    263,561  

Thereafter

    155,779  

Total

  $ 2,135,815  

Less: Present value discount

    (462,421 )

Lease liability

  $ 1,673,394  
v3.24.4
Intangible Assets (Tables)
6 Months Ended
Nov. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets [Table Text Block] Intangible assets consisted of the following at November 30, 2024 and May 31, 2024:
   

November 30, 2024

 
           

Accumulated

                 
   

Gross

   

Amortization

   

Impairment

   

Net

 

License & Customer Relations

  $ 110,000     $ (110,000 )     -       -  

Tradenames - Trademarks

    222,000       (222,000 )     -       -  

Domain Names

    28,151       (19,824 )     -       8,327  

Total

  $ 357,993     $ (351,824 )     -     $ 8,327  
   

May 31, 2024

 
           

Accumulated

                 
   

Gross

   

Amortization

   

Impairment

   

Net

 

License & Customer Relations

    110,000       (110,000 )     -       -  

Tradenames - Trademarks

    222,000       (222,000 )     -       -  

Domain Names

    25,993       (16,015 )     -       9,978  

Total

  $ 357,993     $ (348,015 )   $ -     $ 9,978  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Remaining amortization expense for intangible assets as of November 30, 2024 is as follows:

2025

  $ 2,478  

2026

    3,304  

2027

    2,545  
    $ 8,327  
v3.24.4
Other Assets (Tables)
6 Months Ended
Nov. 30, 2024
Disclosure Text Block Supplement [Abstract]  
Schedule of Other Assets [Table Text Block] Other assets included the following as of November 30, 2024 and May 31, 2024:
   

November 30,

   

May 31,

 
   

2024

   

2024

 

Security deposits

    157,500       157,500  
    $ 157,500     $ 157,500  
v3.24.4
Accounts Payable and Accrued Liabilities (Tables)
6 Months Ended
Nov. 30, 2024
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accounts payable and accrued liabilities consisted of the following at November 30, 2024 and May 31, 2024:
   

November 30,

2024

   

May 31,

2024

 

Trade accounts payable

  $ 3,708,509     $ 2,508,769  

Accrued payroll and payroll taxes

    313,275       313,296  

Accrued liabilities

    378,253       533,994  

Total

  $ 4,400,037     $ 3,356,059  
v3.24.4
Notes Payable (Tables)
6 Months Ended
Nov. 30, 2024
Notes Payable (Tables) [Line Items]  
Schedule of Maturities of Long-Term Debt [Table Text Block] Aggregate maturities of notes payable, convertible notes payable, and notes payable – related parties as of November 30, 2024 are as follows:

2025

  $ 1,769,303  

2026

    866,804  

2027

    309,042  

2028

    1,060,261  

Total

  $ 4,005,410  
Nonrelated Party [Member]  
Notes Payable (Tables) [Line Items]  
Schedule of Debt [Table Text Block]
   

November 30, 2024

   

May 31, 2024

 

Debenture 2

Debenture in the principal amount of $250,000 (the “Debenture 2”) dated December 21, 2021, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 2 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 75,758 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 2 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $10,428 on Debenture 2.

 

On May 31, 2023, the Debenture 2 was amended as follows: (1) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and Interest monthly through the maturity date.

 

On December 31, 2023, the Debenture 2 was amended as follows: The original issue discount in the amount of $187,000 was reduced to $37,500. A gain on extinguishment of debt in the amount of $111,807 was recognized in connection with this transaction, and a discount in the amount of $6,501 was recorded.

 

During the three and six months ended November 30, 2024, the Company amortized discounts on the Debenture 2 in the aggregate amount of $0 and $197, respectively. During the three and six months ended November 30, 2024, the Company made principal and interest payments in the amount of $0 and $17,917, respectively, on Debenture 2. As of November 30, 2024, Debenture 2 has been paid in full.

    -       17,917  

 

   

November 30, 2024

   

May 31, 2024

 

Debenture 6

Debenture in the principal amount of $500,000 (the “Debenture 6”) dated January 4, 2022, which bears interest, payable quarterly commencing nine months after issuance, at a rate of 15% per annum. Principal on Debenture 6 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 6 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,154 on Debenture 6. The Company recorded an original issue discount in the amount of $375,000 on Debenture 6.

 

On May 31, 2023, the Debenture 6 was amended as follows: (1) the maturity date was extended to October 31, 2024; (2) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and interest monthly through the maturity date.

 

On December 31, 2023, the Debenture 6 was amended as follows: The original issue discount in the amount of $375,000 was reduced to $75,000. A gain on extinguishment of debt in the amount of $402,370 was recognized in connection with this transaction, and a discount in the amount of $209,783 was recorded.

 

During the three months and six ended November 30, 2024, the Company amortized discounts in the amount of $183,263 and $193,560, respectively, on Debenture 6. During the three and six months ended November 30, 2024, the Company capitalized interest in the amount of $10,708 on Debenture 6. During the three months and six ended November 30, 2024, the Company made principal payments in the amount of $511,340 on Debenture 6 (see note 17). At November 30, 2024, all amounts due under Debenture 6 have been paid in full.

    -       500,632  
                 

Promissory Note 6 (PN 6)

PN6 in the principal amount of $250,000 (the “PN6”) dated February 22, 2024, which bears interest a rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $11,799 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments in the amount of $29,890 and $58,902, respectively, on PN6. During the three and six months ended November 30, 2024, the Company made interest payments on PN6 in the amount of $5,508 and $11,895, respectively.

    163,600       222,502  

Notes Payable

  $ 163,600     $ 741,052  

Less: Discount

    -       (193,756 )

Notes Payable, Net of Discount

  $ 163,600     $ 547,296  
   

November 30, 2024

   

May 31, 2024

 

Total Notes Payable, Current Portion

  $ 128,898     $ 139,345  

Total Notes Payable, Long-term Portion, net of discount

  $ 34,702     $ 407,951  
Related Party [Member]  
Notes Payable (Tables) [Line Items]  
Schedule of Debt [Table Text Block]
   

November 30, 2024

   

May 31, 2024

 

Promissory Note 1 (APN1)

PN1 Debenture in the principal amount of $475,000 (the “PN1”) dated January 2, 2024, which bears interest at a rate of 12% per annum. Principal and interest payments are due monthly for 36 months in the amount $15,917 beginning February 29, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN1 in the amount of $36,142 and $71,221, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN1 in the amount of $11,610 and $24,284, respectively.

  $ 362,840     $ 434,061  
                 

Promissory Note 2 (PN2)

PN2 in the principal amount of $465,000 (the “PN2”) dated January 2, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 36 months in the amount $15,582 beginning February 29, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN2 in the amount of $35,382 and $69,722, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN2 in the amount of $11,366 and $23,773, respectively.

    355,201       424,923  
                 

Promissory Note 3 (PN3)

PN3 in the principal amount of $450,000 (the “PN3”) dated February 22, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $21,239 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN3 in the amount of $53,802 and $106,023, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN3 in the amount of $9,914 and $21,410, respectively.

    294,480       400,503  
                 

Promissory Note 4 (PN4)

PN4 in the principal amount of $300,000 (the “PN4”) dated February 22, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $14,159 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN4 in the amount of $35,868 and $70,682, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN4 in the amount of $6,609 and $14,274, respectively.

    196,320       267,002  
                 

Promissory Note 5 (PN5)

PN5 in the principal amount of $350,000 (the “PN5”) dated February 22, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $16,519 beginning March 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN5 in the amount of $41,487 and $82,463, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN5 in the amount of $7,711 and $16,653, respectively.

    229,040       311,503  
                 

Promissory Note 7 (PN7)

PN7 in the principal amount of $100,000 (the “PN7”) dated March 6, 2024, which bears interest at the rate of 12% per annum. Interest only payments are due quarterly in the amount of $3,500 for four quarters beginning March 29, 2024. The loan is due on February 28, 2025. During the three and six months ended November 30, 2024, the Company made principal payments on PN7 in the amount of $0. During the three and six months ended November 30, 2024, the Company made interest payments on the PN7 in the amount of $3,500 and $7,000, respectively.

    100,000       100,000  
                 

Promissory Note 8 (PN8)

PN8 in the principal amount of $134,000 (the “PN8”) dated April 30, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $6,308 beginning May 31, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN8 in the amount of $15,664 and $30,867, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on the PN8 in the amount of $3,529 and $6,979, respectively.

    98,164       129,031  

 

   

November 30, 2024

   

May 31, 2024

 

Promissory Note 9 (PN9)

PN9 in the principal amount of $2,600,000 (the “PN9”) dated August 28, 2024. Principal in the amount of $2,200,000 automatically converted into 56,847,545 shares of the Company’s common stock on August 30,2024; the remaining principal in the amount of $400,000 bears interest at the rate of 12% per annum and is due on August 28, 2025. The conversion of the $2,200,000 in principal was at the market price per share of $0.0387 on the date of the note, and no gain or loss was recognized on this transaction. See note 17. No interest was accrued on this note during the three months ended November 30, 2024. During the three and six months ended November 30, 2024, the Company accrued interest on the PN9 in the amount of $12,000.

    400,000       -  
                 

Promissory Note 10 (PN10)

PN10 in the principal amount of $150,000 (the “PN10”) dated October 15, 2024, which bears interest at the rate of 12% per annum. Principal and interest payments are due monthly for 24 months in the amount $7,061 beginning November 30, 2024. During the three and six months ended November 30, 2024, the Company made principal payments on the PN10 in the amount of $5,561. During the three and six months ended November 30, 2024, the Company made interest payments on the PN10 in the amount of $1,500.

    144,439       -  
                 

Total

  $ 2,180,484     $ 2,067,023  
   

November 30, 2024

   

May 31, 2024

 

Total Notes Payable – Related Party, Current Portion

  $ 1,514,362     $ 988,472  

Total Notes Payable – Related Party, Long Term Portion

  $ 666,122     $ 1,078,551  
v3.24.4
Convertible Notes Payable (Tables)
6 Months Ended
Nov. 30, 2024
Debt Disclosure [Abstract]  
Convertible Debt [Table Text Block]
   

November 30, 2024

   

May 31, 2024

 

US Convertible Debenture 2 (Navy Capital Green Fund)

Convertible debenture in the principal amount of $1,000,000 (the “U.S. Convertible Debenture 2”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 2. The U.S. Convertible Debenture 2 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 2 was convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40.

 

On July 26, 2019, U.S. Convertible Debenture 2 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. convertible Debenture 2, the conversion price of U.S. Convertible Debenture 2 would be reduced to such issuance price, and the exercise price of the warrant issuable in connection with U.S. Convertible Debenture 2 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 2 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 2 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $813,724 on the U.S. Convertible Debenture 2.

 

On April 15, 2021, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $509,700 during the year ended May 31, 2021.

 

On September 15, 2022, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of debentures with a principal amount of $675,668 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $11,261 were converted to 2,410,279 shares of common stock and warrants to purchase 1,205,140 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $450,446 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $422,331 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $223,515 and $198,816, respectively.

 

On December 29, 2023, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) principal payments in the amount of $8,000 per month are due for 48 months beginning January 31, 2024, and a balloon payment in the amount of $235,658 will be due on January 31, 2028; (iv) accrued interest in the amount of $54,053 was added to the principal balance. A loss on extinguishment of debt in the amount of $344,036 was charged to operations in connection with this transaction. During the years ended May 31, 2024 and 2023, the Company accrued interest in the amounts of $37,526 and $27,717, on the U.S. Convertible Debenture 2, respectively. During the three and six months ended November 30, 2024, the Company made principal payments in the amount of $471,387 and $481,005, respectively, on the U.S. Convertible Debenture 2 (see note 17). During the three and six months ended November 30, 2024, the Company made interest payments in the amount of $6,381 on the U.S. Convertible Debenture 2. At November 30, 2024, all amounts due under U.S. Convertible Debenture 2 have been paid in full.

  $ -       481,005  

 

   

November 30, 2024

   

May 31, 2024

 

Canaccord Debentures

Convertible debentures payable in the aggregate principal amount of $12,012,000 (the “Canaccord Debentures”) dated December 12, 2018, which bear interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the Canaccord Debentures. The Canaccord Debentures were to mature on a date that was three years following issuance. The Canaccord Debentures were convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. The Canaccord Debentures have other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The Canaccord Debentures are unsecured obligations of the Company and rank pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. During the three months ended November 30, 2019, in two separate transactions, principal in the aggregate amount of $25,857 was converted into an aggregate of 8,081 shares of the Company’s common stock, and warrants to purchase 4,040 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement. No discount was recorded for the fair value of the warrants issued. Because the market price of the Company’s common stock was less than the conversion price on the date of issuance of the Canaccord Debentures, a discount was not recorded on the Canaccord Debentures.

 

On March 31, 2021, the Canaccord Debentures were amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; (ii) the maturity date was extended from December 12, 2021 to December 12, 2022; (iii) the mandatory conversion threshold was reduced from a daily volume weighted average trading price of greater than $4.80 per share to $2.40 per share for the preceding ten consecutive trading days; and (iv) the exercise price of the warrants issuable upon conversion was reduced from $4.40 to $1.60 and the expiration of the warrants extended until March 31, 2024. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $3,286,012 during the year ended May 31, 2021. During the year ended May 31, 2022, principal in the aggregate amount of $281,000 was converted into an aggregate of 234,167 shares of the Company’s common stock, and warrants to purchase 117,084 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement.

 

On September 15, 2022, the Canaccord Debentures were further amended as follows: (i) the conversion price of debentures with a principal amount of $7,965,278 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $132,755 were converted to 28,414,149 shares of common stock and warrants to purchase 14,207,075 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $52,53,873 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $4,547,660 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $2,623,852 and $1,923,808, respectively.

 

On December 28, 2023, the Canaccord Debentures were amended as follows: (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) the maturity date was extended to January 31, 2028; (iv) accrued interest in the amount of $186,111 was added to the principal balance and accrued interest in the amount of $465,012 was forgiven (v) Put Rights (the “Put Rights”) were granted to the debenture holders granting each debenture holder the right to require the Company to redeem all or any part of the debenture in cash at a redemption price of 60% of face value (a loss on extinguishment of debt in the amount of $1,727,071 was charged to operations in connection with this transaction); (vi) interest accruing through February 28, 2025 will be added to the principal balance rather than paid to debenture holders; (v) debenture holders were granted an additional put right in the event the Company’s cash available for debt service for any fiscal quarter exceeds $750,000, subject to pro ration, to require the Company to redeem all or any part of such debenture holder’s outstanding Canaccord Debentures in cash at a redemption price equal to the aggregate principal amount of the Canaccord Debentures being so redeemed, (vi) a provision that the Company shall redeem on the last day of each calendar month beginning March 31, 2025 a portion of the outstanding Canaccord Debentures less the amount of interest paid on such date was added; and (vii) subject to the receipt of regulatory approvals, a security interest in certain of the Company’s assets (such as licenses, inventory (including work in process), equipment (excluding equipment subject to purchase money financing) and contract rights (excluding investments in entities other than wholly owned subsidiaries)) to the holders of the Canaccord Debentures and to other holders of the Company’s debt, now or in the future, as the Company may elect was granted.

 

On January 4, 2024, debenture holders exercised Put Rights with regard to the Canaccord Debentures with a principal amount of $3,875,095, the Company made a cash payment to the debenture holders in the amount of $2,325,056 representing 60% of the principal amount of these debentures, and the principal amount of $1,550,039 representing 40% of the principal amount of these debentures was forgiven. The principal balance of the Canaccord Dentures subsequent to the January 4 Put Rights exercise was $1,544,231. Interest at the rate of 8.0% per annum on this amount will be capitalized monthly through February 28, 2025. Principal and interest payments in the amount of $28,522 will be due monthly beginning March 31, 2025 and continuing through December 31, 2027; on January 31, 2028 a balloon payment in the amount of $1,038,777 will be due. A gain on settlement of debt in the amount of $2,015,051 was recognized in connection with this transaction. During the three and six months ended November 30, 2024, the Company capitalized interest in the amounts of $32,788 and $64,930 on the Canaccord Debentures.

 

On December 27, 2024, the Company executed a Supplemental Indenture to amend that certain debenture indenture by and between the Company and Odyssey Trust Company, as Trustee, dated as of December 12, 2018, as supplemented March 31, 2021, as supplemented September 15, 2022, and as supplemented December 28, 2023, in order to amended the terms of its outstanding $1,378,778 principal amount unsecured convertible debentures Canaccord Debentures issued December 12, 2018 to provide the Company an option to redeem all outstanding Canaccord Debentures in cash at a redemption price equal to $600 per $1,000 principal amount of Canaccord Debentures; any accrued but unpaid interest through to and including the redemption date shall not be paid and shall be cancelled. See note 22.

    1,661,326       1,596,396  

 

   

November 30, 2024

   

May 31, 2024

 

US Convertible Debenture 1 (Navy Capital Green Co-Invest Fund)

Convertible debenture in the principal amount of $4,000,000 to a related party (the “U.S. Convertible Debenture 1”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 1. The U.S. Convertible Debenture 1 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 1 was convertible into units (the “Convertible Debenture Units”) at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. On July 26, 2019, U.S. Convertible Debenture 1 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. Convertible Debenture 1, the conversion price of U.S. Convertible Debenture 1 would be reduced to such issuance price, and the exercise price of the warrant Issuable in connection with U.S. Convertible Debenture 1 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 1 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 1 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $3,254,896 on the U.S. Convertible Debenture 1.

 

On April 15, 2021, the U.S. Convertible Debenture 1 was amended as follows: (i) the conversion price of the debenture was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $2,038,803 during the year ended May 31, 2021 in connection with the amendment.

 

On September 15, 2022, the U.S. Convertible Debenture 1 was further amended as follows: (i) the conversion price of debentures with a principal amount of $2,702,674 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $45,044 were converted to 9,641,118 shares of common stock and warrants to purchase 4,820,560 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $1,801,783 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $1,689,368 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $894,090 and $795,278, respectively.

 

On December 29, 2023, the U.S. Convertible Debenture 1 was amended as follows: (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) the maturity date was extended to January 31, 2028; (iv) accrued interest in the amount of $215,414 was added to the principal balance. A loss on extinguishment of debt in the amount of $1,376,083 was charged to operations in connection with this transaction. During the three and six months ended November 30, 2024, the Company made principal payments in the amount of $1,885,556 and $1,924,030, respectively, on the U.S. Convertible Debenture 1 (see note 17). During the three and six months ended November 30, 2024, the Company made interest payments in the amount of $25,226 on the U.S. Convertible Debenture 1. At November 30, 2024, all amounts due under U.S. Convertible Debenture 1 have been paid in full.

    -       1,924,030  
                 

Total Convertible Notes Payable

  $ 1,661,326     $ 4,001,431  
   

November 30, 2024

   

May 31, 2024

 

Total – Convertible Notes Payable, Current Portion

  $ 126,043     $ 302,005  

Total – Convertible Notes Payable, Long-term Portion

  $ 1,535,283     $ 3,699,426  
v3.24.4
Lease Liabilities - Financing Leases (Tables)
6 Months Ended
Nov. 30, 2024
Disclosure Text Block [Abstract]  
Finance Lease [Table Text Block]
   

November 30, 2024

   

May 31, 2024

 

Financing lease obligation under a lease agreement for extraction equipment dated March 14, 2022 in the original amount of $359,900 payable in forty-eight monthly installments of $10,173 including interest at the rate of 15.89%. During the three and six months ended November 30, 2024, the Company made principal payments on this lease obligation in the amounts of $23,168 and $47,266, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on this lease obligation in the amounts of $6,421 and $13,772, respectively.

  $ 145,851     $ 193,117  
                 

Financing lease obligation under an agreement for equipment dated June 20, 2022 in the original amount of $12,400 payable in forty-eight monthly installments of $350 including interest at a rate of 15.78%. During the three and six months ended November 30, 2024, the Company made principal payments on this lease obligation in the amounts of $456 and $901, respectively. During the three and six months ended November 30, 2024, the Company made interest payments on this lease obligation in the amounts of $69 and $149, respectively.

  $ 2,458       3,359  
                 

Total

  $ 148,309     $ 196,476  
                 

Current portion

  $ 108,410     $ 96,224  

Long-term maturities

    39,899       100,252  

Total

  $ 148,309     $ 196,476  

 

Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Aggregate maturities of lease liabilities – financing leases as of November 30, 2024 are as follows:

2025

  $ 108,410  

2026

    39,899  

Total

  $ 148,309  
v3.24.4
Stockholders’ Equity (Tables)
6 Months Ended
Nov. 30, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] The following table summarizes the significant terms of warrants outstanding at November 30, 2024. This table does not include the unit warrants. See Unit Warrants section below.

Range of

exercise

Prices

   

Number of

warrants

Outstanding

   

Weighted

average

remaining

contractual

life (years)

   

Weighted

average

exercise

price of

outstanding

Warrants

   

Number of

warrants

Exercisable

   

Weighted

average

exercise

price of

exercisable

Warrants

 
                                             
$ 0.40-0.4125       14,549,685       1.12     $ 0.40       14,549,685     $ 0.40  
          14,549,685       1.12     $ 0.40       14,549,685     $ 0.40  

 

Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block] Transactions involving warrants are summarized as follows. This table does not include the unit warrants. See Unit Warrants section below.
   

Number of

Shares

   

Weighted Average

Exercise Price

 

Warrants outstanding at May 31, 2023

    21,181,449     $ 0.40  

Granted

    -     $ -  

Exercised

    -     $ -  

Cancelled / Expired

    (454,548 )   $ 0.41  

Warrants outstanding at May 31, 2024

    20,726,901     $ 0.40  

Granted

               

Exercised

    -     $ -  

Cancelled / Expired

    (6,177,216 )   $ 0.40  

Warrants outstanding at November 30, 2024

    14,549,685     $ 0.40  
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] The following table summarizes the significant terms of options outstanding at November 30, 2024.

Range of

exercise

Prices

   

Number of

options

Outstanding

   

Weighted

average

remaining

contractual

life (years)

   

Weighted

average

exercise

price of

outstanding

Options

   

Number of

Options

Exercisable

   

Weighted

average

exercise

price of

exercisable

Option

 
                                             
$ 0.039       8,000,000       9.15     $ 0.039       2,520,832     $ 0.039  
Share-Based Payment Arrangement, Option, Activity [Table Text Block] Transactions involving options are summarized as follows.
   

Number of

Shares

   

Weighted Average

Exercise Price

 

Options outstanding at May 31, 2024

    8,041,667     $ 0.039  

Granted

    -     $ -  

Exercised

    -     $ -  

Cancelled / Expired

    (41,667 )   $ -  

Options outstanding at November 30, 2024

    8,000,000     $ 0.039  
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] The Company valued options using the Black-Scholes valuation model utilizing the following variables during the six months ended November 30, 2024:
   

November 30,

 
   

2024

 

Volatility

    269.44 %

Dividends

  $ -  

Risk-free interest rates

    3.8 %

Expected term (years)

    5.00  

 

v3.24.4
Gain on Settlement of Debt (Tables)
6 Months Ended
Nov. 30, 2024
Gain On Settlement Of Debt Abstract  
Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions [Table Text Block] The Company valued the warrants using the Black-Scholes valuation model utilizing the following variables during the six months ended November 30, 2024:
   

November 30,

 
   

2024

 

Volatility

    104.68 %

Dividends

  $ -  

Risk-free interest rates

    4.36 %

Expected term (years)

    1.05  
v3.24.4
Income Taxes (Tables)
6 Months Ended
Nov. 30, 2024
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] The components of the income tax provision include:
   

Three Months Ended November 30,

 
   

2024

   

2023

 

Revenue

  $ 4,161,270     $ 5,197,214  

Directly attributable costs

    (1,928,995 )     (3,025,595 )

Deferred

    2,232,275       2,171,619  

Tax rate

    21 %     21 %

Tax expense

  $ 468,778     $ 456,040  
   

Six Months Ended November 30,

 
   

2024

   

2023

 

Revenue

  $ 8,966,435     $ 10,311,741  

Directly attributable costs

    (4,234,657 )     (5,866,196 )

Deferred

    4,731,778       4,445,545  

Tax rate

    21 %     21 %

Tax expense

  $ 993,674     $ 933,564  
v3.24.4
Nature of Business and Significant Accounting Policies (Details) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
May 31, 2024
May 31, 2023
Nature of Business and Significant Accounting Policies (Details) [Line Items]            
Cash and Cash Equivalents, at Carrying Value $ 592,584   $ 592,584   $ 600,007 $ 998,421
Accounts Receivable, Credit Loss Expense (Reversal) 0 $ 93 0 $ 393    
Goodwill 557,896   557,896   $ 557,896  
Other Nonoperating Income 50,103 0 50,103 924,862    
Net Income (Loss) Attributable to Noncontrolling Interest 0 92 0 2,200    
Advertising Expense 96,709 103,448 174,710 227,059    
Research and Development Expense $ 281 $ 431 $ 421 $ 1,887    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)     46,300,414 73,715,637    
Kealii Okamalu, LLC [Member]            
Nature of Business and Significant Accounting Policies (Details) [Line Items]            
Subsidiary, Ownership Percentage, Noncontrolling Owner 50.00%   50.00%      
CLS CBD [Member]            
Nature of Business and Significant Accounting Policies (Details) [Line Items]            
Equity Method Investment, Ownership Percentage 95.00%   95.00%      
Kealii Okamalu, LLC [Member]            
Nature of Business and Significant Accounting Policies (Details) [Line Items]            
Equity Method Investment, Ownership Percentage 50.00%   50.00%      
Warrant [Member]            
Nature of Business and Significant Accounting Policies (Details) [Line Items]            
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)     14,549,685 21,181,449    
Convertible Debt Securities [Member]            
Nature of Business and Significant Accounting Policies (Details) [Line Items]            
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)     23,733,229 52,516,688    
Equity Option [Member]            
Nature of Business and Significant Accounting Policies (Details) [Line Items]            
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)     8,000,000      
Stock Payable [Member]            
Nature of Business and Significant Accounting Policies (Details) [Line Items]            
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)     17,500 17,500    
v3.24.4
Nature of Business and Significant Accounting Policies (Details) - Property, Plant and Equipment
Nov. 30, 2024
Leasehold Improvements [Member]  
Nature of Business and Significant Accounting Policies (Details) - Property, Plant and Equipment [Line Items]  
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration] Term of lease
Minimum [Member] | Office Equipment [Member]  
Nature of Business and Significant Accounting Policies (Details) - Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Minimum [Member] | Furniture and Fixtures [Member]  
Nature of Business and Significant Accounting Policies (Details) - Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Minimum [Member] | Machinery and Equipment [Member]  
Nature of Business and Significant Accounting Policies (Details) - Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Maximum [Member] | Office Equipment [Member]  
Nature of Business and Significant Accounting Policies (Details) - Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Maximum [Member] | Furniture and Fixtures [Member]  
Nature of Business and Significant Accounting Policies (Details) - Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 7 years
Maximum [Member] | Machinery and Equipment [Member]  
Nature of Business and Significant Accounting Policies (Details) - Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 10 years
v3.24.4
Nature of Business and Significant Accounting Policies (Details) - Disaggregation of Revenue - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenue $ 4,161,270 $ 5,197,214 $ 8,966,435 $ 10,311,741
Cannabis Dispensary [Member]        
Disaggregation of Revenue [Line Items]        
Revenue 2,706,856 3,104,064 5,773,932 6,412,606
Cannabis Production [Member]        
Disaggregation of Revenue [Line Items]        
Revenue $ 1,454,414 $ 2,093,150 $ 3,192,503 $ 3,899,135
v3.24.4
Going Concern (Details) - USD ($)
Nov. 30, 2024
May 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Retained Earnings (Accumulated Deficit) $ (114,275,584) $ (113,367,050)
v3.24.4
Accounts Receivable (Details) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
May 31, 2024
Receivables [Abstract]          
Accounts Receivable, after Allowance for Credit Loss, Current $ 1,152,082   $ 1,152,082   $ 682,894
Accounts Receivable, Credit Loss Expense (Reversal) 0 $ 93 0 $ 393  
Accounts Receivable, Allowance for Credit Loss $ 0 $ 0 $ 0 $ 0  
v3.24.4
Inventory (Details) - Schedule of Inventory, Current - USD ($)
Nov. 30, 2024
May 31, 2024
Schedule Of Inventory Current Abstract    
Raw materials $ 287,064 $ 386,803
Finished goods 1,518,597 1,581,770
Total $ 1,805,661 $ 1,968,573
v3.24.4
Prepaid Expenses and Other Current Assets (Details) - Deferred Costs, Capitalized, Prepaid, and Other Assets - USD ($)
Nov. 30, 2024
May 31, 2024
Deferred Costs Capitalized Prepaid And Other Assets Abstract    
Prepaid license fees $ 7,000 $ 14,659
Other prepaid expenses 32,934 34,650
Total $ 39,934 $ 49,309
v3.24.4
Property, Plant and Equipment (Details) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
Property, Plant and Equipment [Abstract]        
Payments to Acquire Property, Plant, and Equipment     $ 16,141 $ 44,248
Depreciation $ 121,219 $ 158,497 $ 254,880 $ 317,250
v3.24.4
Property, Plant and Equipment (Details) - Property, Plant and Equipment - USD ($)
Nov. 30, 2024
May 31, 2024
Property, Plant and Equipment [Line Items]    
Less: accumulated depreciation $ (3,572,740) $ (3,318,550)
Property, plant, and equipment, net 2,184,815 2,423,553
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross 163,126 163,126
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross 149,478 148,358
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross 2,522,795 2,519,455
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross $ 2,922,156 $ 2,911,164
v3.24.4
Right of Use Assets and Liabilities – Operating Leases (Details) - USD ($)
3 Months Ended 6 Months Ended 63 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
Aug. 31, 2024
Right of Use Assets and Liabilities – Operating Leases (Details) [Line Items]          
Operating Lease, Expense $ 140,612 $ 123,408 $ 278,097 $ 257,611  
Operating Lease, Right-of-Use Asset, Periodic Reduction $ 106,422 $ 89,736 209,922 186,424  
Operating Lease, Right-of-Use Asset, Before Accumulated Amortization         $ 4,384,520
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability     $ 120,401 $ 224,899 $ 4,341,120
Minimum [Member]          
Right of Use Assets and Liabilities – Operating Leases (Details) [Line Items]          
Lessee, Operating Lease, Term of Contract         1 year
Maximum [Member]          
Right of Use Assets and Liabilities – Operating Leases (Details) [Line Items]          
Lessee, Operating Lease, Term of Contract         10 years 6 months
v3.24.4
Right of Use Assets and Liabilities – Operating Leases (Details) - Lease, Cost - USD ($)
12 Months Ended 66 Months Ended
May 31, 2024
Nov. 30, 2024
May 31, 2019
Right of Use Assets and Liabilities – Operating Leases (Details) - Lease, Cost [Line Items]      
Operating Lease, Right-of-Use Asset $ 1,475,351 $ 1,385,830 $ 4,504,921
Operating Lease, Liability   1,673,394 $ 4,461,521
Less: current portion (443,467) (484,601)  
Lease liability, non-current 1,318,644 1,188,793  
Amount amortized   (2,788,127)  
Amount amortized (2,913,203)    
Prior Period Impairment of Quinn River Lease $ (205,888)    
Building [Member]      
Right of Use Assets and Liabilities – Operating Leases (Details) - Lease, Cost [Line Items]      
Operating Lease, Liability   1,463,997  
Land [Member]      
Right of Use Assets and Liabilities – Operating Leases (Details) - Lease, Cost [Line Items]      
Operating Lease, Liability   205,888  
Office Equipment [Member]      
Right of Use Assets and Liabilities – Operating Leases (Details) - Lease, Cost [Line Items]      
Operating Lease, Liability   $ 3,509  
v3.24.4
Right of Use Assets and Liabilities – Operating Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)
Nov. 30, 2024
May 31, 2019
Lessee Operating Lease Liability Maturity Abstract    
Twelve months ended November 30, 2025 $ 676,970  
Twelve months ended November 30, 2026 395,348  
Twelve months ended November 30, 2027 321,828  
Twelve months ended November 30, 2028 322,329  
Twelve months ended November 30, 2029 263,561  
Thereafter 155,779  
Total 2,135,815  
Less: Present value discount (462,421)  
Lease liability $ 1,673,394 $ 4,461,521
v3.24.4
Intangible Assets (Details) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization of Intangible Assets $ 825 $ 7,750 $ 1,651 $ 15,501
v3.24.4
Intangible Assets (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)
6 Months Ended 12 Months Ended
Nov. 30, 2024
May 31, 2024
Finite-Lived Intangible Assets [Line Items]    
Intangible Assets, Gross $ 357,993 $ 357,993
Intangible Assets, Accumulated Amortization (351,824) (348,015)
Intangible Assets, Impairment 0 0
Intangible Assets, Net 8,327 9,978
Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible Assets, Gross 110,000 110,000
Intangible Assets, Accumulated Amortization (110,000) (110,000)
Intangible Assets, Impairment 0 0
Intangible Assets, Net 0 0
Trademarks and Trade Names [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible Assets, Gross 222,000 222,000
Intangible Assets, Accumulated Amortization (222,000) (222,000)
Intangible Assets, Impairment 0 0
Intangible Assets, Net 0 0
Internet Domain Names [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible Assets, Gross 28,151 25,993
Intangible Assets, Accumulated Amortization (19,824) (16,015)
Intangible Assets, Impairment 0 0
Intangible Assets, Net $ 8,327 $ 9,978
v3.24.4
Intangible Assets (Details) - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense - USD ($)
Nov. 30, 2024
May 31, 2024
Schedule Of Finite Lived Intangible Assets Future Amortization Expense Abstract    
2025 $ 2,478  
2026 3,304  
2027 2,545  
Finite-Lived Intangible Assets, Net $ 8,327 $ 9,978
v3.24.4
Goodwill (Details) - USD ($)
Nov. 30, 2024
May 31, 2024
Disclosure Text Block Supplement [Abstract]    
Goodwill $ 557,896 $ 557,896
v3.24.4
Other Assets (Details) - Schedule of Other Assets - USD ($)
Nov. 30, 2024
May 31, 2024
Schedule Of Other Assets Abstract    
Security deposits $ 157,500 $ 157,500
Other assets $ 157,500 $ 157,500
v3.24.4
Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)
Nov. 30, 2024
May 31, 2024
Schedule Of Accounts Payable And Accrued Liabilities Abstract    
Trade accounts payable $ 3,708,509 $ 2,508,769
Accrued payroll and payroll taxes 313,275 313,296
Accrued liabilities 378,253 533,994
Total $ 4,400,037 $ 3,356,059
v3.24.4
Due to Related Party (Details) - USD ($)
6 Months Ended
Nov. 30, 2024
Sep. 10, 2024
May 31, 2024
Due to Related Party (Details) [Line Items]      
Share Price (in Dollars per share) $ 0.045 $ 0.044  
Gain on Repurchase and Cancellation of Common Stock $ 22,663    
Other Liabilities, Current $ 40,000   $ 0
Related Party [Member]      
Due to Related Party (Details) [Line Items]      
Stock Repurchased and Retired During Period, Shares (in Shares) 1,125,000    
Payments for Repurchase of Common Stock $ 40,000    
Share Price (in Dollars per share) $ 0.0557    
Other Liabilities, Current $ 40,000    
v3.24.4
Notes Payable (Details) - Schedule of Debt - Notes Payable, Other Payables [Member] - USD ($)
Nov. 30, 2024
May 31, 2024
Notes Payable (Details) - Schedule of Debt [Line Items]    
Debenture $ 163,600 $ 741,052
Less: Discount 0 (193,756)
Nonrelated Party [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable, Net of Discount 163,600 547,296
Total Notes Payable, Current Portion 128,898 139,345
Total Notes Payable, Long-term Portion 34,702 407,951
Debenture 2 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Debenture 0 17,917
Debenture 6 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Debenture 0 500,632
PN6 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Debenture $ 163,600 $ 222,502
v3.24.4
Notes Payable (Details) - Schedule of Debt (Parentheticals) - Notes Payable, Other Payables [Member] - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Jan. 04, 2022
Dec. 21, 2021
Nov. 30, 2024
Nov. 30, 2024
May 31, 2024
Feb. 22, 2024
Dec. 21, 2012
Debenture 2 [Member]                  
Notes Payable (Details) - Schedule of Debt (Parentheticals) [Line Items]                  
Amount       $ 250,000          
Interest payable       payable quarterly commencing six months after issuance          
Interest Rate       15.00%          
Warrants (in Shares)       75,758          
Maturity           Jul. 10, 2024      
Warrants at an exercise price of (in Dollars per share)       $ 1.65          
Payments       The Company shall make additional quarterly payments under Debenture 2 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year.          
Discount   $ 6,501             $ 10,428
Original issue discount   37,500   $ 187,000          
Gain on extinguishment of debt   111,807              
Amortized discounts         $ 0 $ 197      
principal payments         0 $ 17,917      
Debenture 6 [Member]                  
Notes Payable (Details) - Schedule of Debt (Parentheticals) [Line Items]                  
Amount     $ 500,000            
Interest payable     payable quarterly commencing nine months after issuance            
Interest Rate     15.00%            
Warrants (in Shares)     151,516            
Maturity           Jul. 10, 2024 Oct. 31, 2024    
Warrants at an exercise price of (in Dollars per share)     $ 1.65            
Payments     The Company shall make additional quarterly payments under Debenture 6 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year.            
Discount   209,783 $ 17,154            
Original issue discount   75,000 $ 375,000            
Gain on extinguishment of debt   $ 402,370              
Amortized discounts         183,263 $ 193,560      
principal payments         511,340 511,340      
Interest Capitalized         10,708 10,708      
PN6 [Member]                  
Notes Payable (Details) - Schedule of Debt (Parentheticals) [Line Items]                  
Amount               $ 250,000  
Interest Rate               12.00%  
principal payments         29,890 58,902      
payments due $ 11,799                
Interest Expense [Member] | PN6 [Member]                  
Notes Payable (Details) - Schedule of Debt (Parentheticals) [Line Items]                  
interest payments         $ 5,508 $ 11,895      
v3.24.4
Convertible Notes Payable (Details) - Convertible Debt - USD ($)
Dec. 27, 2024
Nov. 30, 2024
May 31, 2024
Convertible Notes Payable (Details) - Convertible Debt [Line Items]      
Total – Convertible Notes Payable, Current Portion   $ 126,043 $ 302,005
Total – Convertible Notes Payable, Long-term Portion   1,535,283 3,699,426
Nonrelated Party [Member]      
Convertible Notes Payable (Details) - Convertible Debt [Line Items]      
Convertible Debenture   1,661,326 4,001,431
Total Convertible Notes Payable   1,661,326 4,001,431
Total – Convertible Notes Payable, Current Portion   126,043 302,005
Total – Convertible Notes Payable, Long-term Portion   1,535,283 3,699,426
Convertible Debt [Member] | US Convertible Debenture 1 [Member]      
Convertible Notes Payable (Details) - Convertible Debt [Line Items]      
Convertible Debenture   0 1,924,030
Total Convertible Notes Payable   0 1,924,030
Convertible Debt [Member] | Navy Capital Debenture 2 [Member]      
Convertible Notes Payable (Details) - Convertible Debt [Line Items]      
Convertible Debenture   0 481,005
Total Convertible Notes Payable   0 481,005
Convertible Debt [Member] | Canaccord Debentures [Member]      
Convertible Notes Payable (Details) - Convertible Debt [Line Items]      
Convertible Debenture $ 1,378,778 1,661,326 1,596,396
Total Convertible Notes Payable $ 1,378,778 $ 1,661,326 $ 1,596,396
v3.24.4
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) - Convertible Debt [Member] - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Dec. 27, 2024
Jan. 04, 2024
Dec. 29, 2023
Dec. 28, 2023
Sep. 15, 2023
Sep. 15, 2022
Apr. 15, 2021
Mar. 21, 2021
Jul. 26, 2019
Dec. 12, 2018
Oct. 31, 2018
Oct. 18, 2018
Oct. 10, 2018
Nov. 30, 2024
Nov. 30, 2019
Nov. 30, 2024
May 31, 2024
May 31, 2023
May 31, 2022
May 31, 2021
Navy Capital Debenture 2 [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Amount                         $ 1,000,000              
dated                         Oct. 31, 2018              
Interest rate                         8.00%              
Conversion price (in Dollars per share)                         $ 3.2              
Discount                         $ 813,724              
Maturity                         3 years              
Debt Amendment             (i) the conversion price of the debentures was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022.                          
Loss on extinguishment of debt           $ 422,331 $ 509,700                          
Convertible     (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) principal payments in the amount of $8,000 per month are due for 48 months beginning January 31, 2024, and a balloon payment in the amount of $235,658 will be due on January 31, 2028; (iv) accrued interest in the amount of $54,053 was added to the principal balance.     (i) the conversion price of debentures with a principal amount of $675,668 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $11,261 were converted to 2,410,279 shares of common stock and warrants to purchase 1,205,140 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $450,446 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40.         The U.S. Convertible Debenture 2 was convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40.                  
Converted shares (in Shares)           2,410,279                            
Converted, warrants (in Shares)           1,205,140                            
Accrued interest                               $ 37,526 $ 27,717      
principal payments                           $ 471,387   481,005        
Gain on settlement of debt           $ (422,331) $ (509,700)                          
outstanding                           0   0 481,005      
Navy Capital Debenture 2 [Member] | Conversion Options [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Loss on extinguishment of debt     $ 344,036   $ 223,515                              
Gain on settlement of debt     $ (344,036)   (223,515)                              
Navy Capital Debenture 2 [Member] | Note Warrant [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Loss on extinguishment of debt         198,816                              
Gain on settlement of debt         (198,816)                              
Canaccord Debentures [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Amount       $ 186,111           $ 12,012,000                    
dated                   Dec. 12, 2018                    
Interest rate   8.00%               8.00%                    
Conversion price (in Dollars per share)                   $ 3.2                    
Maturity                   3 years                    
Debt Amendment       (i) the conversion price of the debentures was reduced to $0.07 per unit; (ii) the conversion price of warrants underlying the units issuable upon conversion was reduced to $0.10 per share; (iii) the maturity date was extended to January 31, 2028;   (i) the conversion price of debentures with a principal amount of $7,965,278 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $132,755 were converted to 28,414,149 shares of common stock and warrants to purchase 14,207,075 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $52,53,873 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40.   (i) the conversion price of the debentures was reduced to $1.20 per unit; (ii) the maturity date was extended from December 12, 2021 to December 12, 2022; (iii) the mandatory conversion threshold was reduced from a daily volume weighted average trading price of greater than $4.80 per share to $2.40 per share for the preceding ten consecutive trading days; and (iv) the exercise price of the warrants issuable upon conversion was reduced from $4.40 to $1.60 and the expiration of the warrants extended until March 31, 2024.                        
Loss on extinguishment of debt       $ 1,727,071   $ 4,547,660                   (2,015,051)       $ 3,286,012
Convertible                   The Canaccord Debentures were convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40.                    
Converted shares (in Shares)                             8,081       234,167  
Converted, warrants (in Shares)                             4,040       117,084  
Converted   $ 2,325,056                         $ 25,857       $ 281,000  
Cash available for debt service       750,000                                
Forgiven   1,550,039                                    
Balloon payment to be paid                           1,038,777   1,038,777        
Capitalized interest                           32,788   64,930        
Gain on settlement of debt       (1,727,071)   $ (4,547,660)                   2,015,051       (3,286,012)
outstanding $ 1,378,778                         1,661,326   1,661,326 1,596,396      
option to redeem option to redeem all outstanding Canaccord Debentures in cash at a redemption price equal to $600 per $1,000 principal amount                                      
Canaccord Debentures [Member] | Conversion Options [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Loss on extinguishment of debt         2,623,852                              
Gain on settlement of debt         (2,623,852)                              
Canaccord Debentures [Member] | Note Warrant [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Loss on extinguishment of debt         1,923,808                              
Gain on settlement of debt         $ (1,923,808)                              
US Convertible Debenture 1 [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Amount                     $ 4,000,000                  
dated                       Oct. 31, 2018                
Interest rate                     8.00%                  
Conversion price (in Dollars per share)     $ 0.07                                  
Discount                     $ 3,254,896                  
Maturity                     3 years                  
Debt Amendment           (i) the conversion price of debentures with a principal amount of $2,702,674 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $45,044 were converted to 9,641,118 shares of common stock and warrants to purchase 4,820,560 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $1,801,783 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. (i) the conversion price of the debenture was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022.   should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. Convertible Debenture 1, the conversion price of U.S. Convertible Debenture 1 would be reduced to such issuance price, and the exercise price of the warrant Issuable in connection with U.S. Convertible Debenture 1 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion.                      
Loss on extinguishment of debt     $ 1,376,083                           $ 1,689,368     2,038,803
Convertible                     The U.S. Convertible Debenture 1 was convertible into units (the “Convertible Debenture Units”) at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40.                  
Converted shares (in Shares)                                 9,641,118      
Converted, warrants (in Shares)           4,820,560                            
principal payments                           1,885,556   1,924,030        
Gain on settlement of debt     $ (1,376,083)                           $ (1,689,368)     $ (2,038,803)
Maturity date     Jan. 31, 2028                                  
added principal     $ 215,414                                  
US Convertible Debenture 1 [Member] | Note Warrant [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Loss on extinguishment of debt                                 894,090 $ 795,278    
Gain on settlement of debt                                 (894,090) $ (795,278)    
Principal [Member] | Navy Capital Debenture 2 [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Converted           $ 675,668                            
Principal [Member] | Canaccord Debentures [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Converted   $ 3,875,095                                    
Principal [Member] | US Convertible Debenture 1 [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Converted                                 $ 2,702,674      
Accrued Interest [Member] | Canaccord Debentures [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Converted       $ 465,012                                
Accrued Interest [Member] | US Convertible Debenture 1 [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
Converted           $ 45,044                            
Interest Expense [Member] | Navy Capital Debenture 2 [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
interest payments                           6,381   6,381        
Interest Expense [Member] | US Convertible Debenture 1 [Member]                                        
Convertible Notes Payable (Details) - Convertible Debt (Parentheticals) [Line Items]                                        
interest payments                           $ 25,226   $ 25,226        
v3.24.4
Notes Payable – Related Party (Details) - Schedule of Debt - Related Party [Member] - USD ($)
Nov. 30, 2024
May 31, 2024
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note $ 2,180,484 $ 2,067,023
Total 2,180,484 2,067,023
Total Notes Payable – Related Party, Current Portion 1,514,362 988,472
Total Notes Payable – Related Party, Long Term Portion 666,122 1,078,551
PN1 [Member]    
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note 362,840 434,061
Total 362,840 434,061
PN2 [Member]    
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note 355,201 424,923
Total 355,201 424,923
PN3 [Member]    
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note 294,480 400,503
Total 294,480 400,503
PN4 [Member]    
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note 196,320 267,002
Total 196,320 267,002
PN5 [Member]    
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note 229,040 311,503
Total 229,040 311,503
PN7 [Member]    
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note 100,000 100,000
Total 100,000 100,000
PN8 [Member]    
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note 98,164 129,031
Total 98,164 129,031
PN9 [Member]    
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note 400,000 0
Total 400,000 0
PN10 [Member]    
Notes Payable – Related Party (Details) - Schedule of Debt [Line Items]    
Promissory Note 144,439 0
Total $ 144,439 $ 0
v3.24.4
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) - USD ($)
3 Months Ended 6 Months Ended
Oct. 15, 2024
Aug. 30, 2024
Aug. 28, 2024
Apr. 30, 2024
Mar. 31, 2024
Mar. 29, 2024
Mar. 06, 2024
Feb. 29, 2024
Nov. 30, 2024
Nov. 30, 2024
Nov. 30, 2023
Oct. 30, 2024
Feb. 22, 2024
Jan. 02, 2024
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Interest payments                   $ 115,333 $ 163,783      
converted   $ 2,200,000 $ 2,200,000             2,200,000 $ 0      
shares (in Shares)   56,847,545 56,847,545                      
accrued interest                 $ 12,000 12,000        
PN1 [Member] | Related Party [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount                           $ 475,000
Interest Rate                           12.00%
Payments               $ 15,917            
Interest payments                 11,610 24,284        
Principal payments                 36,142 71,221        
PN2 [Member] | Related Party [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount                           $ 465,000
Interest Rate                           12.00%
Payments               $ 15,582            
Interest payments                 11,366 23,773        
Principal payments                 35,382 69,722        
PN3 [Member] | Related Party [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount                         $ 450,000  
Interest Rate                         12.00%  
Payments         $ 21,239                  
Interest payments                 9,914 21,410        
Principal payments                 53,802 106,023        
PN4 [Member] | Related Party [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount                         $ 300,000  
Interest Rate                         12.00%  
Payments         14,159                  
Interest payments                 6,609 14,274        
Principal payments                 35,868 70,682        
PN5 [Member] | Related Party [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount                         $ 350,000  
Interest Rate                         12.00%  
Payments         $ 16,519                  
Interest payments                 7,711 16,653        
Principal payments                 41,487 82,463        
PN7 [Member] | Related Party [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount             $ 100,000              
Interest Rate             12.00%              
Payments           $ 3,500                
Interest payments                 3,500 7,000        
Principal payments                 0 0        
Due             Feb. 28, 2025              
PN8 [Member] | Related Party [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount       $ 134,000                    
Interest Rate       12.00%                    
Payments       $ 6,308                    
Interest payments                 3,529 6,979        
Principal payments                 15,664 30,867        
PN9 [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount     $ 2,600,000                      
Interest Rate   12.00%                        
PN9 [Member] | Related Party [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount     $ 2,600,000                      
Interest Rate   12.00%                        
Due   Aug. 28, 2025                        
converted   $ 2,200,000                        
shares (in Shares)   56,847,545                        
conversion price (in Dollars per share)                       $ 0.0387    
PN10 [Member] | Related Party [Member]                            
Notes Payable – Related Party (Details) - Schedule of Debt (Parentheticals) [Line Items]                            
Amount $ 150,000                          
Interest Rate 12.00%                          
Payments $ 7,061                          
Interest payments                 1,500 1,500        
Principal payments                 $ 5,561 $ 5,561        
v3.24.4
Notes Payable – Related Party (Details) - Schedule of Maturities of Long-term Debt
Nov. 30, 2024
USD ($)
Schedule Of Maturities Of Long Term Debt Abstract  
2025 $ 1,769,303
2026 866,804
2027 309,042
2028 1,060,261
Total $ 4,005,410
v3.24.4
Lease Liabilities - Financing Leases (Details) - Finance Lease - USD ($)
Nov. 30, 2024
May 31, 2024
Lease Liabilities - Financing Leases (Details) - Finance Lease [Line Items]    
Financing lease obligation $ 148,309 $ 196,476
Current portion 108,410 96,224
Long-term maturities 39,899 100,252
Total 148,309 196,476
Finance Lease #1 [Member]    
Lease Liabilities - Financing Leases (Details) - Finance Lease [Line Items]    
Financing lease obligation 145,851 193,117
Total 145,851 193,117
Finance Lease #2 [Member]    
Lease Liabilities - Financing Leases (Details) - Finance Lease [Line Items]    
Financing lease obligation 2,458 3,359
Total $ 2,458 $ 3,359
v3.24.4
Lease Liabilities - Financing Leases (Details) - Finance Lease (Parentheticals) - USD ($)
3 Months Ended 6 Months Ended
Jun. 20, 2022
Mar. 14, 2022
Nov. 30, 2024
Nov. 30, 2024
Finance Lease #1 [Member]        
Lease Liabilities - Financing Leases (Details) - Finance Lease (Parentheticals) [Line Items]        
Original amount   $ 359,900    
Payable   forty-eight monthly installments of $10,173    
interest rate   15.89%    
Principal payments     $ 23,168 $ 47,266
Interest payments     6,421 13,772
Finance Lease #2 [Member]        
Lease Liabilities - Financing Leases (Details) - Finance Lease (Parentheticals) [Line Items]        
Original amount $ 12,400      
Payable forty-eight monthly installments of $350      
interest rate 15.78%      
Principal payments     456 901
Interest payments     $ 69 $ 149
v3.24.4
Lease Liabilities - Financing Leases (Details) - Finance Lease, Liability, Fiscal Year Maturity
Nov. 30, 2024
USD ($)
Finance Lease Liability Fiscal Year Maturity Abstract  
2025 $ 108,410
2026 39,899
Total $ 148,309
v3.24.4
Stockholders’ Equity (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Nov. 01, 2024
Sep. 10, 2024
Aug. 30, 2024
Aug. 28, 2024
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
May 31, 2024
Stockholders’ Equity (Details) [Line Items]                  
Common Stock, Shares Authorized (in Shares)         345,000,000   345,000,000   345,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)         $ 0.0001   $ 0.0001   $ 0.0001
Preferred Stock, Shares Authorized (in Shares)         5,000,000   5,000,000   5,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)         $ 0.001   $ 0.001   $ 0.001
Debt Conversion, Converted Instrument, Shares Issued (in Shares)     56,847,545 56,847,545          
Debt Conversion, Original Debt, Amount     $ 2,200,000 $ 2,200,000     $ 2,200,000 $ 0  
Extinguishment of Debt, Amount   $ 2,868,282              
Repayments of Unsecured Debt   $ 2,600,000         $ 2,600,000 0  
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited (in Shares)   15,488,901              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in Shares)   6,177,216              
Share Price (in Dollars per share)   $ 0.044     $ 0.045   $ 0.045    
Shares Issued, Value, Share-Based Payment Arrangement, Forfeited   $ 681,510     $ 681,510   $ 681,510    
Warrants and Rights Outstanding   4,136              
Gain (Loss) on Extinguishment of Debt   $ 949,793     949,793 $ 0 949,793 0  
Other Liabilities, Current         40,000   $ 40,000   $ 0
Class of Warrant or Rights, Cancelled or Expired (in Shares)             (6,177,216)   (454,548)
Share-Based Payment Arrangement, Expense         23,382   $ 52,184 0  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value         $ 16,637 0 $ 16,637 $ 0  
Share-Based Payment Arrangement, Option [Member]                  
Stockholders’ Equity (Details) [Line Items]                  
Share-Based Payment Arrangement, Expense           $ 0      
Director [Member]                  
Stockholders’ Equity (Details) [Line Items]                  
Share Price (in Dollars per share) $ 0.0557       $ 0.0557   $ 0.0557    
Stock Repurchased and Retired During Period, Shares (in Shares) 1,125,000           1,125,000    
Payments for Repurchase of Common Stock $ 40,000           $ 40,000    
Adjustments to Additional Paid in Capital, Other $ 22,663           22,663    
Other Liabilities, Current         $ 40,000   $ 40,000    
Canaccord Debentures [Member]                  
Stockholders’ Equity (Details) [Line Items]                  
Class of Warrant or Rights, Cancelled or Expired (in Shares)             41,667    
v3.24.4
Stockholders’ Equity (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - $ / shares
6 Months Ended
Nov. 30, 2024
May 31, 2024
May 31, 2023
Class of Warrant or Right [Line Items]      
Number of warrants outstanding (in Shares) 14,549,685 20,726,901 21,181,449
Weighted average remaining contractual life (years) 1 year 1 month 13 days    
Weighted average exercise price of outstanding warrants $ 0.4 $ 0.4 $ 0.4
Number of warrants exercisable (in Shares) 14,549,685    
Weighted average exercise price of exercisable warrants $ 0.4    
Warrants Exercisable at $0.40 [Member]      
Class of Warrant or Right [Line Items]      
Number of warrants outstanding (in Shares) 14,549,685    
Weighted average remaining contractual life (years) 1 year 1 month 13 days    
Weighted average exercise price of outstanding warrants $ 0.4    
Number of warrants exercisable (in Shares) 14,549,685    
Weighted average exercise price of exercisable warrants $ 0.4    
Minimum [Member] | Warrants Exercisable at $0.40 [Member]      
Class of Warrant or Right [Line Items]      
Range of exercise prices 0.4    
Maximum [Member] | Warrants Exercisable at $0.40 [Member]      
Class of Warrant or Right [Line Items]      
Range of exercise prices $ 0.4125    
v3.24.4
Stockholders’ Equity (Details) - Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option - $ / shares
6 Months Ended 12 Months Ended
Nov. 30, 2024
May 31, 2024
Share Based Payment Arrangement Outstanding Award Activity Excluding Option Abstract    
Warrants outstanding, Number of Shares 20,726,901 21,181,449
Warrants outstanding, Weighted Average Exercise Price $ 0.4 $ 0.4
Granted, Number of Shares   0
Granted, Weighted Average Exercise Price   $ 0
Exercised, Number of Shares 0 0
Exercised, Weighted Average Exercise Price $ 0 $ 0
Cancelled / Expired, Number of Shares (6,177,216) (454,548)
Cancelled / Expired, Weighted Average Exercise Price $ 0.4 $ 0.41
Warrants outstanding, Number of Shares 14,549,685 20,726,901
Warrants outstanding, Weighted Average Exercise Price $ 0.4 $ 0.4
v3.24.4
Stockholders’ Equity (Details) - Share-Based Payment Arrangement, Option, Exercise Price Range
6 Months Ended
Nov. 30, 2024
$ / shares
shares
Share Based Payment Arrangement Option Exercise Price Range Abstract  
Range of exercise Prices. Lower limit $ 0.039
Range of exercise Prices, Upper limit $ 0.039
Number of options Outstanding (in Shares) | shares 8,000,000
Weighted average remaining contractual life 9 years 1 month 24 days
Weighted average exercise price of outstanding Options $ 0.039
Number of Options Exercisable (in Shares) | shares 2,520,832
Weighted average exercise price of exercisable Option $ 0.039
v3.24.4
Stockholders’ Equity (Details) - Share-Based Payment Arrangement, Option, Activity
6 Months Ended
Nov. 30, 2024
$ / shares
shares
Share Based Payment Arrangement Option Activity Abstract  
Options Outstanding, Number of Shares | shares 8,041,667
Options Outstanding, Weighted Average Exercise Price | $ / shares $ 0.039
Granted, Number of Shares | shares 0
Granted, Weighted Average Exercise Price | $ / shares $ 0
Exercised, Number of Shares | shares 0
Exercised, Weighted Average Exercise Price | $ / shares $ 0
Cancelled / Expired, Number of Shares | shares (41,667)
Cancelled / Expired, Weighted Average Exercise Price | $ / shares $ 0
Options Outstanding, Number of Shares | shares 8,000,000
Options Outstanding, Weighted Average Exercise Price | $ / shares $ 0.039
v3.24.4
Stockholders’ Equity (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions
6 Months Ended
Nov. 30, 2024
USD ($)
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Abstract  
Volatility 269.44%
Dividends (in Dollars) $ 0
Risk-free interest rates 3.80%
Expected term (years) 5 years
v3.24.4
Gain on Settlement of Debt (Details) - USD ($)
3 Months Ended 6 Months Ended
Sep. 10, 2024
Aug. 30, 2024
Aug. 28, 2024
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
Gain on Settlement of Debt (Details) [Line Items]              
Debt Conversion, Converted Instrument, Shares Issued (in Shares)   56,847,545 56,847,545        
Debt Conversion, Original Debt, Amount   $ 2,200,000 $ 2,200,000     $ 2,200,000 $ 0
Extinguishment of Debt, Amount $ 2,868,282            
Repayments of Unsecured Debt $ 2,600,000         $ 2,600,000 0
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited (in Shares) 15,488,901            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in Shares) 6,177,216            
Share Price (in Dollars per share) $ 0.044     $ 0.045   $ 0.045  
Shares Issued, Value, Share-Based Payment Arrangement, Forfeited $ 681,510     $ 681,510   $ 681,510  
Warrants and Rights Outstanding 4,136            
Gain (Loss) on Extinguishment of Debt $ 949,793     $ 949,793 $ 0 $ 949,793 $ 0
PN9 [Member]              
Gain on Settlement of Debt (Details) [Line Items]              
Debt Instrument, Face Amount     $ 2,600,000        
v3.24.4
Gain on Settlement of Debt (Details) - Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions - Warrant [Member]
6 Months Ended
Nov. 30, 2024
USD ($)
Gain on Settlement of Debt (Details) - Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions [Line Items]  
Volatility 104.68%
Dividends (in Dollars) $ 0
Risk-free interest rates 4.36%
Expected term (years) 1 year 18 days
v3.24.4
Related Party Transactions (Details)
3 Months Ended 6 Months Ended
Nov. 01, 2024
USD ($)
$ / shares
shares
Oct. 15, 2024
USD ($)
Aug. 30, 2024
USD ($)
shares
Aug. 28, 2024
USD ($)
shares
Nov. 30, 2024
USD ($)
$ / shares
Nov. 30, 2024
USD ($)
$ / shares
shares
Nov. 30, 2023
USD ($)
Sep. 10, 2024
$ / shares
May 31, 2024
USD ($)
Related Party Transactions (Details) [Line Items]                  
Employee-related Liabilities, Current         $ 313,275 $ 313,275     $ 313,296
Share Price (in Dollars per share) | $ / shares         $ 0.045 $ 0.045   $ 0.044  
Other Liabilities, Current         $ 40,000 $ 40,000     0
Debt Conversion, Original Debt, Amount     $ 2,200,000 $ 2,200,000   2,200,000 $ 0    
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares     56,847,545 56,847,545          
Former Officer [Member]                  
Related Party Transactions (Details) [Line Items]                  
Employee-related Liabilities, Current         16,250 16,250     16,250
Director 1 [Member]                  
Related Party Transactions (Details) [Line Items]                  
Related Party Transaction, Amounts of Transaction         10,000 20,000      
Director 2 [Member]                  
Related Party Transactions (Details) [Line Items]                  
Related Party Transaction, Amounts of Transaction         5,000 15,000      
Director [Member]                  
Related Party Transactions (Details) [Line Items]                  
Related Party Transaction, Amounts of Transaction         $ 15,000 $ 35,000      
Stock Repurchased and Retired During Period, Shares (in Shares) | shares 1,125,000         1,125,000      
Payments for Repurchase of Common Stock $ 40,000         $ 40,000      
Share Price (in Dollars per share) | $ / shares $ 0.0557       $ 0.0557 $ 0.0557      
Adjustments to Additional Paid in Capital, Other $ 22,663         $ 22,663      
Other Liabilities, Current         $ 40,000 $ 40,000      
Related Party [Member]                  
Related Party Transactions (Details) [Line Items]                  
Stock Repurchased and Retired During Period, Shares (in Shares) | shares           1,125,000      
Payments for Repurchase of Common Stock           $ 40,000      
Share Price (in Dollars per share) | $ / shares         $ 0.0557 $ 0.0557      
Other Liabilities, Current         $ 40,000 $ 40,000      
Notes Payable         $ 2,180,484 $ 2,180,484     2,067,023
Number of Related Party Notes Payable         9 9      
PN9 [Member]                  
Related Party Transactions (Details) [Line Items]                  
Debt Instrument, Face Amount       $ 2,600,000          
Notes Payable     $ 400,000            
Debt Instrument, Interest Rate, Stated Percentage     12.00%            
PN9 [Member] | Related Party [Member]                  
Related Party Transactions (Details) [Line Items]                  
Debt Instrument, Face Amount       $ 2,600,000          
Debt Conversion, Original Debt, Amount     $ 2,200,000            
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares     56,847,545            
Notes Payable         $ 400,000 $ 400,000     0
Debt Instrument, Interest Rate, Stated Percentage     12.00%            
Debt Instrument, Maturity Date     Aug. 28, 2025            
Navy Capital Debenture 1 [Member] | Related Party [Member]                  
Related Party Transactions (Details) [Line Items]                  
Debt Instrument, Maturity Date       Aug. 28, 2025          
PN10 [Member] | Related Party [Member]                  
Related Party Transactions (Details) [Line Items]                  
Debt Instrument, Face Amount   $ 150,000              
Notes Payable         144,439 144,439     $ 0
Debt Instrument, Interest Rate, Stated Percentage   12.00%              
Debt Instrument, Term   24 years              
Debt Instrument, Periodic Payment   $ 7,061              
Consulting Fees [Member] | Director [Member]                  
Related Party Transactions (Details) [Line Items]                  
Related Party Transaction, Amounts of Transaction         $ 5,000 $ 5,000      
v3.24.4
Income Taxes (Details)
3 Months Ended
Nov. 30, 2024
USD ($)
Income Tax Disclosure [Abstract]  
Taxes Payable $ 111,441
Accrued Income Taxes 71,959
Income Tax Examination, Penalties Accrued 26,771
Income Tax Examination, Interest Accrued 12,711
Payments for Other Taxes $ 5,000
v3.24.4
Income Taxes (Details) - Schedule of Components of Income Tax Expense (Benefit) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Nov. 30, 2024
Nov. 30, 2023
Schedule Of Components Of Income Tax Expense Benefit Abstract        
Revenue $ 4,161,270 $ 5,197,214 $ 8,966,435 $ 10,311,741
Directly attributable costs (1,928,995) (3,025,595) (4,234,657) (5,866,196)
Deferred $ 2,232,275 $ 2,171,619 $ 4,731,778 $ 4,445,545
Tax rate 21.00% 21.00% 21.00% 21.00%
Tax expense $ 468,778 $ 456,040 $ 993,674 $ 933,564
v3.24.4
Commitments and Contingencies (Details)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 50 Months Ended
Sep. 01, 2022
USD ($)
Feb. 29, 2020
USD ($)
ft²
Feb. 28, 2019
USD ($)
ft²
Jan. 31, 2018
USD ($)
ft²
Nov. 30, 2024
USD ($)
Nov. 30, 2023
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Nov. 30, 2024
USD ($)
Nov. 30, 2023
USD ($)
Feb. 28, 2019
USD ($)
ft²
Sep. 30, 2028
USD ($)
Sep. 30, 2027
USD ($)
Sep. 30, 2026
USD ($)
Feb. 28, 2026
USD ($)
Sep. 30, 2025
USD ($)
Feb. 28, 2025
USD ($)
Sep. 30, 2024
USD ($)
Feb. 29, 2024
USD ($)
Feb. 28, 2023
USD ($)
Feb. 28, 2022
USD ($)
Feb. 29, 2020
USD ($)
ft²
Apr. 17, 2027
Aug. 31, 2024
Oct. 31, 2023
ft²
Apr. 17, 2017
ft²
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense         $ 140,612 $ 123,408     $ 278,097 $ 257,611                                
Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Area of Real Estate Property (in Square Feet) | ft²                                                   14,392
Lessee, Operating Lease, Term of Contract                                             72 months      
Lessee, Operating Lease, Renewal Term                                                   10 years
Minimum [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Lessee, Operating Lease, Term of Contract                                               1 year    
Maximum [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Lessee, Operating Lease, Term of Contract                                               10 years 6 months    
Deposit [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Loss Contingency Accrual, Provision                     $ 50,000                              
Other Expense [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Loss Contingency Accrual, Provision                     10,000                              
Rent Expense [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Loss Contingency Accrual, Provision                     15,699                              
Remaining Amounts Due Under Lease [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Loss Contingency Accrual, Provision                     $ 30,000                              
Las Vegas, NV #1 [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Area of Real Estate Property (in Square Feet) | ft²     1,400               1,400                              
Lessee, Operating Lease, Term of Contract     18 months               18 months                              
Operating Lease, Expense $ 2,084 $ 1,867                                                
Operating Lease, Annual Increase   3.00%                                                
Las Vegas, NV #1 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense     $ 1,785                                              
Las Vegas, NV #2 [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Area of Real Estate Property (in Square Feet) | ft²       1,000                                            
Las Vegas, NV #2 [Member] | Building and Building Improvements [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense                 10,679                                  
Operating Lease, Monthly Amount Increase   $ 600                                                
Las Vegas, NV #2 [Member] | Minimum [Member] | Building and Building Improvements [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense       $ 7,500                                            
Las Vegas, NV #3 [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Area of Real Estate Property (in Square Feet) | ft²     2,504               2,504                              
Lessee, Operating Lease, Term of Contract     18 months               18 months                              
Operating Lease, Expense                 $ 3,758                                  
Operating Lease, Annual Increase   3.00% 4.00%                                              
Las Vegas, NV #3 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Leases, Rent Expense, Minimum Rentals     $ 3,210                                              
Las Vegas, NV #4 [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Area of Real Estate Property (in Square Feet) | ft²   22,000                                       22,000        
Lessee, Operating Lease, Term of Contract   5 years                                       5 years        
Las Vegas, NV #4 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense                                           $ 11,000        
Las Vegas, NV #4 [Member] | Maximum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense               $ 29,000                                    
Las Vegas, NV #4 [Member] | Rent For April May And June 2020 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense             $ 25,000                                      
Las Vegas, NV #4 [Member] | Rent For March 2021 Through February 2022 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense                                         $ 22,500          
Las Vegas, NV #4 [Member] | Rent For March 2022 Through February 2023 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense                                       $ 23,175            
Las Vegas, NV #4 [Member] | Rent For March 2023 Through February 2024 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense                                     $ 23,870              
Las Vegas, NV #4 [Member] | Rent For March 2024 Through February 2025 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense                                 $ 24,586                  
Las Vegas, NV #4 [Member] | Rent For March 2025 Through February 2026 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense                             $ 25,323                      
Las Vegas, NV #5 [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Area of Real Estate Property (in Square Feet) | ft²                                                 2,547  
Las Vegas, NV #5 [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Lessee, Operating Lease, Term of Contract                                                 5 years  
Las Vegas, NV #5 [Member] | Minimum [Member] | Building [Member]                                                    
Commitments and Contingencies (Details) [Line Items]                                                    
Operating Lease, Expense                       $ 5,721 $ 5,554 $ 5,393   $ 5,236   $ 5,083                
v3.24.4
Subsequent Events (Details) - Subsequent Event [Member]
23 Months Ended 24 Months Ended
Dec. 27, 2024
USD ($)
Dec. 31, 2026
Dec. 31, 2026
Jan. 07, 2025
USD ($)
Subsequent Events (Details) [Line Items]        
Debt Instrument, Face Amount $ 1,000,000      
Debt Instrument, Interest Rate, Stated Percentage 12.00%      
Debt Instrument, Term     24 months  
Debt Instrument, Frequency of Periodic Payment   monthly    
Debt Instrument, Maturity Date     Dec. 31, 2026  
Number of Related Party Notes Payable       3
Related Party [Member]        
Subsequent Events (Details) [Line Items]        
Notes Payable       $ 900,000
Canaccord Debentures [Member]        
Subsequent Events (Details) [Line Items]        
Convertible Notes Payable $ 1,378,778      
Debt Instrument, Redemption, Description option to redeem all outstanding December Debentures in cash at a redemption price equal to $600 per $1,000 principal amount of December Debentures; any accrued but unpaid interest through to and including the redemption date shall not be paid and shall be cancelled      

CLS Holdings USA (QB) (USOTC:CLSH)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more CLS Holdings USA (QB) Charts.
CLS Holdings USA (QB) (USOTC:CLSH)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more CLS Holdings USA (QB) Charts.